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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
This thesis presents six studies that stem from the “Implementation project of cognitive 
behavior therapy (CBT) for chronic fatigue syndrome (CFS) in the mental healthcare 
setting”. This chapter gives some background information about CFS and the 
implementation project and ends with a short outline of this thesis.  
 
Chronic Fatigue Syndrome 
In the case definition formulated by the US Centers for Disease Control (CDC) in 
1994, CFS is defined as a ‘persistent or relapsing chronic fatigue, that results in 
substantial reduction in previous levels of occupational, educational, social or personal 
activities, is not substantially alleviated by rest, lasts for at least six months, and is not 
the result of ongoing exertion or a somatic disorder’.1 Other symptoms such as 
muscular skeletal pain, sleep disorders or impaired concentration might also be present. 
Most CFS patients do not recover spontaneously.2 In many cases CFS leads to lost 
employment and a high use of health care services,3, 4 hence it is associated with high 
societal costs.  
Since CFS has no detectable physical cause, its diagnosis is sometimes under dispute 
and not all physicians agree to diagnose CFS patients as such.5,6 Besides, not all CFS 
patients do visit their GP. Due to these issues reliable epidemiological data concerning 
CFS are scarce. The available prevalence figures of CFS patients in GP’s practices vary 
between 112 and 195 per 100.000.7-9 Recently the Health Council of The Netherlands 
made an estimation of about 30.000 to 40.000 CFS patients living in the country.10  
 
Development and evaluation of an effective treatment for CFS   
The Expert Centre Chronic Fatigue (ECCF) of the Radboud University Nijmegen 
Medical Centre has focussed on the study of chronic fatigue since 1990. Besides CFS, 
fatigue has been studied in disease-free patients successfully treated for cancer and in 
other (chronic) diseases such as multiple sclerosis and neuromuscular disorders. From 
the start, most research was designed from a biopsychosocial perspective. Such a 
perspective implies that besides physical and somatic processes also behavioral, 
cognitive and environmental aspects determine and influence the illness or 
complaint.11-13 After developing a multidisciplinary assessment method for CFS14 a 
theoretically based biopsychosocial model of CFS was tested, in which predisposing, 
initiating and perpetuating factors were separately specified.15 It turned out that besides 
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a variety of initiating factors like an infection, an operation or a (psycho) trauma, 
certain behavioral and psychological factors are responsible for the maintenance of 
severe fatigue. These factors are: a low sense of control over symptoms, strong 
physical attributions of fatigue, a strong focus on bodily symptoms, and a low daily 
physical activity level.15 Other studies have also distinguished perpetuating factors 
from initiating factors.16-18 
The model of perpetuating factors of CFS served as guidance for the development and 
evaluation of a treatment for CFS. The model suggested that cognitive behavioral 
therapy (CBT) might be might be of use in decreasing fatigue by changing the 
perpetuating factors. CBT is a general form of psychotherapy directed at changing 
condition-related cognitions and behaviors. In CBT for CFS the focus lies on changing 
irrational and dysfunctional fatigue-related cognitions and in normalizing and/or 
gradually increasing daily activity.  
After pilot studies and uncontrolled trials with successful results,19- 21 several controlled 
trials and RCTs with CBT for CFS were done.22-26 Systematic reviews on treatment for 
CFS have revealed that CBT and GET are the most effective treatments for CFS.27-29 In 
GET the primary focus lies on recovering physical condition by increase of activity, 
assuming that physiological de-conditioning perpetuates the fatigue complaints.30- 32  
Of the RCTs on CBT mentioned above, the study of Prins et al.25 was the first to 
confirm that CBT for CFS could also be performed effectively by CBT therapists who 
were previously inexperienced with CFS. Other trials were all done with only one24 or 
three23 highly experienced therapists. Previous experiences at the ECCF had learned 
that inexperienced therapists encounter several difficulties in the treatment of CFS 
patients and fail to overcome specific problems encountered during the treatment 
process. The most difficult aspects as reported by therapist were: dealing with patient’s 
insufficient motivation for the therapy, dealing with co-morbidities, and challenging 
complaint-enhancing cognitions.33  
Prins et al. used in their trial 13 therapists inexperienced with CFS divided over three 
different treatment locations. This required that the therapists were trained and 
supervised in CBT for CFS. Despite training and two years of supervision the 
therapists reported that CFS patients are difficult to treat.33 However, therapist’s 
treatment results increased as they gained more experience with CFS. The finding that 
with training and under supervision therapists inexperienced with CFS can effectively 
perform CBT for CFS suggested that the treatment could be transferred from the 
medical research setting to clinical practice settings. Such implementation was 
desirable, since in the medical hospital only a limited number of patients could be 
treated, many CFS patients could not profit from effective treatment. The Nijmegen 
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ECCF was the only formal treatment setting of CBT for CFS in The Netherlands, and 
several hundreds of patients were on a waiting list. Implementation of the treatment in 
clinical practice settings would increase accessibility for a much larger number of 
patients. Furthermore, economic evaluation indicated that wider implementation of 
CBT for CFS would be cost effective from a societal perspective.34,35  
 
Scenario for implementation 
After the ECCF research group had agreed that expansion of the treatment capacity in 
The Netherlands was advisable, the question arose in which settings CBT for CFS 
could best be provided. Different options, namely general hopsitals, mental health 
institutions, primary heatlh care psychologists, and rehabilitaiton centres have been 
considered and analyzed,36 which resulted in the following conclusions:  
• General hospitals: An advantage of psychologists in general hospitals is their 
experience with somatic complaints. A disadvantage however is that not all general 
hospitals have a psychologist or their number is limited to only one to three 
psychologists. Since these psychologist are primarily oriented at the inpatient care it is 
difficult for them to find time to realise the 16-sessions outpatient treatment for CFS. 
Another problem is that patients cannot be referred directly by their GP, but first must 
see a medical specialist, which leads to extra costs and unnecessary medicalization.  
• Primary care psychologists: Direct referrals from GPs to primary care psychologists 
are possible. A problem with primary care psychologists is that only a limited number 
of primary care psychologists is educated and registered as a CBT therapist. Secondly, 
they cannot afford to offer treatments lasting longer than 7 sessions as at the time of the 
analysis, the expenses of more sessions were not repaid to the patient. Given its 
specialised character, CBT for CFS does fit better in secondary care. Third, not every 
GP has a direct connection to a primary care psychologist, partly because they are not 
(yet) covering the whole country. A final issue that can be problematic is that primary 
care psychologists have to pay themselves for training and supervision. 
• Mental health centers (MHCs): A disadvantage of psychologists in MHCs is that 
thay have little experience with treating somatic complaints. The acceptance of patients 
being referred to a MHC for a somatic complaint might also be limited. On the other 
hand MHCs have important advantages. First, sufficient CBT therapists are working in 
MHCs and CBT has already been applied succesfully for a range of psychological 
problems. Second, GPs can refer patients directly and mostly do already so with other 
types of patients. Third, 16-session treatments are repaid to patients. Only a small own 
contribution is being asked. And finally sufficient training and supervision can be 
realized.  
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• Rehabilitation centers: The main problem in rehabilitation centers is that they only 
offer multi disciplinary treatments, which include more components than are needed. 
And exactly because of their multi disciplinary treatment modules and good facilities 
for disabled people, rehabilitation centers are especially suitable for treating the very 
severe and bedridden CFS patients who cannot profit from outpatient treatment.36,37  
It was concluded that MHCs are in principle the best option for outpatient treatment of 
CFS patients. A MHC was found that appeared to be willing to train some of their 
therapists and to participate in such a project.36 Hereupon the implementation project 
was set up. The main research question was: What are the prerequisites for successful 
implementation of CBT for CFS in a MHC? As described in planning models for 
effective implementation38, 39 it was tried to anticipate on potential problems by the 
design of the implementation interventions. 
 
Outline of this thesis 
The first step in realizing this implementation project was informing potential referrers 
in the concerning regions about the new treatment. The idea was that CFS patients 
consulting their GP should be recognized and diagnosed as such, and then be motivated 
for and referred to the new treatment in the MHC. Since none of all GPs were very 
familiar with diagnosing or treating CFS, and additionally CFS is a difficult and 
debatable diagnosis for some GPs5,6 we had to put quite some effort in informing and 
educating them. Chapter 2 describes the study in which the effects of educative and 
informative interventions on GP´s knowledge and attitudes towards CFS and on their 
actual referrals of patients to the MHC were investigated.    
The treatment manual applied in the implementation study differed from that used by 
Prins et al.25 and van der Werf et al.40 had found that CFS patients could be divided into 
‘fluctuating active’ and ‘passive’ patients based on their daily physical activity pattern. 
The results of the trial of Prins et al.25 suggested that passive patients need a different 
type of treatment41 and an adapted treatment protocol for passive patients was hence 
being developed42 and tested26 for passive patients. To determine a CFS patient’s 
activity pattern, necessary to decide which treatment version should be used, the ECCF 
uses actometers. But for clinical settings actometers are not feasible and too expensive. 
Hence considering implementation we had to look for alternative assessment methods 
to assess CFS patients activity pattern. Chapter 3 describes the study that evaluated 
three alternative methods for assessing physical activity.  
Chapter 4 presents the whole process and effects of the implementation project. 
Besides the main research question concerning prerequisites for successful 
implementation, the following sub questions are being investigated in detail: Are 
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potential referrers sufficiently informed about the new treatment offer? What are 
possible reasons for not referring? Are sufficient patients being referred to realize the 
implementation and to continue the program? How many patients have been referred 
unjustly? How many patients dropped out of treatment and what are reasons for drop 
out? What are the treatment effects? This chapter finishes with a summary of the main 
prerequisites for successful implementation of CFT for CFS.  
Chapter 5 focuses on the treatment effects of CBT for CFS after implementation 
compared to the previous RCTs using a benchmark strategy. Although it has been 
demonstrated that CBT for CFS can effectively be performed by therapists 
inexperienced with CFS,25,33 the transferability of RCT results to clinical practice 
settings had scarcely been studied. Since RCTs always imply controlled conditions, it 
is not known if their positive effects can always be generalized to clinical practice.43, 44  
In order to let decision makers judge whether implementation of CBT for CFS is 
worthwhile, they also need information about its costs and benefits. Cost effectiveness 
analyses (CEA) of CBT for CFS show positive results but are scarce.34,35 About the 
costs and efficiency of providing and implementing CBT for CFS nothing is known 
yet. It might be possible that the efficiency of CBT for CFS will reduce if the 
implementation costs are high and/or if the effectiveness is reduced. The study 
presented in chapter 6 evaluated the costs and outcomes of the implementation project. 
One of the main expenses for CFS patients is their frequent and intensive health care 
use.3-5, 46 Nothing is known yet about individual characteristics that contribute to their 
high health care use. Chapter 7 investigates the question whether the psychological 
factors that are known to perpetuate their fatigue, and are being addressed in the CBT 
treatment, possibly explain part of the variance in their amount of medical 
consumption.  
Finally, the results of the studies presented in this thesis, implications for clinical 
practice and future directions will be discussed in chapter 8.  
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CHAPTER 2 
THE IMPACT OF INFORMATIONAL INTERVENTIONS  
ABOUT COGNITIVE BEHAVIORAL THERAPY FOR CHRONIC 
FATIGUE SYNDROME ON GP’S REFERRAL BEHAVIOR 
 
 
 
 
Abstract 
Objective: This study investigated the impact of an informational intervention among 
general practitioners (GPs) about a new treatment with cognitive behavioral therapy 
(CBT) for chronic fatigue syndrome (CFS) in a mental health center (MHC). The 
outcome measures concerned GP’s knowledge and attitudes towards CFS and their 
actual referrals of CFS patients to this new treatment setting.  
Methods: Three hundred and one GPs, who all had received written information about 
CFS four times, and who partly had also visited an informational group session, 
completed a short questionnaire survey on CFS knowledge and attitudes. Referral data 
were obtained from the MHC.  
Results: During 16 months 22 percent of all GPs in the concerning region had referred 
at least one CFS patient. Concerning knowledge and attitude, the survey results showed 
that seventy percent of the GPs had remembered the intervention’s main message, 
namely the new treatment possibility. These informed GPs reported better knowledge 
and more positive attitudes towards CFS than the non-informed GPs, who had not seen 
and read the intervention’s information.  
Conclusion: This study showed that disseminating written materials can be a useful 
method for stimulating GPs to refer CFS patients for CBT.  
Practice implications: In future implementation projects concerning CBT for CFS (or 
other ‘new’ treatments for a disputed illness) in a MHC or other institution, the 
informational intervention evaluated here can be a suitable and efficient method to 
inform GPs and let them refer patients.  
 
Introduction 
Chronic fatigue syndrome (CFS) is characterized by persistent or relapsing unexplained 
fatigue, lasting for at least six months and resulting in substantial reduction in previous 
levels of daily functioning. Causes of CFS have not been found and most patients do 
not recover spontaneously.1 Cognitive behavioral therapy (CBT) has proven to be an 
effective treatment for CFS.2,3 Since only a few university medical centers in The 
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Netherlands offer this treatment, a small minority of all CFS patients benefit from it. 
Nationwide implementation is needed to realize access to CBT treatment for the 
majority of CFS patients.   
As a pilot implementation project, CBT for CFS was made available in a mental health 
center (MHC) located in the East of The Netherlands. Effective implementation of this 
new service required appropriate referral of CFS patients by general practitioners 
(GPs). But among GPs knowledge about diagnosing CFS is limited4 and negative 
attitudes towards diagnosing CFS do exist.5,6 And above all, when starting the project 
none of all GPs were familiar with the new treatment possibility. Therefore all GPs in 
the concerning region had to be informed about the diagnostic criteria for CFS, about 
the importance and advantages of diagnosing CFS, and about the new treatment 
service. Dissemination of written educational materials combined with an invitation to 
an informational group session about CFS was used. This study evaluated the impact of 
these interventions on GPs reported knowledge of - and attitude towards CFS and on 
their actual referrals of CFS patients to the MHC.  
 
Method 
Study population and design 
The pilot region contained 452 practicing GPs, who all were sent a short written 
questionnaire in 2005. CFS referral data from the MHC and data from the attendance 
lists of the organized group sessions were collected and linked to the questionnaire 
data. Before starting this study it was judged by the Nijmegen Medical Hospital Ethical 
Commission, who indicated no need for informed consent. 
 
Interventions 
Educational brochures and information letters were sent to all GP practices in the 
concerning region. The brochure contained some background about CFS, a description 
of prior research on causes and treatment of CFS and an explanation about the 
diagnostic criteria and treatment with CBT. The information letter introduced the new 
treatment availability and the concerning referral addresses, including a therapist’s 
telephone number that GPs could consult for extra information about the diagnosis or 
questions about specific patients in their practice. Keeping in mind that GPs receive a 
lot of (written) information and hence might easily overlook our letter and brochure, 
these were sent four times, starting in January 2004 with time intervals of 
approximately 4 months. Furthermore some small group sessions ‘continuing medical 
education’ were organized in cooperation with continuing education committees. 
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During these 1.5-hour informational group sessions possible causes of CFS, the method 
of diagnosing it and the content of the treatment were explained.  
 
Measurements 
• Referral behavior: After referral of a CFS patient, the GPs diagnose was assured 
by validated questionnaires on the main symptoms of CFS7 that were filled in by the 
patient after the first intake session. If the results of these questionnaires contradicted 
the diagnosis of CFS, the patient was marked in the database as ‘non-CFS’ and the 
referral was not registered as valid. The MHC recorded a list of all GPs who had 
referred one or more CFS patients in the last 16 months. The names of these GPs were 
linked to the questionnaire data, and the variable ‘GP referred one or more CFS 
patients’ was added to the research database.  
• Attending a group session: Attendance lists were checked and the names of present 
GPs were added to the questionnaire data, after which the variable ‘GP visited a group 
session’ was also added to the database.  
• Questionnaire about knowledge and attitude: The fourth time the brochure was 
sent to the GPs, it was accompanied by a short written questionnaire (Box 1) containing 
nine questions, mostly multiple choice, about their familiarity with the new treatment 
service, their knowledge about CFS and their attitude towards diagnosing CFS. This 
questionnaire was based on the one developed and used by Prins et al.,8 and was tested 
on face validity in a small group of GPs from outside the research region.  
Operationalisation of these topics are shown in Table 2. To check whether their 
knowledge indeed resulted from our education shots, GPs were also asked when and 
where they were first informed about the new treatment setting for CFS. Reminders 
were sent after 5 and after 9 weeks. 
The questionnaires were filled in anonymously, but they were all given a research code 
by the researcher. After the researcher had linked the questionnaire data to the variable 
‘referring versus non-referring GPs’, the names in the dataset were deleted again. 
 
Analyses 
First the total group of responders was divided into three subgroups. ‘Non-informed 
GPs’ had answered not to be acquainted with the new treatment option for CFS, and 
apparently had not read or remembered the spread information. ‘Informed non-
attending GPs’ knew about the new treatment option, but had not visited a group 
session. ‘Informed attending GPs’ had both read the information and also visited a 
group session. Chi-Square tests in SPSS 12.0.1 were used to test the differences in 
knowledge, attitude and behaviour between these three groups. 
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  Box 1: The questionnaire about CFS for general practitioners  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
In total 301 of the 452 questionnaires were completed and returned, implying a 
response rate of 67%. Table 1 presents the responders characteristics. Of these 301, 212 
GPs (70%) remembered to have been informed by us about CFS and knew about the 
new treatment possibility. During 16 months, 99 of all 452 GPs in the region (22%) had 
referred one or more CFS patients.   
1. How many patients do you have in your practice who fulfill the diagnostic criteria  
for chronic fatigue syndrome (CFS)?  □ ……..  (number) CFS patients   □ none 
2. Did you ever diagnose CFS? □ no □ yes (go to question number 4) 
3. What is a reason for you to not diagnose CFS? (you may select several answers) □ these complaints do not exist in my practice  □ I do not believe in/ I disagree with the diagnosis of CFS   □ I am not familiar with the criteria to diagnose CFS □ I think a medical specialist should diagnose CFS  □ another reason, namely ………..……………… 
4. Do you think you are able to adequately inform a CFS patient about the illness  
 and the treatment possibilities? □ no □ yes 
5. Were you (before today) familiar with the possibility to refer CFS patients for 
cognitive behavioural therapy (CBT) in the mental health center?   □ no (go to question number 9) □ yes 
6. Where did you first hear or read about this treatment option? □ in an information letter and brochure about it  □ in a newspaper article □ in a small group education session □ on the internet  □ other, namely. ……………………… 
7. Did you refer CFS patients for CBT in the mental health center in the last 1,5 year? □ yes (go to question number 9) □ no  
8. What was a reason for you not to refer CFS patients? (you may select several 
answers) □ I do not believe this treatment works for CFS patients □ I did not see CFS patients in my practice □ other, namely..…………………… 
9. Did it happen that a CFS patient did not accept your referral to mental health  
 care for CBT?  □ yes, that happened with ……(number of) patients □ no  
      - How large is the practice you work in?    … … (number of) patients 
             - How many years have you been working as a GP? Since ………….…… 
               - Do you have any further remarks? ..…...…………………………………… 
                 ………………………………………………………………………………….… 
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Differences between the three groups of GPs are shown in Table 2. Informed GPs 
reported better knowledge about CFS than non-informed GPs. Among informed GPs 
who also attended the information meeting, knowledge about CFS was even better. 
Informed GPs also reported fewer objections against the diagnosis of CFS than non-
informed GPs did.  Informed and non-informed GPs were in the same degree of  the 
 
 
Table 2. Differences in knowledge, attitude and reported behavior between informed and non-
informed GPs (N = 301) 
 
Reported knowledge 
‘A’ 
Non 
informed 
GPs 
(N=73 a) 
‘B’ 
Informed GPs 
who did not 
visit information 
meeting (=184) 
‘C’ 
Informed GPs 
who did visit 
information 
meeting 
(N=28) 
 
Chi-2 
P- value 
‘do not know how to     
diagnose CFS patients’ 27% (20/73) 18% (33/184) 4% (1/28) 0.020 
c,d 
‘feel unable to inform  
CFS patients properly’ 59% (41/70 
b) 40% (72/182 b ) 21% (6/28) 0.001 c,d,e 
Attitude 
 
   
‘feel objection against     
diagnosing CFS patients  32% (23/73) 17% (31/184) 14% (4/28) 0.022
 c 
‘think a medical specialist 
should diagnose CFS’ 37% (27/73) 35% (65/184) 25% (7/28)  0.506p 
Actual behavior     
GP’s who referred CFS  
patients to CBT (N=65) 0% (0/73) 28% (52/184) 46% (13/28) <0.001
 c,e 
   
a. Of the 89 non-informed GPs 16 did not fill in the questions shown in table 2. They were    
   therefore left out in this analysis. 
b. This question was not answered by 5 GPs 
c. = significant difference between group A and B, Chi-2 p < 0.05 
d. = significant difference between group B and C, Chi-2 p < 0.05 
e. = significant difference between group A and C, Chi-2 p < 0.05 
Table 1. Group characteristics of all responding GPs (N=301) and comparison with figures 
of Dutch GPs (data from Dutch registration of GPs bearing, NIVEL 2005) 11 
 Survey sample Dutch GPs 
Number of patients per practice (M/SD) 2,559/ 549 2,356 
GP’s number of years working as a GP (M/SD) 16.2/ 8.6 16.1 
Female sex (%) 27% 33% 
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opinion that a medical specialist should diagnose CFS patients. Concerning referrals of 
CFS patients, by definition only informed GPs could have referred CFS patients. 
Consistent with the results in knowledge, a higher percentage of referring GPs was 
found in the GPs attending the information meeting than in the non-attending GPs. 
 
Discussion and conclusion 
Discussion 
This study showed that a majority of GPs, who were repeatedly informed about an 
effective treatment for CFS in their region, had read this information and had 
remembered the main message of it. Furthermore, those GPs who had read the 
information reported both better knowledge about CFS and a more positive attitude 
towards its diagnosis. Moreover, the repeated information about CFS had a clear 
impact on referral behaviour.  
The main limitations of this study were the absence of a control group and a baseline 
measurement. On the other hand, the referral rate was obviously zero at base line and 
for sure none of all GPs knew anything about the new treatment service for CFS at that 
time, since it did not yet exist. Only the base line levels of attitude and knowledge 
about CFS were unsure. When retrospectively comparing the present results with 
earlier studies on CFS among GPs, it seems that reported attitude towards CFS in our 
‘non-informed group’ (Table 2) was similar to the earlier study results: the percentage 
of GPs accepting CFS as a distinct diagnose was found to lie between 69% and    
82%.4-6, 11 Although these figures are no control measurement, they suggest that attitude 
towards CFS of our GPs was at baseline representative for other GPs not having 
received any intervention about CFS, and thus that the intervention has anyway 
influenced their attitude somewhat. A control group would of course have made 
possible a stronger interpretation of data. This was not possible however since the 
MHC did not want to inform only half of all GPs, and GPs in other regions were not in 
the condition of having a new treatment service for CFS in their surroundings.    
A second limitation is that for practical reasons we did not use validated instruments 
for knowledge and attitudes. This implicates that strong conclusions on effectiveness of 
the interventions of the intervention, especially concerning knowledge of and attitude 
towards CFS cannot be made. A strong point of this study however is that the number 
of referrals was based on objective administrative information from the MHC, thereby 
forming a hard effect measurement. Another strength lies in the high response rate of 
67%, which enlarges the generalizability of the findings.   
It has been found earlier that written materials can have small but relevant effects on 
clinical behaviour.9 Our study showed that this was also true for a controversial 
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diagnosis. Feeling objections against the diagnosis5,6 or feeling lack of confidence in 
diagnosing CFS4 might have restrained GPs to diagnose CFS patients, which in turn 
could have led to not referring them to CBT treatment. That the impact found in this 
study was nevertheless achieved might be explained by the possibility that GPs felt a 
need for treatment for their CFS patients, or by the fact that the intervention was 
repeated four times, which may have reinforced its impact.  
The question may rise now whether one instead of four education shots would also 
have sufficed. However, the fact that each of the four interventions resulted in a 
temporary increase in monthly referrals, many of them done by GPs who had not yet 
referred for CFS before, indicates that a repeated intervention was better than one.  
 
Conclusion 
Despite many possible barriers in getting GPs to refer CFS patients for CBT, like GPs 
experienced lack of knowledge about CFS, doubts about diagnosing it, and the fact that 
reaching GPs with an informational message is difficult, disseminating written 
materials has shown to be a useful method for this purpose.    
 
Practice implications 
In future implementation projects concerning CBT for CFS, or other ‘new’ treatments 
for a disputed illness, in a MHC or other institution the informational intervention 
evaluated here can be a suitable and efficient method to inform GPs and let them refer 
patients.  
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CHAPTER  3 
CLINICAL ASSESSMENT OF THE PHYSICAL ACTIVITY 
PATTERN OF CHRONIC FATIGUE SYNDROME PATIENTS:  
A VALIDATION OF THREE METHODS 
 
 
 
 
Abstract 
Background: Effective treatment of chronic fatigue syndrome (CFS) with cognitive 
behavior therapy (CBT) relies on a correct classification of so called ‘fluctuating 
active’ versus ‘passive’ patients. For successful treatment with CBT is it especially 
important to recognize the passive patients and give them a tailored treatment protocol. 
In the present study it was evaluated whether CFS patient’s physical activity pattern 
can be assessed most accurately with the ‘Activity Pattern Interview’ (API), the 
International Physical Activity Questionnaire (IPAQ) or the CFS-Activity 
Questionnaire (CFS-AQ).  
Methods: The three instruments were validated compared to actometers. Actometers 
are until now the best and most objective instrument to measure physical activity, but 
they are too expensive and time consuming for most clinical practice settings. In total 
226 CFS patients enrolled for CBT therapy answered the API at intake and filled in the 
two questionnaires. Directly after intake they wore the actometer for two weeks. Based 
on receiver operating characteristic (ROC) curves the validity of the three methods 
were assessed and compared.  
Results: It appeared that both the API and the two questionnaires had a fair validity and 
none of the instrument was significantly better than the others.  
Conclusions: Because the IPAQ showed to be the best in correctly predicting ‘passive’ 
CFS patients, it was concluded that the IPAQ is the preferable alternative for an 
actometer.   
 
Introduction 
Chronic fatigue syndrome (CFS) is characterized by unexplained severe fatigue that 
does not resolve with bed rest, lasts for at least six months and causes serious 
reductions in daily functioning.1 Spontaneous recovery rates are low.2,3 Reviews of 
randomized controlled trials (RCTs) have shown that cognitive behavior therapy (CBT) 
is the most effective treatment for CFS.4-6 In one of the RCTs included in these reviews 
it was found that CFS patients’ individual level of daily physical activity predicted the 
36   Chapter 3 
 
CBT treatment outcome.7 Based on their daily activity level, CFS patients can be 
divided into two subgroups, distinguishing ‘fluctuating active’ from ‘passive’ CFS 
patients in a proportion of 75% versus 25% respectively.8 Fluctuating active patients 
generally show infrequent bursts of activity followed by extreme exhaustion, whereas 
passive patients usually avoid activities as much as possible. In the trial of Prins et al.7 
it turned out that passive CFS patients showed almost no improvement. It was 
suggested that these passive patients might need a different type of treatment. 
Therefore a more appropriate protocol was developed 9 and tested.10 It is especially 
important that passive patients are being recognized correctly, as they do not recover 
when they receive the protocol for active patients.7, 11 When active patients accidentally 
receive the passive protocol, the consequences are less problematic. They start 
complaining quickly of exhaustion when increasing their already fluctuating activity 
pattern; this protest alerts the therapists and enables them to adjust the protocol so that 
recovery can still be reached. 
One of the major innovations of the new protocol is that whereas fluctuating active 
patients start with practicing a base line activity level that prevents bursts of activity, 
passive patients start directly with increasing physical activity.11,12 The adapted 
protocol has proven to be as effective for passive CFS patients as the original protocol 
is for pervasively active CFS patients.10 Therefore it is now being used in clinical 
practice for passive CFS patients.  
Now in order to decide which protocol should be used, it is necessary to assess the 
patient’s physical activity pattern. An accurate and objective method to do this is using 
an actometer. Actometers are based on an electric sensor and yield highly reliable 
data.8, 13,14 But for clinical settings actometers are not feasible because of its high costs 
and a lack of personnel to instruct patients how to wear the actometer and to read out 
the computerized graphics.  
An alternative method is the short ‘Activity Pattern Interview’ (API) of daily 
activities.9,12 Talking through a typical day by asking concrete questions about 
activities ‘from minute to minute’ should deliver the needed information. Although this 
method is now being used in several settings and is also included in trainings of CBT 
for CFS, its validity has never been tested.  
Another possibility is using self-report questionnaires. Since the outcome of such a 
questionnaire is not dependent on the therapist’s skills, the validity of such a 
questionnaire might be higher and more stable than that of an interview. Several 
'physical activity questionnaires’ are available for this purpose.15-17 In this study the 
widely used and validated International Physical Activity Questionnaire (IPAQ),18 and 
a newly developed CFS Activity Questionnaire (CFS-AQ) were evaluated. We 
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developed the CFS-AQ because it was presumed that the IPAQ, as other existing 
activity questionnaires designed for the general population, might not suit the typical 
low activity levels of CFS patients.  
The present study evaluates and validates these three alternative methods to assess CFS 
patients activity pattern. The research questions of the present study are: (1) What is the 
validity and sensitivity of the API when assessing CFS patients’ activity pattern? (2) 
Do the IPAQ and the CFS-AQ assess activity pattern better than the API? The 
hypothesis was that the CFS-AQ would show a higher validity than the IPAQ and the 
API. 
 
Method 
Subjects and procedure 
In this study 226 consecutive CFS-patients aged between 16 and 65 participated. They 
were all referred between January 2004 and October 2005by a medical specialist or 
general practitioner to the Nijmegen Expert Centre for Chronic Fatigue (ECCF). All 
participants fulfilled the CDC-94 criteria for CFS.1 The main complaint of severe 
fatigue was indicated by scores of 35 or higher on the Checklist Individual Strength 
(CIS) subscale ‘fatigue severity’.19 Severe impairment was defined by a cut off score of 
700 or higher on the Sickness Impact Profile (SIP).20 Data for this study were obtained 
during the patients first two visits to the center. During the intake session the six 
therapists participating in this study performed the API. All therapists were trained and 
experienced in CBT for CFS. Their training included assessing the activity pattern of 
the patient with the API. During the second visit (diagnostic test session) patients 
completed the IPAQ and the CFS-AQ. Additionally they got instructions to wear the 
actometer for the next two weeks.   
 
Measures 
• API: The API (Box 1) consists of a form with three relevant topics that are 
discussed during the intake interview. On basis of these topics the therapists forms a 
final judgment. The therapists were instructed to fill in this form during the intake, their 
definite activity pattern judgment included. Relevant topics are the amount of time 
spent laying on bed, the number of times leaving the house during a day and practicing 
a paid or unpaid job. The passive CFS patient can be recognized by spending a great 
deal of time lying down, going out infrequently and not practicing a job anymore. It 
takes more ore less ten minutes to administer the API.  
• IPAQ: The short form IPAQ 18 is a 9 item scale, providing information on the 
amount of minutes spent  in vigorous and  moderate  intense activity  and  walking,  for  
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which separate sub scale scores can be calculated. Filling in the IPAQ takes about 5 
minutes. The IPAQ has a good test-retest reliability (Spearman’s ρ = 0.80) and a 
moderate criterion validity (Spearman’s ρ = 0.30) with an accelerometer.18  
• CFS-AQ: The activity questionnaire was developed at the ECCF. It contains 10 
items with four sub scales: ‘physical activity’ (four questions), ‘rest’ (four questions), 
‘using aids’ (one question) and ‘social activity’ (one question). Each item is scored on a 
four point Likert scale. It takes about 10 minutes to fill in the CFS-AQ. The CFS-AQ 
internal consistent reliability and test-retest reliability were tested in this study’s 
population and were acceptable (Cronbach’s alpha 0.73; Spearman’s ρ 0.72).  
 
 
Box 2: The CFS –Activity Questionnaire 
Instruction: The following questions deal with several activities that you possibly did during 
the last two weeks. Please indicate how often you performed the concerning activity. Keep in 
mind a period of two weeks.   
 
Daily 
A few 
times a 
week
Once a 
week 
Not/ 
Never 
When I had to walk more than ten minutes, I 
used aids 1 2 3 4 
I went to bed before 9 pm 1 2 3 4 
I did not wake up before 10 am 1 2 3 4 
I laid in bed for at least one hour during the day 1 2 3 4 
I left home at least once (shopping, visiting 
somebody, etc.) 4 3 2 1 
I walked for at least 15 minutes outside 4 3 2 1 
I biked for at least 15 minutes  4 3 2 1 
I exercised  4 3 2 1 
I visited friends or relatives 4 3 2 1 
Box 1: Short form to be filled in by the therapist after the Activity Pattern Interview 
    Interview items:  Passive Fluctuating  active        
1. Based on patients description of 
 a typical day the impression is that 
the activity pattern is: 
 
  
2. Does the patient have a paid or  
unpaid job? 
Yes: fluctuating active.  
No: passive   
3. Does the patient leave the house  
at least once a day? 
Yes: fluctuating active.  
No: passive   
4. My final judgment is:    
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• Actometer: The actometer (©Actilog V3.0) is a little box (43*29*16mm) that has a 
piëzo-electric sensor, which is sensitive in three directions. It is worn on the ankle, 
usually for 14 days in order to retain 12 complete registration days. Sensor acceleration 
results in an output signal, all signals above a certain threshold are added to a pulse 
generator. This pulse generator triggers a 2-bit counter that adds the registered value to 
an ‘integration counter’ every five minutes,13 from which daily scores are computed. 
The activity pattern of passive patients is defined by scoring zero or one of the 12 days 
above a healthy control reference score.8 Fluctuating active patients score two or more 
of the 12 days above this reference score and mostly present an irregular, ‘fluctuating’ 
graphic.  
 
Analyses 
First, correlations between the three instruments and the continuous actometer scores 
were computed. After that logistic regression analyses were performed with the IPAQ 
and the CFS-AQ, using actometer typology as dependent variable, to gain their 
predicted probability scores and a dichotomous outcome scale of activity level. From 
the regression analysis results we obtained the parameters for the CFS-AQ and the 
IPAQ that are needed to prescribe a formula that can predict a patients activity pattern 
according to the actometer. The formula for the CFS-AQ predicting the probability that 
a particular patient is active became:  
                                            1 
p (active) =    ---------------------------------------------------------------------- 
              1 + e - (- 3.667 + 0.243 * physical + 0.088 * rest + 0.418 * aids - 0.192 * social) 
 
(‘physical’ = score on subscale ‘physical activity’, ‘rest’= score on subscale ‘rest’, 
‘aids’ = score on subscale ‘using aids’, and ‘social’ = score on subscale ‘social 
activities’). The formula for the IPAQ predicting the probability that a particular patient 
is active became: 
  1  
p (active) =    --------------------------------------------------------------------- 
        1 + e  - (0.197 * walking + 0.144 * moderate + 0.046 *heavy) 
  
(‘walking’= score on subscale ‘walking’, ‘moderate’= score on subscale ‘moderate 
activities’, ‘heavy’= score on subscale ‘heavy activities’). The API did not need such 
analysis, since it resulted in a dichotomous outcome directly.  
With the predicted probability scores derived from the regression analysis, receiver 
operating characteristic (ROC) curves were constructed for all three instruments in 
order to analyze sensitivity and specificity levels (Figure 1). ‘Sensitivity’ represented 
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the proportion of passive patients correctly classified as passive, whereas ‘specificity’ 
was defined as the proportion of active patients correctly classified as active. A ROC 
curve shows the trade-off between sensitivity and specificity for all possible predicted 
values. The ROC area under the curve represents the validity of a model. The higher 
the curve and the more it follows the vertical axis, the more accurate the model.21 An 
area of 1 represents a perfect validity whereas an area of 0,5 would be identical to just 
guessing. A rough guide for classifying the accuracy of a diagnostic test is the 
traditional academic point system: .90-1 = excellent, .80-.90 = good, .70-.80 = fair, .60-
.70 = poor, .50-.60 = fail. For each curve, at one ‘cut off’ point the combination of 
sensitivity and specificity is optimal.21 The best cut off points for the IPAQ and the 
CFS-AQ were determined by calculating and computing sensitivity and specificity at 
different cut off points and find the point with the highest score. Cross tabs were 
constructed to support comparison of the three methods. Finally it was investigated 
whether the areas under ROC curves were significantly different by calculating a Z-
score using the formula of Hanley & Mc Neil.22 All statistical analyses were conducted 
using SPSS version 12.01. 
 
Results 
Descriptives and demographics 
The mean age of participating patients was 37 years (SD 11.3 range 15-68). The 
male/female ratio was 26%/ 74% (59 male, 167 female), median duration of fatigue 
was 5 years (range 2-32). According to the actometer measures, 29% of the patient 
population had a passive activity pattern and 71% had a fluctuating active one.  
 
Validity of the instruments  
The correlation of the API and the IPAQ with the analogous actometer scores appeared 
to be weak (Spearman’s ρ = 0.27 and ρ = 0.33 respectively). The CFS-AQ showed a 
moderate correlation with the actometer (Spearman’s ρ = 0.41). Figure 1 and Table 1 
show the area under the curve (representing the validity) for the CFS-AQ, the IPAQ 
and the API. As can be seen, the validity of the API (0.643) was somewhat smaller than 
that of the two questionnaires (0.710 and 0.711). Following the method of Hanley and 
Mc Neil22 the validities of the three instruments were not significantly different 
however.  
 
Sensitivity of the instruments 
Based on the API, 52.3% of all passive CFS patients were correctly classified as 
passive (sensitivity) and 75.8% of all active patients were correctly classified as 
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fluctuating active (specificity) (table 2). The optimum predicted probability cut off for 
the CFS-AQ was at 0.73, by which a sensitivity of 64.6% was reached combined with a 
specificity of 65.2% (table 3). For the IPAQ the best predicted probability cut off was 
at 0.67 with a sensitivity of 70.1% and a specificity of 62.7% (table 4). 
For scoring the IPAQ and the CFS-AQ the formulas given in this article have to be 
filled in a follows: the scores on the different subscales of a particular patient have to 
be filled in at the corresponding place in the formula. Afterwards the formula has to be 
calculated, which can best be done by using a program like Excel. Finally one should 
check whether the outcome of this calculation lies above or below the cut off point of 
0.73 (when scoring the CFS-AQ) or 0.67 (when scoring the IPAQ). 
 
Discussion 
This study investigated whether the structured ‘Activity Pattern Interview’ (API), the 
International Physical Activity Questionnaire (IPAQ) and the CFS- Activity 
Questionnaire (CFS-AQ) could accurately assess the daily activity pattern of CFS 
patients.  
It appeared that all three instruments had a fair validity, and none of the instrument was 
significantly better than the others. Contrary to our hypothesis, the CFS-AQ, a 
questionnaire specifically developed for CFS, was not more accurate than the IPAQ or 
the API. This implies in the first place that the design of a questionnaire especially for 
CFS patients did not result in a significantly higher validity. Secondly, this result shows 
that apparently some training and experience in performing the API are enough to 
almost equal a questionnaire.  
A strong point of this study is the fact that it concerns a clinically relevant question 
with important treatment consequences. A methodological limitation of this study is the 
fact that the predicted models of the questionnaires were derived from the same 
population as in which afterwards the ROC curves were constructed. This implies that, 
when tested in a possible validation study, the instruments might show a somewhat 
lower validity, although probable still better than ‘just guessing’.  
Compared to other studies, the correlations of the three tested instruments with 
objective measurements are not different from other established self-report physical 
activity questionnaires. None of the regularly used physical activity questionnaires that 
have been validated against objective measurements, e.g. the SQUASH18 the LASA17 
or the Baecke questionnaires16 have shown correlations above 0.45.  
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Figure 1: Receiver operating characteristic (ROC) curves of the IPAQ, CFS-AQ and 
API predicting CFS-patients daily activity typology, best cut-off points of CFS-AQ and 
IPAQ marked with ● 
 
 
Table 1. Area under the ROC curve (accuracy level) of the API, CFS-AQ and the IPAQ.  
Test results variables 
Area under 
the curve  
Std. 
Error 
Asymptotic 
significance b 
Asymptotic 95% 
Confidence Interval 
    
 
Lower 
bound 
Upper 
bound 
Activity Pattern 
Interview 0.643 0.042 0.001 0.562 0.725 
CFS Activity 
Questionnaire 0.710 0.036 0.000 0.640 0.781 
IPAQ  0.711 0.039 0.000 0.634 0.788 
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Table 3: Sensitivity and specificity of the CFS-AQ with the cut off point at 0.3 (N=226) 
     Actometer typology  
       Passive N (%) Active N (%) Total N (%) 
CFS-AQ Passive  42 (64.6%) 56 (34.8%) 98 (43.4%) 
   Active  23 (35.4%) 105 (65.2%) 128 (56.6%) 
      65 (100%) 161 (100%) 226 (100%) 
Predictive value of a positive test  (sensitivity) PV+ =  42  /   65 = 0.646 
Predictive value of a negative test (specificity)  PV-  = 105 / 161 = 0.655 
 
Table 4: Sensitivity and specificity of the IPAQ with optimum cut off  point at 0.67 (N=226)  
        Actometer typology  
    Passive N (%) Active N (%) Total N (%) 
IPAQ Passive  46 (70.1%) 60 (37.3%) 106 (47%) 
Active  19 (29.3%) 101 (62.7%) 120 (53%) 
     65 (100%) 161 (100%) 226 (100%) 
Predictive value of a positive test  (sensitivity) PV+ =   46 /   65 = 0.701 
Predictive value of a negative test (specificity)  PV-  = 101 / 161 = 0.627 
 
 
A review that summarized reliability and criterion validity for seven questionnaires, 
reported a median validity correlation of about 0.3.23 All self report measurements of 
physical activity seem to suffer from the inherent problem that people are not able to 
report this kind of behavioral aspects correctly. Probably more profits can be gained 
with a daily registration by the patient of physical activity. Another option could be to 
include the opinion of a direct partner of the patients in the reporting of daily activities.   
A remaining question is: what should be advised for clinical practice? Which of the 
three instruments could best be used if no actometers are available? Although the 
Table 2: Sensitivity and specificity of the (API) (N=226) 
  Actometer typology  
  Passive N (%) Active N (%) Total N (%) 
Activity Pattern 
Interview 
Passive  34 (52.3%) 39 (24.2%) 73 (32%) 
Active  31 (47.7%) 122 (75.8%) 153 (68%) 
  65 (100%) 161 (100%) 226 (100%) 
Predictive value of a positive test  (sensitivity) PV+ =  34  /   65 = 0.523 
Predictive value of a negative test (specificity)  PV-  = 122 / 161 = 0.758 
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validity of the three instruments appeared to be the same, the percentage of correctly 
classified passive patients was the highest by the IPAQ (namely 70.1%, table 5). Given 
that fact that especially the unjust classification of passive patients as active should be 
minimized, since they do not recover,11 we advise to use the IPAQ in places where no 
actometers are available. 
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CHAPTER  4 
COGNITIVE BEHAVIOR THERAPY FOR CHRONIC FATIGUE  
SYNDROME DELIVERED IN A COMMUNITY MENTAL HEALTH 
CENTER: RESULTS OF A TRIAL IMPLEMENTATION 
 
 
Abstract 
Background: Prompted by the limited availability of effective treatment for patients 
with chronic fatigue syndrome (CFS) in the Netherlands, the present study investigates 
the prerequisites for successful delivery of CFS-specific cognitive behavioral therapy 
(CBT) within community-based mental health care.  
Method: In preparation of an implementation and effect study, various informative 
meetings and training courses were delivered to familiarize behavior therapists 
associated with GGNet, a regional mental health center (MHC) and local general 
practitioners (GPs) with the CFS-specific CBT programme. The CFS patients in 
GGNet’s catchment area were also informed of the treatment and newly referred 
patients were subsequently treated at the center’s two sites. Effects were analyzed 
using patient inflow and progress records, telephone surveys, validated symptom 
checklists and pre- and post treatment inventories, and semi-structured interviews with 
the therapists. Based on the obtained results critical criteria for future MHC 
implementation were formulated.  
Results: A sufficient number of adequately diagnosed patients were referred for 
treatment, although referrers did need repeated encouragement (additional information) 
to maintain referrals. Sufficient patients accepted the referral and, provided they were 
adequately motivated, treatment was successful. The number of therapists leaving the 
study was high, requiring extra therapists to be trained, which delayed the treatment of 
new referrals. Non-starter and dropout rates were also high and mainly attributable to 
the long waiting times and insufficient motivation of patients by therapists.  
Conclusion: If specified criteria are met CBT for CFS can effectively be delivered in 
community MHCs. Future implementations should allow for the most persistent 
bottlenecks identified. Whether the centers will be able to continue delivering treatment 
at the required level remains to be seen.  
 
Introduction 
This implementation report describes the first results and implications of a cognitive 
behavioral programme for chronic fatigue syndrome as delivered by GGNet, a Dutch 
regional community-based facility for mental health care.  
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Chronic fatigue syndrome (CFS) is defined as a serious, debilitating fatigue that does 
not resolve with (bed) rest, has persisted for at least six months and cannot be 
explained by any physical or psychiatric deficit or disorder.1 Although no single cause 
has been identified, several maintaining cognitive and behavioral factors have.2 Besides 
environmental factors these include a somatic attribution, low self-efficacy for the 
fatigue-related complaints, a heightened focus on bodily sensations and a low or 
deregulated physical activity pattern. These perpetuating factors are addressed in CFS-
specific cognitive behavior therapy (CBT), and controlled trials have shown that such a 
targeted cognitive-behavioural approach is the only effective treatment for the 
syndrome.3-5  
The current implementation project was prompted by the urgent need to expand the 
treatment capacity for CFS in the Netherlands.6,7 Up until 2003 the Nijmegen Expert 
Centre Chronic Fatigue (EFFC) was the only institute to deliver this targeted 
programme. As a specialized, tertiary facility, the ECCF’s treatment capacity is, 
however, limited. To cater adequately for the estimated 30,000 to 40,000 CFS patients 
in the Netherlands more regional treatment facilities are required that can offer tailored 
CBT.8 Expansion would also help reduce the high socio-economic burden resulting 
from the patients’ high medical care use and work absence. Based on an earlier 
inventory of potential implementation options6 our research group concluded that 
community mental health centres (MHCs) were the most feasible facilities for such an 
expansion. GGNet, located in the east of the country, was interested in enhancing its 
existing range of treatments and was found willing to take part in our study and take in 
the new target group.  
The main object of the present implementation project was to determine the 
prerequisites for successful further implementation of CBT for CFS in a MHC setting. 
We therefore sought to answer the following questions: 1a) Are referrers adequately 
informed about the new treatment option for CFS? 1b) What are the underlying reasons 
for non-referral? 2a) Are CFS patients sufficiently referred for CBT? 2b) How many 
referrals are inappropriate? 3a) How many referred patients leave prematurely? 3b) 
What are the main causes for dropping out? And finally: 4) Are specially trained 
behavioral therapists associated with MHCs capable of effectively delivering CBT for 
CFS?  
 
Method 
Implementation strategy 
In accordance with the model for implementation research proposed by Grol and 
Wensing9 we developed various implementation interventions based on a problem 
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 Table 1:  Implementation interventions 
Interventions Potential problems Intervention provisions 
 
Training and 
supervision of 
therapists 
 
As their main focus is on psychological 
and psychiatric syndromes, treating 
physical complaints is a novelty for 
community mental health centres 
(MHCs). The risk that MHC-based 
therapists would hence focus on 
concomitant psychiatric problems was 
deemed high. At worst, a comorbid 
psychiatric complaint a third of all CFS 
patients tend to present might be treated 
rather than the fatigue as such.  
 
 
During their training and subsequent 
supervision the selected behaviour therapists 
were repeatedly and explicitly warned about 
this risk. All therapists attended a four-day 
training course on the CBT Care Protocol 
for CFS and received two-weekly 
supervisory sessions for two years. The 
minimal requirement for participation was 
successful completion of a basic course in 
behaviour therapy as this has proven to be a 
prerequisite for effective transfer.  
Informing 
potential 
referrers 
1.As general practitioners daily receive 
abundant amounts of letters and mailings 
there was the risk that the letter we sent 
them would go unnoticed and remain 
unread.  
 
 
 
 
 
2. We knew there are GPs who think 
they are unable or who do not wish to 
diagnose CFS themselves.  
 
 
 
3. GGNet expressed concerns that GPs 
might refer ‘all kinds of difficult’ cases 
that they found hard to fathom. 
1. We accordingly opted for a repeat 
strategy exploiting different information 
channels. In addition, small-scale further 
training courses on CFS were organised 
conjointly with the ‘work groups on 
expertise enhancement’. Moreover, a 
referrers’ telephone helpdesk was set up for 
queries concerning diagnosis and related 
matters.  
 
2. When informing the GPs we hence 
explicitly stressed the importance of a CFS 
diagnosis and further provided them with 
transparent, scientifically proven data about 
the treatment. 
 
3. To preclude inappropriate referrals, 
before intake all referred patients were to be 
cursorily screened using several self-report 
questionnaires to confirm or refute the GPs’ 
diagnoses of CFS. 
 
Public 
informative 
meetings for 
potential 
patients 
Referral to an MHC might have a 
stigmatising effect for the patients. 
Especially the prevalent notion that CFS 
is a purely mental affliction might 
prevent CFS patients from following up 
their MHC referral. 
When informing CFS patients we tried to 
prevent or take away any biases by, among 
other courses, explaining the treatment in as 
clear terms as possible.  
Patient-oriented PR activities comprised 
press releases, dissemination of brochures 
via referrers and public organisations and 
notifications (advertorials) in (free) local 
papers. 
 
Informative 
meetings for 
GGNet staff  
If key figures in the organisation are ill 
informed, CFS patients might receive 
incorrect information or be offered 
inappropriate treatment. Since GGNet, 
the participating regional MHC, is a 
large organisation with two treatment 
sites, reaching all staff might pose 
problems. 
We hence chose to repeatedly offer GGNet 
staff comprehensive information through 
various presentations and written sources. 
We would, moreover, verify in the course of 
the process whether relevant staff members 
had meanwhile been informed or not.   
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analysis, to allow for the most likely bottlenecks and practicalities.7 Table 1 
summarizes the anticipated problems and the proposed interventions.  
The interventions comprised: a) selection and training of behavior therapists in CBT 
for CFS. Years of experience have shown that adequate delivery of this tailored 
program poses many problems with therapists requiring intensive training.10 b) 
Informing GPs and other clinicians about the new treatment option to induce them to 
diagnose and subsequently refer CFS patients. c) Informing CFS patients about the 
treatment to enable them to inform their GP and request a referral; and d) Informing all 
other parties involved about and familiarizing them with the new CFS treatment.  
 
Study design 
Trial implementation and subsequent evaluation study. 
 
Study time schedule 
The implementation project was conducted between 2003 and 2006. Behavior 
therapists from GGNet were first selected and trained. GPs were first informed at the 
end of 2003, shortly after which the first advance referrals and patients inquiries were 
received. Actual referral, intake and treatment of patients started in January 2004. All 
referrals received until the end of September 2005 were considered in our evaluations 
and in March 2006 the last CBT programs delivered within the framework of the 
present study were concluded.   
 
Treatment protocol 
The 16-session CBT program for CFS aims at full recovery with which we mean that 
after program completion patients should be able to function normally again.11 A return 
to work may be part of the treatment goals. At the start of the program the patient and 
therapist jointly define concrete goals all in terms of recovery. The following 
components are most commonly addressed: regulating the patient’s sleep-wake cycle, 
challenging and changing dysfunctional cognitions about fatigue and activity,12 
reducing the patient’s tendency to focus on bodily sensations, and adjusting activity 
levels contingent on the patient’s current pattern.13 ‘Passive’ patients will generally 
show little physical activity out of fear that their complaints will increase, whereas 
patients with a ‘fluctuating active’ pattern will regularly overexert themselves despite 
the negative consequences. In the first instance the program will usually start with an 
early, gradual and low-level step up of activities, while with the latter type of patients 
activity levels first need to be decreased before a new activity pattern can be trained. 
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The patient’s partner or any other significant other is also involved in the program. In 
the latter stages of the treatment relapse prevention is addressed. 
 
Patient assessment and selection 
Patients with a diagnosis of CFS as confirmed by a GP or other physician were 
included for CBT. The diagnosis implied that the fatigue and impairments were both 
serious and had persisted for 6 months in the absence of any physical explanations.1 Co 
morbidity was not contraindicative for treatment unless it was prominent; in the latter 
case the co morbid complaints first needed to be addressed prior to CBT. Temporary 
contraindications for starting CBT for CFS were ongoing alternative treatments for 
fatigue or current legal procedures regarding disability claims.14 
 
Implementation evaluations 
• Referral process: In May 2005 when the information activities for referrers 
scheduled within the study’s framework had been concluded, GPs were requested to 
participate in a survey on CFS. All 452 GPs in GGNet’s catchment area received a 
short questionnaire probing the extent of their awareness of the new CFS treatment. It 
also inquired into their ideas and policy on the diagnosis and treatment of CFS.  
• Patient flow: At the two MHC offices records were kept of all CFS patients that 
were referred for treatment and these patient monitoring reports were sent to the 
researcher at the end of each week. As soon as these showed that large numbers of 
patients left the study prematurely during the waiting-list period, we decided to analyze 
the reasons for declining the offered CBT at GGNet. To this end we conducted a 
telephone survey among the non-starters in March 2006. 
• Evaluation of treatment effect: CBT outcomes were analyzed based on validated pre 
and post treatment questionnaires that all completers filled in. The threshold for 
recovery was set at a score <=35 on the ‘fatigue severity’ subscale of the Checklist 
Individual Strength (CIS 20)15 and a score >= 65 on the RAND Short Form subscale 
‘physical functioning’.16 
• Problems and bottlenecks: By using the monthly progress reports, identified 
setbacks and obstacles were charted and discussed on a monthly basis.  
 
Analyses  
To establish the efficacy of the implementation process the project group reached 
consensus about the relevant criteria: 1) At least 50% of all GPs in the area needs to 
have been reached and be aware of the new treatment option for CFS; 2) At least 50% 
of referred CFS patients must have acted on their referral to GGNet; 3) At least 150 
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CFS patients should have been referred; 4) Less than 15% of all referred patients were 
inappropriately diagnosed or referred; 5) Less than 30% of all starters drop out of CBT. 
The 150 mark for referrals mentioned in the third criterion was based on an estimation 
of the number of CFS patients in the region as well as on a threshold of 100 cases we 
set to allow a reliable assessment of predictors of treatment success or failure.7,17 
Results were analyzed using Chi-2 and T tests; all computations were conducted using 
SPSS version 14.00.  
 
Results 
Applied implementation interventions 
The interventions for referrers and CFS patients were effectuated as planned and 
prescribed. As regards therapist training and presentations for GGNet staff, the 
following modifications to the original arrangements were required: 
• Additional training of new therapists: In the course of the project four of the six 
initially selected behavior therapists left the project prematurely for various reasons 
(personal circumstances, prolonged illness, moving house, change of function within 
the organization) necessitating two additional training cycles which, inevitably, 
delayed the treatment of (newly) referred patients. Recruitment of new therapists who 
were willing to be trained took some time. After completion of their training, the 
therapist subsequently also needed time to build a caseload. 
• Additional information for GGNet staff: When an interim evaluation showed that 
not all GGNet staff were sufficiently informed, targeted steps were taken involving 
extra informative letters and meetings on CFS for all social psychiatric nurses affiliated 
with the local GP surgeries.  
 
Study results 
• 1a) Referrers’ awareness of CBT for CFS. Of the 452 GPs we contacted for our 
survey 301 GPs (67%) returned the completed forms. The data showed that 212 (70%) 
of the respondents had learned about the new CBT program through our activities, 84% 
of whom judged themselves capable of adequately diagnosing CFS, whereas this was 
73% for the GPs who had indicated to have missed our communications (Chi-2 test: 
p=0.02). Sixty-three per cent of the informed GPs further indicated feeling sufficiently 
capable to adequately inform CFS patients about their condition and the available 
treatments, which was 41% for the non-informed GPs (Chi-2 test: p=0.00). Our 
information strategy had thus augmented both the GPs’ awareness of the treatment and 
their knowledge of CFS. 
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• 1b) Reasons for non-referral. Between January 2004 and October 2005 99 GPs 
(25%) had referred at least one CFS patient for treatment, with an average of 1.4 
patient. Figure 1 depicts the ratios for the mentioned grounds for non-referral. Fifty-
four of the informed GPs gave ‘having seen no (new) CFS cases’ as the reason for the 
absence of referrals; 12 indicated that potentially eligible patients were already 
undergoing treatment with them or elsewhere; 9 judged treatment not (yet) opportune; 
4 deemed CBT unsuitable for their particular patients and 3 indicated that the patient 
had declined the referral. One third of the respondents failed to indicate a reason. 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 2a) Number of referrals. During the project’s official patient intake period (Jan. ’04/ 
Oct.’05) a monthly average of 6.8 patients was referred, ranging from 3 to 13 a month 
(totaling 143 patients in 21 months). This rate fell below the agreed threshold of 150. 
Referrals appeared to follow frequently shortly after our informative interventions. 
Figure 2 provides an overview of the monthly referrals and our PR activities, 
demonstrating the association of these activities with increments in referrals in the 
succeeding period.  
Our survey among the local GPs had shown that few patients turned down the referral 
for treatment at the MHC: only 30 of the 212 informed GPs (14%) indicated one or 
more of their patients doing so.  
• 2b) Inappropriate referrals. The GPs were well able to diagnose CFS: only 13 of the 
125 intake assessments (10.4%) yielded an incorrect diagnosis. As to the use of the 
referrer’s helpdesk at our expert center (also see Table 1), in 2004 on average 2 GPs a 
month called for diagnostic advice; in 2005 this rate had dropped to several a year.   
• 3a) No show, non-starter and dropout rates. Table 2 lists the number of patients that 
completed the CBT as well as the referred patients that failed to start with the program 
  Figure 1: Reasons for non-referral as reported by informed GPs (N=82)
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and those that dropped out. Most manifest (25%) are the patients that dropped out 
immediately after intake. In the course of the implementation period it became clear 
that the waiting times for intake and treatment became increasingly protracted 
especially after three of the original six therapists left the project almost at the same 
time and replacements needed to be found and trained. Further analysis uncovered a 
correlation between the two. The average waiting period between referral and intake 
was 7.3 weeks and between intake and treatment start another 4.8 weeks. The mean 
interval to intake for the non-starters (i.e. patients declining treatment after intake, 
excluding those who did not comply with the CBT inclusion criteria) proved, on 
average, to be three weeks longer than the interval for the starters, which difference 
was statistically significant (Chi2 test: p = 0.03). 
• 3b) Reasons for no show, non-start and dropout. Figure 3 charts the grounds for 
patients not appearing at intake and failing to start treatment. We were able to contact 
12 of the 18 ‘no show’ cases and 18 of the 28 non-starters by telephone to inquire after 
the underlying reasons.  
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Figure 2: Associations between PR activities for GPs and patients and referrals 
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The main reason for patients to not show up was that they had already found another 
suitable treatment or doctor. Their seeking alternative treatment was prompted by the 
long waiting times, which offered patients both the time and motive to look elsewhere 
for help. In the first year the waiting-list period from referral to start of the CBT had 
soon increased to an average of 12 weeks (SD 5.3 weeks), which increment was mainly 
caused by a) an inadequate scheduling and use of treatment slots and b) an unevenly 
distributed patient inflow. As to the first cause, the weekly patient monitoring reports 
showed that the time the therapists had allotted for CFS was seldom fully exploited, 
which seemed to be related to the way GGNet operated. Intake and treatment 
scheduling of new referrals was not centralized. Instead, at each of the two MHC sites 
each individual therapist indicated when they were available for a new CFS patient and 
Table 2: The number and ratios of ‘no show’ patients, incorrect diagnoses, non-starters and 
dropouts for the various stages of the referral-treatment process (N= 143) 
 
Number 
% of total 
referrals 
(N=143) 
% of referrals, 
excluding ‘no 
show’ (N=125) 
% of correct 
diagnosis 
(N=112) 
% of the 
completed  
CBTs (N=84) 
No show 18 12.6 %    
No CFS 13  10.4 %   
Non-starters 28   25.1 %  
Dropouts 12    14.3 % 
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thus scheduling was chiefly unsupervised. Although the problem became increasingly 
more manifest in the course of the study and the issue was addressed more than once, 
no improvements could be put in place. As to the second cause, the two MHC 
treatment sites were found to receive different numbers of referrals with a ratio of 3:2. 
Possibly, this was due to the fact that one of the sites was located more centrally in 
GGNet’s catchment area. The uneven distribution of new patients delayed treatment at 
the latter location while at the other there was a surplus in therapist time. In hindsight, 
in view of patient traveling time we should have opted for more centrally located 
treatment facilities.  
Non-starters mostly justified their decision by indicating that they thought the proposed 
CBT was ‘not suitable for me’, mostly expecting that the treatment to be too strenuous. 
It is plausible that the initial treatment information they received had been 
demotivating. Motivating patients with CFS is complicated because they tend to get 
easily discouraged by information about what the treatment entails for them in terms of 
demands and activities. Additionally, CFS patients with a pronounced somatic 
attribution style will not be easily motivated for a psychological treatment. Having 
explained the difference between causal and perpetuating factors2 while allowing for 
the patients’ attributions, patience and the right motivational techniques of the therapist 
are indispensable to persuade patients for identifying and look at their maintaining 
factors from this novel perspective. If the non-starters’ main justification for declining 
treatment (‘CBT does nog fit me’) had been handled with more care or more 
adequately in the initial stages, this might possibly have prevented several patients 
from abstaining from treatment.  
• 4) Treatment effects. Table 3 shows the proportion of recoveries. For recovery from 
CFS various definitions are in use.18 Based on the CIS fatigue score criterion (≤ 35) of 
the 72 patients having completed treatment 44 (61%) could be classified as having 
recovered. If daily life impairment as expressed by the RAND-36 physical functioning 
score (>65) is also considered, 41 (57%) could be denoted as recovered. However, 
recovery rates depend on the set of patients for which they are computed. Thus, the 
proportion of recoveries as based on fatigue symptoms and physical impairment ranged 
from 57% for the 72 completers to 37% for all 112 intention-to-treat patients seen at 
intake. Table 4 lists the pre treatment and post treatment fatigue (CIS) and physical 
impairment (RAND-36) scores for the various patient sets, with the notation that the 
average fatigue score for healthy individuals is 17.3 (SD 10.1) while this is 51.7 (SD 
4.6) for CFS patients.15 
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Discussion and conclusions  
Our evaluation of a first implementation of our CBT programme for CFS in a regional 
mental health facility yielded both favourable and unfavourable outcomes. To start 
with the latter, one of the major drawbacks was the disappointingly high number of 
patients that left the study prematurely, both after referral and after intake. Together 
with the lower than espected referral rate we were therefore unable to meet the 
threshold for completed treatments within the study period. Furthermore it caused the 
effects for the intention-to-treat cohort to be substantially lower than the effects for the 
completers.  
Our implementation was successful in that it induced a large volume of GPs to start 
diagnosing CFS and referring patients for CBT at the MHC. However, as mentioned, 
the number of referrals fell below the 150-threshold set for the evaluation, rendering us 
unable to compute predictors of treatment success or failure. The repeated PR 
interventions among potential referrers were sufficiently effective though to set off a 
large enough and continuous flow of referrals to allow all other components of the 
Table 4: Pre- and post-treatment fatigue and physical functioning scores 
 CIS Fatigue   RAND-36 Physical functioning 
 Intake Post treatment         Intake Post treatment 
 M (SD) Median M (SD) Median M (SD) Median M (SD) Median 
Completers 
(N=72) 
48.8 
(7.2) 50  
28.1 
(13.7) 25 
53.4 
(21.4) 55 
77.2 
(20.9) 85 
Completers incl. 
dropout (N=84) 
48.5 
(7.1) 50 
29.3 
(14.0) 27 
52.8 
(21.2) 55 
75.6 
(22.3) 85 
Intention-to-treat 
(N=112) 
48.7 
(7.1) 50 
35.4 
(15.3) 38 
53.5 
(23.2) 55 
69.1 
(25.6) 75 
Table 3: Proportion of patients classified as having fully recovered 
 Recovery according 
to fatigue cut-off 
scores 
Recovery according to 
fatigue and physical 
functioning cut-off scores 
Completers (N=72) 44 (61.1%) 41 (57.0%) 
Completers including dropouts (N=84) 44 (52.4%) 41 (49.0%) 
Intention-to-treat cohort (N=112) 44 (39.3%) 41 (36.6%) 
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implementation to go ahead. Moreover, the greater majority of the CFS patients that 
were referred for treatment had been diagnosed correctly.  
Another positive result was that, as far as we were able to establish on the basis of the 
data the GP and MHC offices provided, almost all referred patients accepted their 
referral to the MHC. Furthermore, the effects for the treatment completers were good, 
indicating that also therapists working in a non-specialist setting that had no previous 
experience in CBT for CFS were capable of delivering an effective treatment after 
adequate training and supervision.  
Together, the results allow the conclusion that community MHCs are suitable settings 
for delivery of CFS-specific CBT provided several conditions are met. Based on the 
current and earlier findings of our group we have drawn up criteria for effective 
delivery of our program (see Appendix 1). The criteria will allow the current positive 
results to be replicated and will help anticipate and possibly prevent the bottlenecks 
and problems we encountered in our pilot implementation.  
As regards patient referrals, analyses showed that it was a relatively small proportion of 
GPs, viz. 99 of the 425 regional GPs, which had actually referred patients. Given that 
GPs gave ‘not having seen patients with CFS’ as the main reason for the absence of 
referrals, we suspect that many CFS cases go undetected either because patients do not 
see their GP (any more) or because the GP fails to identify them as such. Continued 
efforts to raise the awareness of the possibility of CFS-specific CBT among patients 
and doctors are hence recommended. In addition, more time and money might be spent 
on more intense educational activities like further training courses for GPs and other 
clinicians or health professionals.  
In preparation of the present project our group had tried to find the most optimal setting 
for delivery of our tailored CBT. MHCs came up top, but of course also primary care 
psychologists, general hospitals and rehabilitation facilities might be considered. A 
more medical environment might, for instance, prevent the stigmatizing effects 
resulting from a referral to a mental health facility. On the other hand, such services are 
often limited in their capacity for more prolonged or monodisciplinary treatment 
schemes (which particularly applies to rehabilitation centers), and they might 
exacerbate somatic attributions in patients. In view of the ongoing advances in and 
changing views of our health-care system, we may not exclude these services as future 
CFS treatment sites.  
One important aspect that has so far not been addressed but does have great relevance 
for future implementations is the aspect of cost-effectiveness. Although with their 
randomized controlled trials (RTCs) Prins et al.19,20 already demonstrated that our CFS 
program in itself is cost-effective, this does not automatically imply that 
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implementation and delivery in clinical practice will be similarly favorable. This would 
require a controlled and randomized implementation study, which our study was not. 
We did calculate the costs associated with our implementation activities and treatment 
delivery itself, which revealed a post treatment drop in health and associated costs 
(including costs due to work absence) that fully compensated the costs for 
implementation and delivery. Finally, we need to mention the limited time-scale of the 
project, which prevented us from monitoring the activities of the two participating 
MHC sites longer. It accordingly remains to be seen whether in the longer term GGNet 
will be able to maintain quality of treatment unsupervised. As activities were 
monitored by an external researcher and the participating centers were aware of the 
final study evaluation, implementation conditions were reasonably ‘controlled’ 
throughout the project. Moreover, a project group in which GGNet managers were 
represented convened once a month to discuss problems and possible solutions. It 
would be preferable if the organization itself could monitor the process for a more 
extended period to see whether continued implementation will remain effective and 
result in a full institutional embedding of the new treatment, which will hence no 
longer require close scrutiny.21 
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Appendix 1. Prerequisites for successful implementation of cognitive behaviour 
therapy for chronic fatigue syndrome in community mental health centers.  
 
 
1.Careful selection, training and supervision of adequate numbers of therapists 
1a. Prior qualifications: When selecting therapists it is recommended to especially or 
only invite those therapists within the organization that have successfully completed a 
formally recognised, basic course on behavioural therapy as offered by the VGCt, the 
association of behaviour and cognitive therapists in the Netherlands. Experience has 
shown that such schooling and a VGCt candidacy for membership were prerequisites 
for a proper acquisition and adequate delivery of the CBT for CFS protocol.  
 
1b. Number of candidate therapists: To determine the number of therapists for training 
an accurate estimation of annual CFS diagnoses needs to be made. Two aspects 
warrant special attention. On the one hand numbers need to be controlled, as therapists 
need to see a sufficient quantity of cases to allow them to gain sufficient experience. 
On the other, numbers also need to allow for loss and turnover of therapists. Having to 
recruit and train extra therapists will needlessly prolong waiting times and increase 
costs. Accordingly, it is recommended to adhere to a ratio of one therapist for every 20 
projected referrals, which will amount to 7 to 9 therapists for averaged-sized MHCs. 
 
1c. Distribution of treatment sites: To contain patient traveling time and allow an even 
spread of patients it is advisable to also select therapists on the basis of location in the 
facility’s catchment area when feasible.  
 
1d. Training and supervision: Years of experience have shown that adequate delivery 
of CBT for the treatment of CFS can be problematical. Motivating patients, identifying 
and effectively challenging relevant cognitions, addressing the subject of recovery as 
the aim of the treatment, managing fatigue related pain complaints during sessions and 
dealing with co morbidity tend to pose the most problems. Adequate training, 
supervision and regular refresher or further courses are hence indispensable to ensure 
successful treatment delivery.  
 
2. Targeted information provision for referrers and patients  
2a. Essential information: At the start of the implementation process it is plausible to 
assume that few or none of the medical doctors in the region are familiar with the new 
CFS treatment. Furthermore, GPs and other clinicians will need to be instructed how to 
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identify and diagnose patients with CFS and learn to motivate candidates for treatment. 
As GP training programs in the Netherlands generally do not address aspects like these, 
GPs need to be provided with informative material detailing the new CFS treatment as 
well as instructional material focusing, among other topics, on diagnostic and 
motivational aspects.  
 
2b.Frequency and means of information provision: GPs are usually flooded with 
information and advertising material and letters you send may remain unread. To 
ensure the information actually reaches the GPs it is recommended to send material 
more than once using different means of communication.  
 
3. Adequately informed supporting staff to ensure appropriate patient handling 
3a. Tailored patient routing: A pilot study underscored the importance of having 
newly referred CFS patients be met by staff familiar with the new treatment option for 
CFS, who may, to some extent, also answer queries about the treatment.  
 
3b.Informing less directly involved staff: It has also proven important for other, less 
directly involved MHC staff to also be sufficiently informed of the newly introduced 
treatment option. As most MHCs have an extensive staff often located at different 
treatment sites, reaching all staff members may be complicated. Ideally, information 
and instruction activities should cover all staff at all sites and be repeated more than 
once. Intermediate evaluations testing who is and who is not informed are 
recommended.  
 
4. Reliable assessment of treatment effects 
Effect assessment: CBT for CFS aims at full recovery and hence does not train coping 
skills. To establish whether the treatment goal has been achieved and whether the 
MHC is adequately equipped to deliver effective treatments it is vital that each 
completed treatment as well as all follow-up assessments are evaluated by means of 
the same reliable and validated instruments. For patients and therapists adequate 
knowledge of standardized treatment results may both be useful and beneficial.  
 
5. Timely interventions to foster smooth patient flow 
5a. Limiting waiting times: The trial implementation demonstrated that prolonged 
waiting times coincided with higher no show, non-starter and dropout rates. As long 
delays and dropouts will have implications for subsequent stages of the 
implementation process (in terms of insufficient numbers of patients per therapist 
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impeding their experience with the programme, and a decrease of the mean treatment 
effect across referrals), a timely intake and prompt treatment is vital.  
 
5b. Adequate scheduling and use of treatment time: The trial implementation revealed 
that allocation and use of treatment time were deficient. It is therefore recommended to 
make firm arrangements about the number of hours therapists will be spending on CFS 
treatment in advance and to monitor the adequacy and use of the allotted time.  
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IMPLEMENTING COGNITIVE BEHAVIORAL THERAPY FOR 
CHRONIC FATIGUE SYNDROME IN A MENTAL HEALTH 
CENTRE: A BENCHMARKING EVALUATION 
 
 
 
Abstract 
Objective: This study evaluated the success of implementing cognitive behavioral 
therapy (CBT) for chronic fatigue syndrome (CFS) in a representative clinical practice 
setting and compared the patient outcomes with previously published randomized 
controlled trials (RCTs) of CBT for CFS.  
Method: The implementation interventions were: spreading information about the new 
treatment setting to GPs and CFS patients; training MHC therapists in CBT for CFS; 
and realizing organizational structuring at the MHC. Patient outcomes were 
documented with validated self-report measures of fatigue and physical functioning 
before and after treatment. The comparison of the treatment results with RCT results 
was done following the benchmark strategy.  
Results: 143 CFS patients were referred to the MHC, of whom 112 started treatment. 
The implementation was largely successful, but a weak point was the fact that 32% of 
all referred patients dropped out shortly after or even before starting treatment. 
Treatment effect sizes were in the range of those found in the benchmark studies.  
Conclusions: CBT for CFS can successfully be implemented in a MHC. Treatment 
results were acceptable, but the relatively large early drop out of patients needs 
attention.  
 
Introduction 
Chronic fatigue syndrome (CFS) is characterized by severe and unexplained fatigue 
that lasts for at least six months.1 It results in a strong reduction in physical and mental 
functioning.2,3 Systematic reviews have shown that cognitive behavioral therapy (CBT) 
and graded exercise therapy (GET) are currently the only evidence-based treatments for 
CFS 4-6 with improvement rates of around 70% and 55% respectively. CBT for CFS is 
only scarcely available in some specialist medical hospitals, hence many CFS patients 
have no access to it or can only start treatment after a waiting time of several years.7 
Therefore, as a step toward nationwide implementation, a pilot implementation and 
evaluation project was set up which took place in an outpatient mental health center 
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(MHC). The present paper focuses on the success of this implementation and on the 
treatment outcomes in patients.  
It has been demonstrated that, after training, CBT for CFS can effectively be performed 
by therapists who are inexperienced with CFS.8,9 The transportability of randomized 
controlled trial (RCT) results to clinical practice settings however has scarcely been 
studied as yet. So far only one study evaluated whether CBT for CFS can be delivered 
with the same effectiveness outside the RCT context.10 But this study was done in a 
CFS specialist clinic that had previously participated in a clinical trial of CBT for CFS.  
Since rigorous evaluations such as RCTs always imply controlled conditions, it is 
unclear to what extent their positive effects can be generalized to clinical practice.4,11,12 
Treatment effects may be more modest outside RCTs because of lower criteria for 
including patients and absence of direct access to CFS experts.12,13 This study therefore 
evaluated the treatment results of CBT for CFS in a clinical practice setting in 
comparison with previous RCT results.  
When performing a benchmark study, it is important that the treatment location that is 
being compared to a RCT condition represents a real practice setting. Shadish et al.14 
have formulated ten ‘clinical representativeness codes’ that can be checked to see to 
what degree a certain setting is ‘clinically representative’. These codes concern issues 
like the kind and heterogeneity of the patient problems, the referral route, or the 
connection with a research institute. In the present study a MHC was chosen as clinical 
practice setting because it has the right facilities and sufficient CBT therapists to 
perform the 16-sessions CBT for CFS treatments, and at the same time fulfils most of 
the Shadish criteria for clinical representativeness. 
Secondly, the present study aimed to evaluate the success of the implementation itself 
and to assess the problems that arose during the implementation process. Based on 
explorations of possible barriers to implementation the following implementation 
interventions were applied to create the basic conditions for successful implementation. 
Firstly, general practitioners (GPs) were informed, since none of the GPs in the 
concerning concerned were familiar with the availability of CBT for CFS in the MHC. 
Secondly, CFS patients themselves were informed. Since not all CFS patients are still 
visiting their GP after several years of illness, informing them directly might increase 
the number of CFS patients entering the MHC. The third intervention implied selecting 
and training behavioral therapists in CBT for CFS and making arrangements with them 
about the treatment procedures. Finally, many employees of the MHC that might get in 
contact with CFS patients needed to be informed to pay attention to and cooperate with 
the CFS implementation project. The process evaluation aimed to assess the impact of 
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these implementation interventions on the delivery of CBT to CFS patients and to 
analyze the problems that might occur during such an implementation process.  
 
Method 
Study design 
This study is a clinical evaluation of implementing CBT for CFS and a comparison of 
the clinical MHC treatment results with relevant RCTs, using the so-called benchmark 
strategy.12,15  
 
Treatment setting 
The MHC was a regional mid-sized institution located in the east of the Netherlands, 
covering mostly rural and some urbanized areas. It had locations in four separate sub 
regions, the CBT for CFS treatment was offered at two of them. This MHC was the 
main provider of mental health care in this area, offering services for the full range of 
problems and patients, both outpatient and inpatient.    
 
Patients and procedures 
Inclusion criteria for referral to the MHC were as follows: all patients had to be 
referred by a GP or another physician, had to be diagnosed by this doctor as CFS based 
on the CDC-94 criteria,1 should be 18 years or older and should not be engaged in a 
claim for disability-related benefits. This last criterion was an exclusion criterion since 
this is known to be a predictor for a negative treatment outcome.16 Patients were 
classified as CFS and included in this study if they scored at least 27 (which is the point 
of 1 SD above the mean score of healthy individuals) on the subscale ‘fatigue severity’ 
of the Checklist Individual Strength (CIS-20),17 and <70 on the sub scale ‘physical 
functioning’ or ‘social functioning’ of the Rand-36.18 The patient inclusion period was 
six months shorter (namely 20 months) than the implementation and evaluation period 
(26 months), so all included patients could finish their treatment in time.    
 
Implementation interventions 
• Informing GPs and CFS patients. Information letters and brochures were distributed 
repeatedly to all GPs in the surrounding regions, namely four times with time intervals 
of about four months. Additionally some small group education sessions about CFS 
were organized, and announcements about the new treatment setting were made in 
local newspapers. The focus was on informing GPs about the treatment possibility, to 
educate them about the diagnostic criteria for CFS and also to stimulate them to refer 
CFS patients. To inform CFS patients, brochures were spread among libraries, 
pharmacies, etc. and articles were placed in local newspapers.  
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• Training therapists. Nine behavioral therapists, three male and six female, took part. 
They were selected based on their prior education in CBT, and on their willingness and 
availability to participate one day per week during at least two years in this project. 
None of the therapists had previous experience with CFS. Their number of years 
working as a behavioral therapist varied from two to 13 years. At the start of the project 
two experts in CBT trained the therapists for CFS during two blocks of two days each. 
Additionally, the therapists were supervised every two weeks during two years.    
• Informing and instructing MHC employees. Employees directly involved in the 
project, like some secretaries and diagnostic assistants, were settled into the procedures 
and were asked to cooperate in the development of the patient flow design. Less 
involved employees were informed about the project and instructed whom to contact 
when having to do with a CFS patient.   
• Treatment protocol. The CBT for CFS treatment protocol has been described in a 
manual for therapists.19,20 It prescribes 16 one-hour sessions over a period of six to 
eight months. In the treatment first the model of perpetuating factors is being explained 
and the therapist attempts to motivate the patient for CBT. Next, fatigue related 
cognitions are being challenged to diminish somatic attributions, to improve sense of 
control over symptoms and to facilitate behavioral change. Parallel on this a structured 
physical activity program starts. After a regulating and gradual increasing physical 
activities a work rehabilitation plan is worked out. Patients without a paid job aim at 
rehabilitation in other personal goals. From the start patients define their own criteria 
for recovery and formulate personal therapy aims. The final sessions deals with relapse 
prevention and further improvement of self-control.   
 
Measurements  
• Treatment outcomes: treatment results were measured with validated measures for 
fatigue severity and physical functioning. Severe fatigue was measured using the 
subscale ‘fatigue severity’ of the Checklist Individual Strength 17,21 which has a high 
reliability (Cronbach’s α 0.92) and a good discriminative validity and is also used in 
two of the four benchmark RCTs.9, 22 Physical functioning in daily life was measured 
with the ‘physical functioning’ subscale of the Rand-36.18  
• Impact of the implementation interventions: to determine the impact of the 
implementation, ‘positive impact’ was operationalized with five separate criteria that 
were formulated in cooperation with the MHC project group members. These criteria 
were: (a) Sufficient GPs (≥50%) are informed by us about the new treatment setting for 
CFS; (b) The majority of CFS patients (≥50%) accepts their GP’s referral of the MHC; 
(c) Sufficient CFS patients (≥150) are referred during the project; (d) A limited number 
of these referred patients (≤15%) are falsely being diagnosed as CFS; (e) A limited 
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number of referred patients (≤30%) drop out of CBT. The number of 150 referred 
patients in the third criterion was based on the calculation of the number of CFS 
patients living in the implementation region, assuming a prevalence of 180 adult CFS 
patients per 100.000 and an incidence of 60 per 100.000 per year.5, 23 
The measurements related to these criteria were done as follows: (a) One year after 
starting the project a short questionnaire was distributed among all GPs in the 
concerning regions, which investigated how many GPs were informed about the new 
treatment setting and about how to diagnose CFS;24 (b) On this questionnaire GPs were 
also asked to fill in the number of their CFS patients that did not accept their referral to 
the MHC; (c) the number of CFS patients referred to the MHC was registered each 
week; (d) after the intake session, the patient filled in a questionnaire on the main 
complaints and criteria for CFS; and (e) the number of patients that showed up at 
intake, did not show up at intake, started treatment, did not start treatment, and that 
dropped out during treatment were also registered each week, and dates of these events 
were included.  
‘No show’ patients we called those patients who were referred and registered at the 
MHC, but did not show up at intake. ‘Not starting’ patients decided not to start 
treatment directly after the intake. ‘Drop out’ patients were those who ended treatment 
after at least one and maximum 11 treatment sessions. ‘Completers’ decided to stop 
treatment after 11 or more treatment sessions or finished the whole treatment. In cases 
of not starting and drop out both patient and therapist were asked to fill in a form about 
the reason for it. Additionally a structured telephone interview was held with 30 no 
show and not starting patients to further investigate these reasons.  
 
Problems during the implementation process  
These were measured and registered by a monthly diary, which was kept by the 
researcher and discussed with the project group every month. This diary contained 
aspects like the weekly registration of the numbers of referred and treated patients, the 
mean waiting time between referral and intake, the experiences of therapists and other 
people concerned with the project, and unforeseen problems like trained therapists 
quitting the project or organizational changes influencing the implementation process.  
 
Analysis 
• Treatment results. The recovery rate was analyzed by calculating the percentage of 
patients being clinically significant improved (CSI). Patients were defined as being CSI 
at post treatment if they had a reliable change index >1.96 on the CIS fatigue severity 
subscale, a fatigue severity score ≤35 and a Rand-36 physical functioning score ≥ 65.17 
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For missing data the method of last observation carried forward was used, indicating 
that intake measurements were used at post treatment.  
• Selection of the benchmark RCTs. In the most recent systematic reviews 
concerning treatment for CFS4-6 seven RCTs investigating the effect of CBT for CFS 
have been included 9,22,25-29 In this study, four of these RCTs 9,22,26,27 were included to 
create the benchmark. Our decisive criterion for including trials, additionally to 
methodological criteria that the reviews already adjusted, was homogeneity of the 
treatment manual.30 In the RCTs of Lloyd et al.25and Ridsdale et al.28 the therapy 
protocol counted only six to eight sessions within six to twelve weeks time. This is 
about half as much as in the other trials, which may partly explain why little effect was 
found. In the RCT of Whitehead and Campion29 treatments were performed by GPs 
instead of behavioral therapists. Table 1 gives the characteristics of the trials included 
in this study.   
• Creation of the statistical benchmark and comparison of the treatment effects: three 
of  the  four benchmark RCTs consisted of one  intervention condition  tested  against a 
control condition, one also had a support group condition.9 
 
 
 
 
 
 
 
Table 1. Comparison of the implementation study characteristics with the benchmark RCTs. 
 Implemen-
tation study 
Sharpe 
et al. 
Deale  
et al. 
Prins  
et al. 
Stulemeijer 
et al. 
Treatment characteristics 
    
Sessions 1 18 16 13 16 10 
Duration 6-8 months 5 months 4-6 months 6-8 months 5 months 
Therapists 9 non experienced 
3 
experienced 
1 
experienced 
13 non 
experienced 
2 
experienced 
Sample size     
Patients (N) 112   30 30 92 36 
Not starting  28 0 0 10 4 
Drop out 12 0 3 23 3 
Criteria 2 CDC criteria  Oxford criteria  CDC criteria CDC criteria CDC criteria   
Assessment scales 
    
Fatigue  CIS 20  
(8-56)  
Inclusion cut 
off >27 
Likert scale 
(0-10).  
No inclusion 
cut off  
Chalder fat. 
scale  (0-11) 
Inclusion cut 
off >= 40 
CIS 20  
(8-56) 
Inclusion 
cut off >40 
CIS 20 
 (8-56) 
Inclusion cut 
off >40 
Physical  
functioning 
SF 36 (0-100) 
Inclusion cut 
off <70 on 
physical or 
social funct.   
 
Karnofski 
(0-100). 
Inclusion cut 
off < 80  
SF-36 
 (0-100) 
Inclusion cut 
off < 83 
SIP 
 (0 - 5799) 
Inclusion cut 
off > 800 
SF 36 
 (0-100) 
Inclusion cut 
off < 65  
1  Number of performed sessions 
2  Inclusion criteria for CFS 
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For the purpose of this study only the outcome data of the CBT conditions were used 
(since the implementation study also included only a treatment group) to compose a 
benchmark indexing the mean change of CBT under RCT conditions. The primary 
outcome measurements used in the benchmark RCTs are shown in Table 1. Since the 
different outcome measurements could not be compared directly, uncontrolled effect 
sizes of all studies were calculated to standardize the treatment effects.30 Uncontrolled 
effect sizes obviously may inflate the effects of therapy as compared to conventional 
controlled effect sizes, since they do not control for spontaneous recovery. However, 
for the purpose of just comparing different study results it provides a useful measure. 
The calculation of the composite benchmark thus involved two steps: First 
uncontrolled pre-post effect sizes were calculated as (M Start - M End)/pooled SD. 31 
Second, an average effect size was calculated, taking into account the size of the 
patient group in the different trials.32 When outcomes were reported at multiple time 
points (e.g. post-treatment and follow up) we coded the effect size closest to the time 
interval of the other studies, which was about six months. The MHC’s effect sizes for 
fatigue severity and physical functioning were calculated using the same formula and 
on basis of intention to treat, as was done in the RCTs.  
 
Results 
Treatment results 
• Sample characteristics. Table 2 provides the sample characteristics of the 
implementation study and the four benchmark studies. Of the 143 patients being 
referred to the MHC 18 did not show up at intake and 13 appeared not to fulfill the 
criteria for CFS (Table 5). In four cases the fatigue and/or impairments were not severe 
enough, three patients yet had a possible somatic explanation their fatigue (two for 
obesity (BMI>40) and one for recently detected diabetes), three suffered primarily 
from depression, one was primarily addicted to alcohol, one had primarily pain 
complaints and in two cases the reason for rejecting the CFS diagnosis was not 
registered.  
The mean pre-treatment score on CIS-20 fatigue severity was 48.7 (SD 7.1), on Rand-
36 physical functioning 53.5 (SD 23.2), and on Rand-36 social functioning 39.1 (SD 
22.9). The mean total score on the SCL-90 was 162.4 (SD 39.1) and on the Beck 
Depression Inventory- Primary Care 33 patients (30%) were indicated as having co-
morbid depressive disorder. Pain medication was used by 97 patients (87%), 
antidepressants were used by 21 patients (19%). Overall patients attributed their fatigue 
more to physical than to psychological causes.  
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 Table 3. Percentages of significant improved patients and mean fatigue severity and physical    
 functioning scores before and after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
A remarkable difference did exist in CFS illness duration, which was longer in the 
MHC sample. Age, gender and marital status were not statistically different, except for 
the study of CBT for CFS in adolescents22 of course. No significant differences were 
found on any demographic characteristic or pre-treatment illness score between 
patients who did not start or not finish CBT or who finished the treatment.  
MHC treatment results. The mean number of treatment sessions of all 84 patients 
starting treatment was 14.5 (SD 5.6) varying from 3 to 31 treatment sessions. Table 3 
shows the mean scores of Fatigue Severity and Physical Functioning at intake and 
follow up. Table 3 also shows the percentage of patients being clinically significant 
improved after treatment. 
Table 2. Comparison of the implementation sample with the benchmark RCT samples.  
 
Implementa
tion study 
(N=112) 
Sharpe  
et al. 
(N=30) 
Deale 
 et al. 
(N=30) 
Prins 
 et al. 
(N=92) 
Stulemeije
r et al. 
(N=36) 
Years of illness 
(mean/SD) 5.5 (4.9) 2.8 (0.8) 3.4 (2.1) 4.9 (4.8) 1.4 
Age (mean/SD) 39 (10.2) 34 (9.1) 31(9.0) 36 (9.4) 16 (1.3) 
Gender (% M/F) 34% / 66% 40% / 60% 30% / 70% 24% / 76% 11%/ 89% 
Marital status (% 
married/cohabiting) 72% 63% 57% * 70% - 
Unemployed or not 
attending school 53% 87% 63% 46% 89% ** 
*   This percentage was not presented directly in the article, but was derived from the fact that 43% 
     were single.  
** Including partial non attendance 
Clinically significant 
improved patients (N/%) 
 
Fatigue 
severity score 
intake 
Fatigue 
severity score 
FU 
SF-36 score 
intake 
SF-36 score 
FU 
Mean SD Mean SD Mean SD Mean SD 
Finished 
treatments 
incl. drop out 
(N=84) 
46/ 
54.8% 48.5 7.1 29.3 14.0 52.8 21.2 73.6 22.9 
Intention to 
treat  (N=112) 
46/ 
41.1% 48.7 7.1 35.4 15.3 53.5 23.2 69.1 25.6 
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Figure 1. Mean non-controlled pre-post treatment effect sizes and confidence intervals of fatigue 
severity at the MHC and the benchmark RCTs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mean non-controlled pre-post treatment effect sizes and confidence intervals of physical 
functioning at the MHC and the benchmark RCTs. 
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Comparison of treatment effects. The non-controlled effect sizes of the implementation 
study and the benchmark studies are given in Table 4 and in Figure 1 and 2. The mean 
pre-post treatment effect size of the four benchmark studies for fatigue was: {1.02 
(Sharpe) + 2.05 (Deale) + (3*1.25 (Prins) + 1.83 (Stulemeijer)}/6 = 1.44 (95% 
confidence interval [CI] = 0.97- 1.89). This is somewhat higher than the effect size of 
fatigue in the MHC, which was 1.12 (95% CI 0.85-1.38). For physical functioning the 
mean pre-post treatment effect size of the benchmark studies was: {1.93 (Deale) + 3 * 
0.71 (Prins) + 1.19 (Stulemeijer)} / 5 = 1.04 (CI 0.63-1.44). This is again somewhat 
higher than the effect size at the MHC for physical functioning, which was 0.64 (CI 
0.38- 0.89). 
 
Impact of the implementation 
Table 5 provides the results on the research questions that defined the overall impact of 
the implementation. It reveals that three of the five sub questions  (1,2, and 5) got 
positive results and two (3 and 4) got results that did not meet the criteria for positive 
Table 4. Mean scores at intake and follow up and effect sizes of the 4  benchmark studies and 
the implementation study.  
 Sharpe et al. 
Deale 
 et al. 
Prins 
et al. 
Stule-
meijer  
et al. 
Statistical 
benchmark 
Implemen-
tation 
study 
Fatigue severity       
   Intake score    
   (M/SD) 
7.8  
(1,5) 
10.2 
(1,3) 
52.2 
(3.9) 
52.5 
(3.8)  48.7 (7.1) 
   Follow up  
   score (M/SD) 
4.7 
 (4.1)* 
     4.1  
   (4.0) 
42.0 
(10.9) 
30.2 
(16.8)  35.4 (15.3) 
   Pooled SD 3.1 3.0 8,2 12,2  11.9 
   Effect size 1.02 2.05 1.25 1.83 1.44 1.12 
   Confidence 
   interval 
0.47–
1.54 
1.40–
2.65  
0.93– 
1.56 
1.21– 
2.41 0.97-1.89 0.85–1.38 
Physical functioning      
   Intake score    
   (M/SD) 
71  
(3.3) 
25.5 
(18.9) 
1752 
(611) 
42.1 
(16.5)  53.5 (23.2) 
   Follow up  
   score (M/SD) Ng ** 
71.6 
(28.0) 
1285 
(703) 
69.4 
(28.0)  69.1 (25.6) 
   Pooled SD Ng 23.9 659 23.0  24.2 
   Effect size Ng 1.93 0.71 1.19 1.04 0.64 
   Confidence 
    interval Ng 
1.29–
2.51 
0.41–
1.00 
0.62–
1.71 0.63–1.44 0.38–0.89 
*     The follow up SD was not given in the article of Sharpe et al., it was estimated based on   
       the assumption that a SD at FU is in general about 2,8 times higher a SD at intake 
**   The article of Sharpe et al. did not give follow up data of the Karnofski, hence this study   
       was not included in the analysis of the benchmark effect size of physical functioning 
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impact. The high percentages of ´not starting´ and ´not finishing´ patients were the 
most problematic result. As can be seen in Table 6, of the 112 patients eligible for CBT 
only 72 finished treatment. In an additional analyze it was checked on what 
characteristics ‘not starting’ and ‘drop out’ patients differed from completers. The 
results showed no differences between these groups.  
• Reasons for no show, not starting and drop out. The main reason for no show and 
not starting treatment, reported by eight patients, was having found another doctor or 
(alternative) therapist. Seven patients thought to have a medical reason for their fatigue 
and hence thought they would not profit from psychological treatment. Another seven 
patients were of the opinion that the treatment did not suit them, mainly because it 
would be too heavy. The other eight patients had practical reasons. The main reasons 
for drop were the opinion that CBT was not the right treatment for CFS (four patients), 
experiencing too much pain or other complaints during treatment (four patients), and 
feeling sufficiently recovered after some sessions already (three patients).  
Table 5: Operationalisation of ‘positive impact’ of the implementation, formulations of the 
related sub-questions, and their results.  
Sub questions related to  
criteria for implementation Results on the sub questions 
1) How many general 
practitioners (GPs) were 
familiar with the new 
treatment setting for CFS 
after 1.5 year? 
1)  Of the 452 questionnaires that were send to all GPs 301 
were completed and returned, implying a response rate of 67%. 
Of these 301, 212 GPs (70%) remembered to have been 
informed by us about CFS and knew about the new treatment 
possibility 
2) How many CFS patients 
did not accept being 
referred to the MHC? 
2)  Thirty of all 212 informed GPs (14%) reported to have met 
one or more patients that did not want being referred to the 
HMC. In total this concerned 41 patients, which is 22% of all 
the 143+41=184 patients that were proposed a referral to the 
MHC by their GP. 
3) How many CFS patients 
were referred for CBT?  
3) During the 20 months inclusion period, 143 patients were 
referred for CBT. The number of patients being referred per 
month varied from 3 to 13.   
4) How many patients were 
diagnosed incorrectly or 
unjustly as CFS? 
4) From the 143 referred patients 125 actually appeared at 
intake, the other 18 did no show up at intake. Of these 125  
patients, 13 (10,4 %) turned out to be referred unjustly because 
they did not meet the CDC-94 criteria for CFS. 
5) How many patients 
finished treatment and what 
were reasons for not 
finishing treatment? 
5) From the 112 patients that showed up at intake and appeared 
to have CFS, 72 finished treatment, implying a total drop out 
rate of 36 %. Reasons for not finishing treatment are described 
in the text.  
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Problems during the implementation process   
• Loss of trained therapists. Within one year four therapists dropped out of the project 
for several reasons. Twice an extra training had to be organized and new therapists had 
to be found. Since this took several months, this loss of expertise lead to delays in the 
patients flow. 
• Long waiting list. During the first year the waiting times before intake were 
increasing and the second year they stayed on this level. The mean waiting time was 
7.3 weeks. Waiting time was significantly higher for ‘not starting’ than for starting 
patients, (M 9.5 weeks, SD 5.6 and M 6.8 weeks, SD 5.1 respectively, T-test p= 0.02).  
• Limited use of the time reserved for CFS patients. Therapists appeared not to use all 
the time reserved for CFS treatments. The problem was that although beforehand it was 
said that per therapist one day was reserved for CFS, in which they should be able to 
see 6 to 7 patients, in practice they saw only 3 to 6 patients per week. What we did not 
find out is whether this had to do with non-efficient use of time, or with just seeing 
more of the ‘usual’ non-CFS patients at the expense of CFS.   
• Long treatment duration. Therapists appeared to have difficulties with ending a CFS 
treatment within the prescribed 16 sessions, which also hindered the patient flow. We 
had not expected that deviations in number of sessions would turn out to be so large. 
Generally in RCTs, and also in the present benchmark RCTs, this issue does not 
become a problem.  
Extra analyses were performed to gain more insight in this problem. It turned out that 
especially among beginning therapists some treatments were long, up to maximum 31 
sessions. None of the therapists with some experience in CBT for CFS, having finished 
Table 6: Numbers of patients that were referred to the MHC, did not show up at intake, 
appeared to be referred unjustly, did not start treatment after intake, dropped out during 
treatment and finished treatment  (N= 143). 
Category of patients N % Remaining patients 
Patients being referred to the MHC 143   
‘No show’ patients not showing up at intake (% of  
the 143 referrals)  18 12.6 % 125 
‘No CFS’ patients, being referred unjustly (% of  
the 125 intakes) 13 10.4 % 112 
Patients that after intake decided to not start treatment 
(% of the 112 CFS patients after intake)  28 25.0 % 84 
Patients dropping out during treatment (% of the  
84 started treatments) 12 14.3 % 72 
Patients finishing treatment 72   
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5 or more treatments, used more than 19 sessions for a treatment. Analyses on 
predictors of treatment success did not reveal any relations except for pre-treatment 
fatigue severity. Neither treatment duration nor number of sessions correlated with 
treatment effect.  
 
Discussion 
The treatment results of CBT for CFS in a MHC compared quite favorably with the 
benchmark RCTs. The effect on fatigue severity at the MHC was comparable with 
previous RCT results, while the effect on physical functioning was somewhat smaller 
at the MHC. And overall, apart from the high levels of not starting and drop out 
patients, the impact of the implementation of CBT for CFS could be called successful.  
Because of the flexible prerequisites for patient inclusion, the treatment results are in 
fact quite remarkably. No strict minimum fatigue or physical impairment scores were 
required for participation, hence these complaints, especially on physical functioning, 
were initially somewhat mild compared to those in RCTs, providing a conservative test 
of pre-post comparisons. And if the MHC will manage to reduce the numbers of not 
starting patents in future, the treatment effects might even increase.  
The most worrying aspect of the implementation was the relatively high number of 
patients not showing up at intake and deciding not to start treatment after the intake 
(together more than 32% of all referrals). In the benchmark RCTs the number of 
patients refusing to start CBT was generally much lower. Namely, 2 of 62 (3%) refused 
RCT participation and 0 of 30 refused CBT after randomization in Sharpe et al. (1995), 
and 7 of 67 (10%) refused RCT participation and 0 of 30 refused CBT after 
randomization in Deale et al.27 The study of Stulemeijer et al.22 did not report any 
refusals. Only Prins et al. 9 had relatively higher refusal rates, namely 99 of 476 (21%) 
refusals to participate in the RCT and 10 of 92 (11%) refusals for CBT after 
randomization. Probably the Sharpe and the Deale study had lower refusal rates 
because they offered therapy from experienced ‘expert’ therapists, which was not the 
case in the trial of Prins et al. and in the present implementation study. One explanation 
might be that apparent experience of the therapist stimulates patients to start with CBT.  
However, the higher refusal rate after intake in the present study (25%) compared to 
the rate after randomization (11%) in the study of Prins et al. cannot be explained by a 
difference in therapist expertise.  In the MHC patients could have been motivated better 
during the intake session. The most reported reasons for not starting treatment were ‘I 
think this treatment does not fit me’ and ‘I think there is a medical reason for my 
fatigue.’ With the right and timed information about the treatment at least part of those 
patients could presumably have been convinced to at least try the treatment with CBT. 
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Looking back we conclude that ‘motivating CFS patients during the first contacts’ has 
got too little attention in training and supervision. MHC therapists are not used that 
they need to motivate patients for psychological treatment. We recommend paying 
attention at this point, in training as well as in supervision, in future implementation 
projects.    
In the present MHC benchmark study a clear connection could be seen between waiting 
time and this high rate of ‘lost’ patients. The loss of trained therapists and the 
shortcoming of the MHC to find new ones quickly, a limited use by therapists of their 
time reserved for CFS patients, and a long duration of treatments were all partly 
responsible for the increasingly long waiting times. These long waiting times on their 
turn appeared to facilitate patients to quit; it gave them reason and opportunity to look 
further for other treatments. Future implementation projects of CBT for CFS should 
therefore take care to minimize the waiting times.  
Regarding the selection of Benchmark studies the question may rise whether including 
the Stulemeijer study was sensible, since it is an adolescent’s study. Our reasons to 
include it are that the study of Stulemeijer et al.22 used the same and most recent 
version of the Dutch protocol 20 that was also used in this implementation study. Yet an 
adolescent study population of course has a lower age and shorter illness duration than 
adults do, which probably makes it incorrect to compare these studies. However, it has 
been demonstrated before that neither age nor illness duration do influence effects of 
CBT for CFS.27  
Concerning the MHC population characteristics, only illness duration was different, 
namely longer, compared to the three benchmark RCTs in adults. This is quite 
remarkable; one might just expect that specialized hospital settings attract patients with 
a severe, complex and longer during fatigue. Possibly there was a ‘reservoir’ of CFS 
patients with long illness duration in the MHC region that can have developed during 
the many years that no effective treatment was available. Since this reservoir might 
now have dwindled, CFS patients being referred to day and in the coming years 
probably have shorter illness duration.   
The present study fulfils most of the Shadish criteria for clinically representativeness.14 
Two criteria were not met, namely the ‘monitoring’ and the ‘therapist pre-therapy 
training’ criteria. However, training therapists inexperienced with CFS is quite usual 
and also promoted by us, since treating a somatic complaint with CBT is new for most 
therapists working in a MHC. The monitoring included mainly supervising therapists, 
which is like pre therapy training, quite useful and always accompanies a training of 
CBT for CFS. Only the monitoring aspects like measuring treatment results, registering 
the reasons for drop out, and reporting the problems during the implementation process 
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contradicted full clinical representativeness. Overall though, from our point of view the 
MHC setting is clearly clinically representative. This means that this study 
demonstrated that CBT for CFS is also effective after implementing it in the clinical 
practice of a MHC.  
The present study results contradict the results of the Quarmby et al. study, which 
found a discrepancy in treatment effect between their RCT and clinical results. But 
those effect differences might be explained by the fact that their RCT was extremely 
effective, which was the result of including only one specialized therapist who was 
very experienced with CFS.   
The question arises whether the treatment results will remain sufficiently also on the 
long term. Given the rather high turnover of therapists and other related persons, the 
treatment program might loose some of its strengths and effectiveness. Secondly, 
during this project the MHC knew an external researcher would evaluate it. In fact this 
makes the study less representative for clinical practice, although this is not a criterion 
that Shadish et al. defined. It might be interesting to perform a longer lasting but much 
less confrontational and less visible study, to investigate the ‘lifetime’ and development 
of a CBT for CFS implementation project after the first years of the research period 
have been past.   
To conclude, the results of this study suggested that implementing CBT for CFS in an 
MHC can be successful and that treatment results were comparable to RCT results. The 
positive outcome should facilitate the decision for health care providers to adopt CBT 
for CFS in their institution so that more CFS patients can get a chance to recover after 
years of illness.  
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CHAPTER  6  
IMPLEMENTING COGNITIVE BEHAVIOR THERAPY FOR  
CHRONIC FATIGUE SYNDROME IN MENTAL HEALTH CARE:  
A COSTS AND OUTCOMES ANALYSIS 
 
 
 
 
Abstract 
Background: This study investigated the costs and outcomes of implementing cognitive 
behavior therapy (CBT) for chronic fatigue syndrome (CFS) in a mental health center 
(MHC). CBT is an evidence-based treatment for CFS that was scarcely available until 
now. To investigate the possibilities for wider implementation, a pilot implementation 
project was set up.  
Method: Costs and effects were evaluated in a non-controlled before- and after study 
with an eight months time-horizon. Both the costs of performing the treatments and the 
costs of implementing the treatment program were included in the analysis. The 
implementation interventions included: informing general practitioners (GPs) and CFS 
patients, training therapists, and instructing the MHC employees. Given the non-
controlled design, cost outcome ratios (CORs) and their acceptability curves were 
analyzed. Analyses were done from a health care perspective and from a societal 
perspective. Bootstrap analyses were performed to estimate the uncertainty around the 
cost and outcome results.  
Results: 125 CFS patients were included in the study. After treatment 37% had 
recovered from CFS and the mean gained QALY was 0.03. Costs of patients’ health 
care and productivity losses had decreased significantly. From the societal perspective 
the implementation led to cost savings and to higher health states for patients, 
indicating dominancy. From the health care perspective the implementation revealed 
overall costs of  €5,320 per recovered patient, with an acceptability curve showing a 
100% probability for a positive COR at a willingness to pay threshold of € 6,500 per 
recovered patient. 
Conclusions: Implementing CBT for CFS in a MHC appeared to have a favorable cost 
outcome ratio (COR) from a societal perspective. From a health care perspective the 
COR depended on how much a recovered CFS patient is being valued. The strength of 
the evidence was limited by the non-controlled design. The outcomes of this study 
might facilitate health care providers when confronted with the decision whether or not 
to adopt CBT for CFS in their institution.  
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Background 
Chronic Fatigue Syndrome (CFS) is characterized by persistent or relapsing 
unexplained fatigue that lasts for at least six months and results in substantial reduction 
in previous levels of daily functioning.1 Causes of CFS have not been found and most 
patients do not recover spontaneously.2 Based on the CDC-94 criteria, CFS prevalence 
figures of 112 and 420 per 100.000 were found.3, 4  
Cognitive behavior therapy (CBT) has proven to be an effective treatment for CFS.5, 6 
Since the treatment of CFS with CBT has been available only in a few specialized 
university medical centers in The Netherlands, just a small minority of CFS patients 
can benefit from it. Nationwide implementation is needed to realize access to CBT 
treatment for all CFS patients. However, when decision makers have to judge whether 
such implementation is worthwhile and should be paid for, they need information about 
its costs and benefits for individual patients, the healthcare system and society.  
The number of cost effectiveness analyses (CEA) of CBT for CFS and chronic fatigue 
(CF) are few compared to clinical evaluations. One study performed a cost 
consequence analysis of CBT for CF in general practice compared to regular 
counseling by a GP. It reported that counseling was a less costly intervention than 
CBT, and that both interventions led to reductions in fatigue. But no overall cost-
effectiveness advantage was found for either form of therapy.7 Another study, 
concerning a CEA of CBT for CF,8 found similar cost effectiveness for CBT and 
graded exercise for CF. It also reported a high probability that these therapies are cost-
effective compared to usual care. A third study reported a CEA of CBT for CFS and 
found, although with some statistical uncertainties, that regarding a time horizon of 14 
months, total costs to society were lower for (ex) CFS patients that had followed CBT 
treatment than for those who had received usual care or guided support groups.9 Taken 
together these studies indicate that CBT for CFS or CF might be cost effective for 
society compared to usual care.  
Until now nothing is known about the costs and efficiency of implementing CBT for 
CFS in a clinical practice setting. It might be possible that the efficiency of CBT for 
CFS reduces if the implementation costs are high or if the treatment effectiveness 
reduces. The present study therefore evaluated the broader so-called policy costs and 
effects of a pilot implementation project in which CBT for CFS was made available in 
a mental health center (MHC). In a policy study all extra costs of implementing the 
treatment (like training therapists, informing GPs, organizing and meetings) are being 
included as fixed costs in the analysis, in addition to the costs and effects of just 
performing the treatment.10, 11   
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The MHC of this study was a regional middle-sized institution located in the East of 
The Netherlands, covering mostly rural and some urbanized areas. It had locations in 
four separate sub-regions and the CBT for CFS treatment was offered at two of them. 
This MHC was the main provider of mental health care in this area, offering outpatient 
and inpatient services for the full range of problems and patients.    
 
Methods 
Design  
The evaluation was a prospective, non-controlled before and after comparison in a 
MHC with an observation period of 8 months. 
 
Implementation interventions  
The implementation program contained four major interventions. First, six behavior 
therapists who were working in the concerning MHC were trained at the Nijmegen 
Expert Centre for Chronic Fatigue. They were selected on bases of their prior education 
in CBT and on their willingness and possibility to participate in this implementation 
project. None of these therapists had previous experience with CFS patients. Their 
number of years working as a behavioral therapist varied from two to 13 years. Second, 
because GPs in the region were not familiar with this new treatment setting for CFS, 
announcements were made in the media and information brochures were distributed to 
GPs. GPs could also order copies of these brochures for their waiting rooms. Third, 
informational interventions were performed that were directed at the patient population. 
These consisted of several media announcements and distribution of patient brochures. 
Fourth, employees of the mental health care institution were informed and, if 
applicable, settled into the project.  
 
Patients and treatment procedure 
Patients who attended the treatment were all diagnosed as CFS and referred to the 
MHC by their GP or a medical specialist. Inclusion criteria were as follows: a GP’s 
diagnosis of CFS (based on the CDC-94 criteria), not enrolled in a new claim for 
disability-related benefits, and being 18 years or older. After the first session the patient 
had to fill in several fatigue related paper and pencil questionnaires. At 8 months 
follow up, when treatment was finished, the questionnaire had to be filled in again. 
Before starting this study it was judged by the Nijmegen Medical Hospital Ethical 
Commission, who indicated no need for informed consent. 
To measure fatigue we used the Checklist Individual Strength (CIS20), which is a self-
report measure on a 7-point Likert scale for fatigue severity over the last two weeks. 
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The CIS has good reliability (Cronbach’s alpha varying from 0.83 to 0.92) and 
discriminative validity.12 Physical functioning in daily life was measured with the 
‘physical functioning’ subscale of the SF-36.13 This subscale is a validated 10-item 
scale with a score varying from 0 (maximum of limitations) to 100 (no limitations). 
The Euroqol-5d was used to measure quality of adjusted life-years (QALYs).14  
In some instances the questionnaire results contradicted the diagnosis of CFS. For 
example, when a psychiatric co-morbidity was found that could explain the severe 
fatigue. In such occasions treatment was not started and the patient was referred to 
another treatment program in the organization.  
The CBT treatment protocol prescribes 16 sessions in a period of 8 months.15 In this 
treatment, first the model of psychological and behavioral perpetuating factors of 
fatigue is explained to the patient. Then the patient formulates his or her goals for 
therapy. Afterwards the patient starts a structured graded activity program beginning 
with some daily minutes of walking or bicycling, which is tailored to their base line 
daily activity level. Subsequently, dysfunctional fatigue related cognitions are being 
challenged to diminish somatic attributions of fatigue, to improve a sense of control 
over symptoms and to facilitate behavior change. Finally a plan for work rehabilitation 
is outlined and worked out. Patients without a paid job focus on rehabilitation in other 
personal activities. The last session deals with relapse prevention and further 
improvement of self-control.  
 
Measurement and valuation 
1. Treatment implementation costs: Personnel costs, for therapists’ trainings, 
coordinating activities and monthly working group assemblies, were calculated by 
counting the total amount of hours that concerned people had invested and by 
multiplying these hours with personnel’s gross salary per hour, including 39% 
employers’ charges. For training and supervision only the hours that were actually 
attended were calculated, per person. The hours that people had spent on the 
implementation were counted retrospectively by interviewing concerned people. 
Traveling costs related to these activities were calculated by summing up the total 
amount of kilometers by car and counting  €0.16 per kilometer. Material costs for 
informing GPs and patients were determined by summing up all printing, copying and 
distributing costs of used materials. Accommodation costs were calculated as 10% of 
personnel costs.16  
2. CBT integral treatment costs: For the CBT for CFS treatments integral prices were 
calculated, implying that all direct (executing) and indirect (overhead) costs of the 
MHC for offering the treatment were included in the calculation. Total costs of 
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performed treatment sessions were determined by summing up all therapists, diagnostic 
assistants and secretaries invested time per treatment. For each patient the total number 
of attended therapy sessions was registered. Planned sessions that were cancelled less 
than 24 hours before the session were also calculated. Per session one hour of work 
was counted for a therapist. Per treated patient 15 minutes secretary work was counted. 
Per intake and per post treatment session 30 minutes work for a diagnostic assistant 
was counted. The personnel costs for secretaries and diagnostic assistants were also 
based on gross salary plus 39 % charges. Then, for overhead costs and building use, 
20% and 10% respectively of personnel costs were added to the personnel costs.16 
Treatment material costs were too small to count. 
3. Direct medical costs (apart from CBT treatment): Volumes of medical consumption 
were measured with a paper and pencil questionnaire that was filled in by the patient at 
base line and after treatment. Patients were asked how many visits that they had made 
in the previous six months to a GP, medical specialist, physiotherapist, psychologist, 
psychiatrist and alternative medical practitioner. Use of home care support (average 
hours per week in the last 6 months) hospitalization (number of nights in 6 months) and 
use of (prescribed and not prescribed) medication were also asked. To value patients’ 
medical consumption, cost prices were used as given in the Dutch cost analyses 
manual16 after recalculating them to the 2004 price level (Table 1). Costs of prescribed 
medication were calculated based on the Dutch indicated market prices per month 
based on ‘defined daily doses’. Six percent taxes and € 6,51 pharmacy costs per patient 
using medication were added to this market costs. Patients were asked to give a price 
indication per month of their costs incurred in purchasing over-the-counter medication. 
 
Table 1: cost-prices used to value the different health care volumes  (Oostenbrink et al. 2004) 
measured at patient level before and after treatment  
Health care volume Cost price 
General practitioner (per visit) €    20.39 
Medical specialist (per visit) €    63.99 
Physiotherapist (per visit)  €    22.96 
Psychologist (per visit) €  125.14 
Psychiatrist (per visit) €    88.81 
Non-physician alternative medicine practitioner (per visit) €    48.87 
Home care (per hour) €    21.90 
Informal home support (per hour) €      8.38 
Hospitalization (per night) €  333.40 
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4. Direct non-medical costs: For each CFS patient traveling costs for attending the CFS 
treatment sessions were applied. Distances from patients’ homes to the MHC’s 
treatment location were found at www.routenet.nl. This distance was multiplied by 
each patient’s total number of attended sessions. Again €0.16 per kilometer was 
calculated. 
5. Indirect non-medical costs: Patients’ lost productivity costs due to absenteeism from 
paid work were also measured with the paper and pencil questionnaire. The 
questionnaire contained questions about work and daily activities, based on the ‘Health 
and Labour Questionnaire’.17 The number of hours of paid work in the last two weeks 
was filled in. We valued the days of absenteeism from paid work with Dutch standard 
productivity costs specified for age, sex and education level16 and using the human 
capital method. Transfer payments related to occupational disability insurances were 
not included since these are neither a gain nor a cost to society.10 The productivity costs 
per two weeks were then multiplied by 13 to provide the costs per 6 months.  
Informal care was measured at baseline and after treatment with a paper and pencil 
questionnaire about the number of hours per week that patients had received informal 
care. This was costed at € 8.38 per hour,16 the wage rate for a cleaner. Time costs for 
patients attending the treatment sessions were excluded.  
 
Economic evaluation method 
• Perspective. Total costs of implementing CBT for CFS were analyzed both from a 
societal perspective (including also non medical costs such as traveling expenses and 
productivity costs, regardless of who carried them) and from a health care perspective 
(indicating that only medical costs were relevant).10 For the societal perspective we 
calculated costs per gained QALY. For the health care perspective instead we 
calculated costs per recovered patient, being a measure of health rather than a measure 
of general welfare, which corresponds better to the more limited scope of the health 
care perspective.18 
• Calculation methods. Total costs were divided into costs for implementing the new 
treatment facility (the fixed, so called ‘organizing’ costs), and costs for facilitating and 
using the CBT for CFS treatments (the variable, so called ‘executing’ costs).19 Fixed 
costs were related to assembly and organizing activities of the working group, 
informational interventions towards GPs and the public and training and supervising 
the initial therapists. Variable costs comprised of: (1) Costs for continuing the 
treatment facility, comprising of repeatedly providing training and supervision for new 
therapists (we assumed that because of personnel turnover every two years two new 
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therapist need to be trained and supervised) and continuing PR activities; (2) Costs for 
patients attending the treatment sessions (e.g. traveling costs); (3) Costs for organizing 
and facilitating the treatments (mainly labor costs); (4) Societal costs (including use of 
healthcare services other than CBT and lost productivity costs due to absenteeism from 
paid work) and (5) Costs for performing the treatment program (time for therapists 
performing the treatment sessions, costs for building use, etc).  
Because the time period between costs and effects was less then 12 months, we did not 
apply the principle of discounting. All costs were recalculated to 2004 by using the 
2004 ‘derivative cost-of-living index figures’.20 All cost prices included in the analyses 
were valued in terms of integral cost prices.16  
 
Calculation methods  
Total costs were divided into costs for implementing the new treatment (the fixed, so 
called ‘organizing’ costs), and costs for facilitating and using the CBT for CFS 
treatments (the variable, so called ‘executing’ costs).19 Fixed costs consisted of 
assembly- and organizing activities of the working group, several PR activities like 
informing GPs and public about the new treatment possibility and training and 
supervising the initial therapists. Variable costs comprised of: (1) Costs for continuing 
the treatment facility, comprising of repeatedly providing training and supervision for 
new therapists (we assumed that because of personnel turnover every two years two 
new therapist need to be trained and supervised) and continuing PR activities; (2) Costs 
for patients attending the treatment sessions (e.g. traveling costs); (3) Costs for 
organizing and facilitating the treatments (mainly labor costs); (4) Societal costs 
(including use of healthcare services other than CBT and lost productivity costs due to 
absenteeism from paid work) and (5) Costs for using the treatment program (time for 
therapist performing the treatment sessions, costs for building use, etc).  
Because the time period between costs and effects was less then 12 months, the 
principle of discounting was not applied. All costs were recalculated to 2004 by using 
the 2004 ‘derivative cost-of-living index figures’.20 All cost prices included in the 
analyses were valued in terms of integral cost prices.16  
 
Data analysis 
Missing data: in the original database an average of 0.5 cases per item were randomly 
missing because some patients had failed to answer all questions of a particular 
questionnaire. These missing data were filled in with the median value for the 
particular item. In the cases of missing data due to loss of follow up the method of last 
observation carried forward was used,21 indicating that intake measurements were used 
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as post treatment. Analyses were performed on basis of intention to treat; patients who 
attended an intake but did not start treatment and patients who dropped out of treatment 
were all included in the cost analyses.  
 
Cost and outcome calculations 
Given the non-controlled design of the present study, it did not fulfill the criteria of a 
‘full economic evaluation’,10 and hence the usually calculated incremental costs 
effectiveness ratios (ICER) could not be analyzed. Instead we calculated cost outcome 
ratios (CORs). CORs are concerned with the joint difference in costs and outcomes 
before and after (implementing and) performing a certain treatment.10 This ratio thus 
indicates the financial investment that is needed to gain a certain treatment effect, 
based on the assumption that autonomous change regarding the patients is negligible.  
The COR was calculated in two ways. The first was by defining treatment effect as 
‘percentage of recovered patients’ (health care perspective), and second by using 
QALYs as a measure for treatment effect (societal perspective). The recovery rate was 
analyzed by calculating the percentage of patients experiencing significant clinical 
improvement (CSI). Patients were defined as being CSI at post treatment if they had a 
reliable change index >1.96 on the CIS fatigue severity subscale,22 a fatigue severity 
score <= 35 and a Rand-36 physical functioning score >= 65.12 Quality of life was 
measured using utility scores of the Euroqol.14 This utility score, lying between 0 
(health state equal to death) and 1 (perfect health state), represents the QALY due to 
some intervention.  
Since the health care costs were measured over a period of 6 months, while the 
individual durations of treatment differed between 2.2 and 16.2 months, all medical and 
non-medical costs at follow up were extrapolated to the individually defined treatment 
period, before including them in the cost outcome analyses.  
Utility scores were measured two times, at intake and at follow up. Since the difference 
in utility scores between the two measurements was presumably reached gradually 
instead of at once, and because the duration of treatment differed per patient, the gained 
QALYs at post treatment were calculated as: 0.5 * (utility score post treatment - utility 
score intake) /12 * individual number of months of treatment.10 
 
Analysis of uncertainty  
Because it was presumed that, as usually, the measured medical costs would follow a 
skewed distribution, a normality assumption would be problematic when estimating 
confidence intervals. Therefore the non-parametric bootstrap method 23 was used to 
quantify the uncertainty of the calculated COR. In the bootstrap method this 
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uncertainty is quantified by plotting cost-effectiveness acceptability (CEA) curves by 
means of repeated re-sampling of the costs and outcome data (the bootstrapping), 
which generates a distribution of mean costs and outcomes of two situations.24 These 
distributions are then used to calculate the probability that one of the situations is the 
optimal choice, given a range of possible maximum values (ceiling ratio) that a 
decision maker might be willing to pay for a unit of improvement in outcome. Because 
the present study did not calculate cost effectiveness, we used the term ‘COR 
acceptability curve’ instead of ‘ICER acceptability curve’. 
 
Scenario calculation  
For both the societal and the healthcare perspective, the COR of implementing CBT for 
CFS in a MHC was also calculated for a period of 5 years.  
 
Results 
Descriptives 
Of the 143 patients that entered the MHC during the observation period, 18 ‘no show’ 
patients never showed up at the intake session. Since they only caused negligible costs 
they were excluded from this study. The remaining 125 patients were included. At 
intake 13 patients appeared not to fulfill the diagnostic criteria for CFS, these patients 
did not start treatment. Of the 112 patients that started treatment, 28 dropped out of 
treatment quickly after the intake session. Of the 84 patients that followed treatment 12 
dropped out half way or later and 72 finished treatment.  
 
Missing data 
At 8 months follow up 74 of the 84 treated patients filled in the questionnaire and 10 
patients failed to do this (7 drop out patients and 3 treatment completers). Of the 13 
‘non CFS’ and the 28 ‘non starting’ patients their intake measurements were used as 
post treatment, since no treatment effect was to be expected within less than 2 sessions.  
 
Sample characteristics  
Patients’ characteristics are shown in Table 2. Of the 77 patients (62%) that had a paid 
job (42 fulltime and 35 part time) 54 were actually working and 23 were on sickness 
benefit. 
 
Treatment characteristics 
The mean duration of the 84 performed treatments was 8.4 months (SD 3.3) and varied 
from 2.2 to 16.2 months. No relations were found between duration of treatment and
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   Figure 1: included and dropped out patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
several other variables, like treatment effect, decrease in medical consumption or lost 
productivity costs after treatment. The mean number of treatment sessions was 14.5 
(SD 5.6) and varied from 6 to 23 sessions.  
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up at intake 
143 - 18 = 125  
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treatment
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Table 2: Patient’s characteristics (N=125)  
Categorical variables (N / %) 
      Sex (man/ women) 42 (34%) / 83 (66%) 
      Higher education 51 (41%) 
      Having a paid job 77 (62%) 
      Married/ living together/ living with parents 98 (78%) 
Continuos variables M (SD) 
      Age 38.7 (10.2) 
      Duration of fatigue (years) 6.3 (7.0) 
      Fatigue severity (Cis20) 48.3 (8.0) 
      Physical impairment (Rand 36) 54.0 (23.4) 
      Social impairment (Rand 36) 41.5 (23.7) 
      Psychosocial well-being (SCL-90)  165.1 (42.1) 
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Treatment effects 
Effect based on fatigue severity: after treatment 46 of 125 patients (37%) were 
recovered. Effect based on Euroqol: the mean utility score at intake was 0.57 (SD 0.27) 
and post treatment 0.65 (SD 0.30) (Table 3).   
 
 
 
 
 
 
 
 
    
Costs results 
Table 4 shows the total fixed and variable costs of preparing and introducing the 
implementation of CBT for CFS, with a total of €90,765 and €59,300 respectively. The 
costs results of performing and using CBT (table 5) reveal that per patient a mean of 
€597 were spent per CBT treatment.  
Table 6 gives the amounts of medical care other than CBT treatment. These results 
were used for calculating all (non) medical costs (table 7). As can be seen, total 
medical costs decreased from €1,112 per six months before treatment to € 810 after 
treatment (95% CI -€784 to -€26). Total non-medical costs also decreased, from €1,249 
per six months before treatment to € 1,012 after treatment (95% CI -€813 to €271).  
In table 8 the figures on work and absenteeism are given, showing that the mean 
number of working hours according to contract had fallen from 16.4 per week before 
treatment to 14.9 after treatment (95% CI -5.4 to 3.2). The number of real worked 
hours however had risen from 9.3 before treatment to 11.4 hours per week after 
treatment (95% CI -2.6 to 5.5), implying that the number of lost productivity hours and 
its costs decreased, from € 218 per patient per week before treatment tot € 122 after 
treatment (95% CI -€173 to -€6).  
 
Cost outcome ratios 
From the societal perspective the mean societal costs per patient per six months were € 
8,030 before implementing CBT for CFS and € 6,869 after it (95% CI -€ 3.489 to € 
1,083). The mean gained QALY per patient was 0,03. Given the lower cost level and a 
higher health state of patients, the COR-estimate indicates dominancy. The five years 
scenario calculation analysis, in which the total amount of treated patients was upscaled 
Table 3: Mean utility scores at intake and 8 months follow up (N=125)  
 Intake Follow up Δ Follow up - intake 95 % CI P 
Mean (SD) 0.57 (0.27) 0.65 (0.30) 0.078 (0.028) 0.03 to 0.09 < 0,001 
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Table 4: Costs of developing and introducing the implementation of CBT for CFS, 
divided in fixed and variable costs. All volumes valued in terms of Dutch integral cost 
prices at the price level of 2004 (Oostenbrink et al., 2004).    
 Volume Calculated costs value per volume Costs 
Personnel costs    
 Fixed    
     Therapists 647 hours € 55.50 / hour € 35,909 
     Management 312 hours € 73.17 / hour € 22,829 
     Others 793 hours € 35.87 / hour € 28,444 
Total fixed   € 87,182 
Variable    
    Therapists 460 hours € 55.50 / hour € 25,530 
    Management 20 hours € 73.17 / hour € 1,463 
    Supervisor 266 hours € 62.52 / hour € 16,625 
    Others 6 hours € 35.87 / hour € 215 
Total variable   € 43,833 
TOTAL     € 131,015 
Material costs  
 
 
Fixed    
   Building use       10% of personal costs € 8,718 
   PR activities 2000 information letters and brochures € 1,705 
Total fixed   € 10,423 
Variable    
   Building use             10% of personal costs € 4,383 
   PR activities 2500 information letters and brochures € 1,983 
Total variable   € 6,366 
TOTAL    € 16,789 
Travelling costs  
  
Fixed     
   Therapists 3605 km € 0.18 / km € 649 
   Management 3328 km € 0.18 / km € 599 
    Others 1411 km € 0.18 / km € 254 
Total fixed   € 1,502 
Variable    
   Supervisor  5300 km € 0.18 / km € 954 
   Therapists 1275 km € 0.18 / km € 230 
   Management  40 km € 0.18 / km    € 7 
Total variable   € 1,191 
TOTAL    € 2,693 
TOTAL fixed costs  € 90,675 
TOTAL variable costs  € 59,300 
TOTAL DEVELOPING AND INTRODUCING COSTS € 149,975 
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Table 5: Mean costs per patient (in €) of using and performing CBT for CFS in mental health 
care (N=125) 
 Mean SD Median Max 
Personal costs of CBT treatment (only therapist 
costs) € 417 € 314 € 435 € 1,349 
Personal costs of CBT treatment (secretary and  
test assistants costs)  € 28 € 7 € 34 € 34 
Overhead costs and costs for building facilities € 143 € 101 € 146 € 442 
Patients travelling costs (return price) € 9 € 6 € 7 € 43 
TOTAL mean costs per patient of using and 
performing CBT for CFS € 597 € 424 € 628 € 17,892 
Table 6: Volumes of medical consumption (except CGT for CFS treatment) over a period of 6 
months measured at patients level intake and follow up, with the first column (N) showing the 
number of patients that had been using this form of healthcare (N=125) 
 Intake Follow up 
 N Mean (SD) Median N Mean (SD) Median 
Medical care       
GP (number of visits) 111 3.1  (3.7) 2 93 2.0 (1.9) 2 
Medical specialist (n.o.  
visits) 55 1.2  (1.8) 0 38 0.9 (1.5) 0 
Physiotherapist (n.o. 
visits)  29 3.8  (9.0) 0 23 2.7 (7.4) 0 
Psychologist (other than  
CBT for CFS)  22 1.0  (3.1) 0 13 0.4 (1.4) 0 
Psychiatrist (number of  
visits) 9 0.2  (1.2) 0 7 0.2 (1.2) 0 
Home care (hours per 6  
months) 21 26.9 (104.3) 0 23 22.7 (88.4) 0 
Hospitalisation (nights) 13 0.4  (2.0) 0 9 0.2 (1.5) 0 
Using prescribed 
medication (yes/ no) 92 77 %  87 72 %  
Non-medical care           
Informal home care 
(hours per six months) 37 
132.3 
(268.3) 0 33 
110.6 
(182.8) 0 
Altern. med. practitioner  
(n.o. visits) 30 1.0 (2.3) 0 21 0.8 (2.0) 0 
Non prescribed 
medication (yes/ no) 56 53 %  27 35 %  
 
104   Chapter  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to 3.33 times the amount of patients that were treated in the implementation period of 
1,5 years (also figure 2), revealed a greater than 90% probability for a favorable COR 
for all acceptability thresholds.    
From the health care perspective it was found that mean costs per patient per six 
months were € 1,117 before implementation and treatment and € 2,586 after it (95% CI 
€ 958 to € 1,876). Given the recovery rate of 37% the COR of implementing CBT for 
CFS was  € 5,320 per recovered  CFS patient. The  COR acceptability  curve  (figure 3)  
Table 7: Mean medical and non-medical costs per 6 months measured at patient level at 
intake and follow up (N=125) 
 Intake Follow up 
 Mean SD Median Mean SD Median 
Medical costs       
GP € 63 € 67 € 41 € 41 € 40 € 41 
Medical specialist € 77 € 103 € 0 € 58 € 95 € 0 
Physiotherapist € 87 € 202 € 0 € 62 € 181 € 0 
Psychologist € 125 € 377 € 0 € 50 € 172 € 0 
Psychiatrist € 18 € 107 € 0 € 18 € 95 € 0 
Home care  € 589 € 1,629 € 0 € 498 € 1,235 € 0 
Hospitalisation € 134 € 720 € 0 € 67 € 509 € 0 
Prescribed medicine € 19 € 50 € 3 € 16 € 52 € 3 
Non medical costs       
Alternative med. pr. € 56 € 114 € 0 € 39 € 94 € 0 
Non prescr. medicine € 52 € 121 € 0 € 25 € 53 € 0 
Informal homecare € 1,109 € 2,322 € 0 € 927 € 1,573 € 0 
Travelling costs € 32 € 32 € 23 € 21 € 28 € 11 
Total medical costs € 1,112 € 2,258 € 362 € 810 € 1,350 € 241 
Total non-medical costs € 1,249 € 2,396 € 112 € 1,012 € 1,822 € 72 
Table 8: Patient volumes of work and lost productivity costs per week (measured at 
patient level before and after treatment) (N=125) 
 Intake Follow up 
 Mean SD Median Max Mean SD Median Max 
Number of 
contract hours  16.2 16.3 10 40 14.9 16.2 7 40 
Number of real 
worked hours  
9.4 13.5 0 45 11.4 14.7 0 46 
Absenteeism in 
hours  7.4 12.3 0 40 4.1 8.8 0 40 
Lost 
productivity  
€ 218 € 392 € 0 € 1544 € 122 € 292 € 0  € 1544 
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shows that the probability that implementing CBT for CFS has a favorable COR is 
100% when the decision maker values a recovered CFS patient at least € 6.500.  
The 5 years scenario calculation (also figure 3) showed that the 100% guarantee for an 
acceptable COR was reached at the willingness to pay threshold of € 4.500. 
Figure 2:  Acceptability curve showing the probability that implementing CBT for CFS has a 
favorable cost outcome ratio over a range of willingness to pay regarding societal costs per QALY. 
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 Figure 3: Acceptability curve showing the probability that implementing CBT for CFS has a 
favorable cost outcome ratio over a range of willingness to pay regarding health care costs per 
recovered patient. 
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Sensitivity analysis 
In sensitivity analysis applied for the societal perspective, the costs for (informal) home 
care and productivity costs were varied. As also has been found in other studies7, 8 
(informal) home care appeared to cause major costs. Besides that questions may be 
raised about the accuracy of the measured amounts of home care. It is a difficult aspect 
to measure, for example the distinction between informal care and normal household 
activities is not clearly defined, both for researchers and for patients, especially if the 
informal caregiver shares a household with the patient.25 
Since patients have a tendency to overestimate their hours of informal care, we 
performed a calculation reducing informal home care to 50% and leaving it out at all. 
In a third calculation both informal and formal home care were omitted from the 
analyses. These calculations showed that if informal home care was omitted from the 
analysis, and when both informal and formal homecare were omitted, the probability 
that implementing CBT for CFS has an acceptable COR remained above 80% for all 
acceptability thresholds.  
In addition, two extra analyses were done, in which productivity costs were set to 70 % 
and to 30 % of the original base case level. This revealed a drop in cost savings of CBT 
to -€ 16,800 and -€ 18,730 respectively. It appeared that implementing CBT for CFS 
remained dominant at both the 70% and the 30% level.  
Finally, to get an impression of this study’s results when compensating for spontaneous 
recovery, an additional analysis was performed. This was done from the health care 
perspective, presuming a spontaneous recovering rate of 5%,2 implying a recovery rate 
due to treatment of 32%. It revealed that the COR would rise from € 5,320 to about  
€5,969 per recovered patient.  
 
Discussion 
This study has shown that from a societal perspective the cost outcome ratio (COR) 
after implementing CBT for CFS in a MHC was dominant compared to before. From a 
healthcare perspective the COR after implementation was more costly but also more 
effective than before, and the 100% probability that the COR is acceptable was reached 
at the willingness to pay threshold of € 4.500 is positive. Given that CBT is the only 
effective treatment for CFS and has been scarcely available until now, this is relevant 
information in favor of nationwide implementation. Although some studies have 
already examined the cost effectiveness of behavioral treatments for chronic fatigue 
(CF) 7,8 and for CFS,9 there has been no research into the cost effectiveness of such a 
treatment that also took into account the costs of designing the implementation 
interventions needed for implementing the treatment and the costs of actually 
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implementing the treatment in a non-academic setting. Such a study implies a less 
homogenous patient population and less control over the content of performed 
treatment sessions than an academic setting can guarantee.  
Concerning age and gender, the patient population was fully representative of the CFS 
population. Compared to other trials in the area of CFS, the baseline fatigue severity 
was a little lower and relatively many patients had a paid job.26,27 These differences 
could be explained by the fact that the treatment facility at the mental health care 
institution was more easily accessible. Patients may be recognized as CFS by their GP 
and referred to CBT in an earlier phase than patients referred (mostly by a medical 
specialist) to a specialized hospital setting.   
As was also found in earlier cost effectiveness studies,8,9 an overall lower use of health 
care facilities was measured after CBT for CFS than before it. This may be explained 
by the fact that during treatment with CBT patients are instructed not to use other 
treatments or medication and by the fact that when starting treatment all patients were 
diagnosed as CFS. Looking for a diagnosis and a lack of affective treatment are the 
main reasons for CFS patients’ high use of health care facilities.28 Concerning work 
productivity, fewer patients had a paid job after treatment than before, but the mean 
hours of paid work per week had increased after treatment. Given the short time 
horizon (8 months) the full influence of CBT for CFS on work productivity might be 
revealed to be larger and the impact on cost-effectiveness more pronounced.  
In this study we used a conservative method, last observation carried forward, in cases 
of missing data. This imputation method might have influenced the results in a 
conservative, negative direction. However the proportion of missing data was in our 
opinion rather small (<12%) thus the chance that significantly different results were 
obtained is small. 
A serious limitation of this study is it’s non-controlled before and after design, which 
implies that incremental cost effectiveness compared to a natural course control group, 
or compared to a guided support group controlling for any placebo effect, could not be 
analyzed. However, the incremental cost effectiveness ratio (ICER) of CBT for CFS 
compared to usual care was recently reported by Severens et al.9 The focus and 
contribution of the present study was primarily to investigate costs and consequences 
of implementing this evidence based treatment in a clinical practice setting. This is a 
relevant issue in bridging the gap between science and research, since proven (cost) 
effectiveness under laboratory conditions of RCTs does not guarantee the same in the 
practice field of health care. Both smaller treatment effects due to the less controlled 
situation and accompanying costs of including costs for implementing the treatment 
might change the cost-outcome ratio.    
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Another weak point in this study is the variable follow up time. Although the mean 
time period between intake and post treatment was 8.4 months, and analyses were done 
using this time horizon for all patients, the real time interval varied considerable. The 
problem hereby is that in fact we do not know what this implies for the results that 
were found. A strong point though is the fact that, besides the usual included medical-, 
productivity-, and patient related costs also protocol driven- and implementation related 
costs were included,29 giving a more complete and more relevant view on the cost and 
outcomes of providing nationwide CBT for CFS. 
 
Conclusions 
To conclude, the results of this study suggest that implementing cognitive behavioral 
therapy for chronic fatigue syndrome in a mental health center is feasible and 
advisable. This strategy appeared to be dominant (resulting in lower costs and higher 
health states) compared to the starting situation from a societal perspective. From a 
health care perspective the implementation also implied better health states, but also 
higher costs, and the probability of a positive cost outcome ratio depended on how 
much value is placed on a recovered CFS patient. The outcomes of this study might 
facilitate the decision for health care providers whether or not to adopt CBT for CFS in 
their institution.  
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CHAPTER 7    
 
DETERMINANTS OF HEALTH CARE USE IN CHRONIC FATIGUE 
SYNDROME PATIENTS: A CROSS SECTIONAL STUDY 
 
 
 
Abstract 
Background: Chronic Fatigue Syndrome (CFS) is associated with a high use of health 
care services. To reduce the related costs for patients and society, it will be useful to 
know which factors determine CFS patients amount of health care use. Little is known 
however about these factors.  
Method: The present study retrospectively performed cross sectional analysis to 
investigate possible factors determining CFS patient’s health care use. A total of 263 
CFS patients, derived from two subgroups (149 from tertiary care and 114 from 
primary/secondary care) participated. Health care use was measured with a 
questionnaire asking details on consumption over the past six months. Fatigue severity 
and physical functioning were measured with the subscale Experienced Fatigue of the 
Checklist Individual Strength (CIS-20) and the subscale Physical Functioning of the 
SF-36 respectively. Multiple regression analysis, T-tests and Chi-2 tests were 
performed.  
Results: The regression analysis revealed that, after controlling for patient 
characteristics (explaining 13%), fatigue factors added 4% predictive value and certain 
perpetuating factors of fatigue, including focus on bodily symptoms and attributions of 
fatigue, added another 5%. The analysis of subgroups revealed that, compared to the 
tertiary care population, fewer patients from primary/secondary care had visited a 
medical specialist (50% vs. 71%), used antidepressants (16% vs. 25%) and 
tranquilizers (3% vs. 18%) and had spend a night in hospital (7% vs. 10%). However, 
overall costs of health care between these subgroups did not differ.  
Conclusions: This study showed that illness duration, physical impairment due to 
fatigue, and psychological perpetuating factors of fatigue do determine the variance in 
CFS patient’s health care use. These results give clear directions for treating CFS 
patients and managing health care for CFS.  
 
Introduction 
Chronic Fatigue Syndrome (CFS) is characterized by persistent or relapsing severe 
fatigue that lasts for at least six months, leads to considerable reductions in daily 
functioning and can not be explained by a medical condition.1 CFS is associated with a 
high use of health care services, and hence with high societal costs.2-6 It has been found 
116       Chapter  7 
 
that 39% of the CFS population in the UK uses at least one type of prescribed 
medication and 71% of them receives informal home care.2 Jones et al.5 found that 
compared to non-fatigued controls, more CFS patients reported to use any kind of 
(un)prescribed medication (92% vs. 82%, p < 0.00), and to use more different types of 
medication (5 vs. 2, p < 0.00). In two earlier studies it was revealed that the mean of 
health-care visits per year that CFS patients reported was above 20.7,8 There are several 
reasons for CFS patient’s frequent use of health care services. First, in trying to get 
more certainty about their complaints, CFS patients might frequently visit GPs and 
medical specialists, but mostly go home again with the information that no medical 
cause for the fatigue was found. Second, many CFS patients do try a lot of different 
therapies, but most therapies that are available do not lead to recovery.9,10 Third, many 
CFS patients suffer from depression, anxiety or sleeping problems11 for which a lot of 
medication is being prescribed. 
Although CFS patient’s high use of health care services are familiar, little is known 
about the factors determining the individual decisions of CFS patients to seek or not to 
seek help.2,12 Knowing these factors might be of importance though when making 
decisions concerning treatment and management of CFS, for these factors then could 
get special attention in the treatment of CFS patients and in the organization of 
healthcare.   
There might be many factors that influence the use of health care services, such as 
illness related characteristics, personal characteristics, psychological mechanisms, 
social aspects, and financial factors.2 For the present study a selection of predictors was 
made, based on clinical experience and empirical research at the Nijmegen Expert 
Centre for Chronic Fatigue (ECCF). Vercoulen et al.13 have found that certain 
psychological factors are responsible for the perpetuation of severe fatigue in CFS, and 
they tested a model explaining the perpetuating processes. The concerning factors are: 
1) a high level of somatic attributions and a low level of psychological attributions of 
fatigue, 2) a strong focus on bodily symptoms, 3) a low self-efficacy towards 
symptoms of fatigue, and 4) a low level of physical activity. The model explains that 
attributing fatigue complaints to a somatic cause leads to low levels of physical 
activity, which in turn contributes to fatigue severity. Self-efficacy and focusing on 
bodily symptoms both have a direct influence on fatigue. In the present study we aim to 
investigate into what degree these factors also explain variance in CFS patient’s health 
care use. We assumed that these factors, by enhancing severe fatigue, might also lead 
to a higher use of health care services.  Additionally, we expected a direct influence of 
these factors on health care use. A high somatic attribution (and low psychological 
attribution) might stimulate patients to ask a GP for medication and for referral to a 
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medical specialist to find a somatic answer for the unexplained fatigue. Correlations 
between somatic causal attributions and increased health care use have been found in 
previous studies among patients with somatoform disorders14 and in the general 
population.15 Focusing on bodily symptoms is known to increase perceived pain16, 17 
and might thus stimulate the use of health care services. A low level of self-efficacy 
towards symptoms of fatigue might undermine patient’s own strengths to deal with 
complaints and may make them feel dependent on doctors. In the general population an 
absence of regular physical activity increases the risk for a lot of different acute 
complaints and (chronic) diseases that lead to medical consumption.18 Overweight and 
obesity, as frequently being a consequence of physical inactivity, was found to lead to 
more frequent visits to a GP and to higher use of prescribed medication.19  
Secondly, concerning possible differences between specific patient populations, the 
present study compared and analyzed the health care use of CFS patients referred to a 
primary/secondary care institution with that of CFS patients referred to a tertiary care 
institution. The hypothesis hereby was that patients selected at specialized tertiary care 
CFS clinics might suffer from more severe and longer existing fatigue and therefore 
might have a higher use of health care services than those referred to primary or 
secondary care.  
The research questions of the present study were: 1) To what extent do illness variables 
and the perpetuating factors of severe fatigue determine the volume of CFS patient’s 
health care use? 2) Is the pattern and volume of health care use of CFS patients in 
primary/secondary care different from that in tertiary care CFS patients?  
 
Method 
Patients and design 
The present study is a retrospective cross sectional survey based on two samples of 
CFS patients. A total of 263 CFS patients, aged between 15 and 72, participated. They 
were all enrolled between January 2004 and March 2006 at either a community MHC 
(N= 114) or at the Nijmegen Expert Centre for Chronic Fatigue (ECCF) (N=149). All 
patients fulfilled the CDC-94 criteria for CFS.1 The MHC was a middle-sized 
primary/secondary health care institution located in the East of The Netherlands and 
covering mostly rural and some urbanized areas. It offered mainly mental services for 
the full range of problems and patients, both outpatient and inpatient. The majority of 
CFS patients from the MHC (108 of 114) was referred by a GP. To investigate the 
second research question of this study, patients from this setting were compared with 
those from the ECCF. The ECCF is a tertiary care institution of the Radboud 
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University Nijmegen Medical Centre. At the ECCF the majority of CFS patients (92 of 
149) was referred by a medical specialist.  
 
Measurements  
Dependent variable: Health care use was measured with an elaborate questionnaire 
asking details about health care use over the past six months. It contained questions 
about the amount of visits to GPs, medical specialists, psychiatrists, psychologists, 
physiotherapists or alternative practitioners, about the mean amount of hours per week 
of (in)formal home care, of hospital care (number of nights and reason for hospital 
staying) and about medication use (categorized as antidepressants, pain medication, 
anxiety medication and tranquilizers). The patients filled in this questionnaire during 
their first visit to the clinic or MHC. Health care related traveling costs all were 
calculated by using mean distances to different health care services as derived from 
Oostenbrink et al.20  
Independent variables: Fatigue was measured with the subscale ‘fatigue severity’ of the 
Checklist Individual Strength (CIS-20).21 In this questionnaire, the patient is asked 
about the his experienced fatigue in the two weeks preceding the assessment. The 
fatigue severity subscale contains 8 questions scored on a 7 point Likert scale (range 8-
56). The CIS has good internal-consistency reliability (Cronbach’s alpha varying from 
0.83 to 0.92), test-retest reliability (0.86) and discriminative validity.22  
Impairment in physical functioning was measured with the ‘Physical Functioning’ 
subscale of the SF-36,23 which is a widely used generic health status measure. The PF 
subscale measures the extent to which health interferes with a variety of activities like 
sports, carrying groceries, climbing stairs and walking. It is a validated 10 item scale 
with a score varying from 0 (maximum of limitations) to 100 (no limitations) and has a 
good internal-consistency reliability (Cronbach’s alpha 0.93) and discriminative 
validity.23, 24 
Additional CDC-94 symptom criteria were measured with a short screening list 
summing up all CDC-symptoms (impaired memory or concentration, post-exertional 
malaise, un-refreshing sleep, muscle pain, multi joint pain, headaches, sore throat, and 
tender cervical or axillary lymph nodes) 1 and asking whether the patient had suffered 
from the symptom, if yes how often and how long. A symptom was scores as ‘existent’ 
if it existed for at least 6 months at least several times per week.  
Self-efficacy towards symptoms of fatigue is the factor that determines into what 
degree a patient believes he of she is able to control the symptoms related to the severe 
fatigue.13 It was measured with the ‘Self Efficacy Scale-28, which measures self-
Determinants of helthcare use    119 
 
efficacy specifically in relation to CFS complaints. The SES-28 consists of 7 questions 
on a 4 point Likert scale (Cronbach’s alpha for reliability 0.74).13  
Patient’s opinions concerning the causes of their fatigue were measured with the 
Causal Attribution List (CAL), which has been developed specifically for patients with 
severe fatigue. It presents 10 possible causes of the fatigue, distinguishing between 5 
physical and 5 psychological causes that are scored on a 4-point Likert scale. The CAL 
results in two scores, one for physical and one for psychological attributions. 
Reliability of this questionnaire ranges from 0.71 to 0.74.25, 22  
Focusing on bodily symptoms, which in CFS patients implies: paying much attention 
towards fatigue related bodily signals and sensations, was measured with the subscale 
‘somatization’ of the symptom checklist 90 (SCL-90) 22,26 This subscale consists of 12 
items scored on a 5-point Likert scale and has a good internal consistency reliability 
among CFS-patients.13  
Physical activity was measured with the ‘CFS-Activity Questionnaire’ (CFS-AQ). This 
questionnaire contains 10 questions about specific and concrete physical activities of 
the patient over a period of two weeks before the assessment. Each item is scored on a 
four point Likert scale. The CFS-AQ test-retest reliability is acceptable (Spearman’s ρ 
0,72).  
 
Control variables 
The relevant demographic factors age, sex, living situation and somatic co-morbidity 
were included as control variables. Somatic co-morbidities were verified in patient’s 
referral letters and/or derived from specific medication use. Diseases that fulfilled 
diagnosis of a chronic disease that were still existent at the time of this study and for 
which the patient had consulted a medical specialist, were coded as co-morbidity. Co-
morbidity was scored on a dichotomous scale.  
 
Analyses 
All different health care resources, measured both in hours, number of visits or number of 
nights, were first expressed in costs (€) to generate a common numerator. Calculation of 
these costs was based on prices as given in the Dutch manual for health care cost 
analysis.20 Table 1 shows the cost-prices used to value the different resource volumes. All 
costs were adjusted to the year of 2004 by applying the health care consumer price indices 
(CPI) to all medical recourses and the gross national product CPI to the unit costs of 
formal and informal home care.27  
Pearson’s correlations and multivariate linear regression analyses were then applied to 
investigate the association and (in) direct correlations between the independent variables 
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and total volume of health care use. The regression analysis was done in a three-step 
model, with model 1 including only the control variables, in model 2 the fatigue related 
illness variables were added and in model 3 the perpetuating factors of severe fatigue 
were added. Finally, Chi-2 and T-tests were performed to analyze the differences in total 
volume and in subcategories of health care use between the two patient samples. All data 
were analyzed using SPSS version 14.0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1: Cost-prices used to value the different health care volumes (Oostenbrink et al., 2004) 
Health care category Volume Cost price 
General practitioner Visit €    20.39 
Medical specialist Visit €    63.99 
Physiotherapist Visit €    22.96 
Psychotherapist Visit €  125.14 
Psychiatrist Visit €    88.81 
Alternative caregiver Visit €    48.87 
Home care One hour €    21.90 
Informal home support One hour €      8.38 
Hospitalisation One night €  333.40 
Table 2: Sample characteristics of the survey population.   
 
Total group 
(N=263) 
MHC 
sample 
(N=114) 
ECCF 
sample 
(N=149) T test  sign.  
Continuos variables M (SD) M (SD) M (SD) 
 
Age 37.9 (10.8) 40.0 (9.4) 36.6 (11.6) 0.02 
Illness duration 7.4 (79) 6.5 (5.8) 8.0 (9.1) 0.09   
Fatigue severity  50.2 (6.7) 48.8 (7.9) 51.3 (5.3) 0.00 
Physical functioning  52.3 (22.6) 52.4 (23.0) 53.2 (22.4) 0.94 
Focussing on bodily symptoms 288 (7.8) 27.7 (7.4) 296 (8.0) 0.05 
Psychological attributions 10.3 (25) 10.8 (26) 9.9 (2.5) 0.01 
Physical attributions 12.1 (2.5) 11.9 (2.5) 12.2 (2.4) 0.58 
Sense of control over symptoms 18.1 (3.2) 18.6 (3.1) 17.7 (3.2) 0.02 
Physical activity 28.3 (4.3) 41.8 (6.4) 40.9 (5.8) 0.25 
Categorical variables  (N/%) (N/%) (N/ %) 
Pearson 
Chi2 sign. 
Sex (female) 226 (75%) 77 (68%) 122 (82%) 0.01 
Somatic co morbidity (yes) 95 (32%)  31 (27%) 55 (37%) 0.09 
Marital status     0.06 
    Married/cohabiting 237 (79%) 112 (84%) 125 (75%)  
    Single/ widowed 64 (21%) 22 (16%) 42 (25%)  
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Results 
Sample characteristics are given in Table 2. They are in line with previously described 
CFS-populations.3, 6, 9,10 As can be seen, the MHC and ECCF groups differed on several 
aspects, including age (MHC patients being older), sex (more female at the ECCF), 
fatigue severity (more severely fatigued at the ECCF), focusing on bodily symptoms 
(stronger focus at the ECCF), psychological attributions (more psychological 
attributions at the MHC) and self-efficacy  (more self-efficacy at the MHC).   
 
Volumes and costs of health care use 
The volumes of CFS patient’s use of different health care resources are given in Table 
3. It shows that most doctor visits concerned GPs and physiotherapists, and by far the 
most hours of care were spent on (informal) homecare. Table 4 shows the total costs of 
health care utilization in six months, as calculated with the cost prices given in Table 
1. The higher costs per visit to a psychotherapist compared to a GP or physiotherapist 
(Table 2) make visits to a psychotherapist the highest cost carrier among doctor visits. 
Conform the high number of hours spent on formal and informal homecare; these were 
the most important cost drivers, as they accounted for 23% (formal homecare) and 
48% (informal homecare) of the total costs of health care use. 
 
Predictors of variations in health care use  
The results of the regression analysis (Table 5) show that, after controlling for 
demographic patient characteristics (Model 1), the fatigue factors (Model 2) added 4%  
Table 3. Volumes of CFS patient’s utilization of different resources of health care, measured at 
patient level over a period of six months. 
 Total group 
(N=263) 
MHC sample 
(N=114) 
ECCF sample 
(N=149)  
 Mean (SD) Mean (SD) Mean (SD) T test sign. 
General Practitioner (n.o. 
visits) 3.2 (3.2) 3.1 (3.5) 3.2 (3.0) 0.91 
Medical specialist (n.o. visits) 1.8 (2.2) 1.3 (1.7) 2.1 (2.4) 0.00 
Physiotherapist (n.o. visits) 3.4 (7.6) 3.6 (7.9) 3.3 (7.4) 0.70 
Psychotherapist (n.o. visits) 1.2 (3.1) 1.2 (3.0) 1.3 (3.3) 0.52 
Psychiatrist (n.o. visits) 0.3 (1.3) 0.2 (1.2) 0.3 (1.4) 0.77 
Alternative practitioner (n.o. 
visits) 1.3 (3.1) 1.1 (2.4) 1.4 (3.6) 0.44 
Hospital (n.o. nights) 0.4 (1.6) 0.3 (1.4) 0.4 (1.7) 0.69 
Home care (n.o. hours) 24.3 (71.9) 25.6 (78.6) 23.7 (68.2) 0.80 
Informal homecare (n.o. hours) 133.9 (246.2) 123.9 (220.7) 142.0 (265.2) 0.53 
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predictive value, and the perpetuating factors of fatigue (Model 3) added another 5%.  
Thus together the variables of the model added 9% to the explained variance in health 
care use above the 14% of the control variables. 
In Model 2 a longer duration of fatigue and more physical functioning appeared to be 
positively related to a higher health care use. In Model 3 a strong focus on bodily 
symptoms and a high self-efficacy towards fatigue symptoms showed a positive 
relation with a higher healthcare use, whereas psychological attributions showed a 
negative relation with healthcare use.  
 
Comparison between MHC and medical hospital (ECCF) patients  
Table 3 reveals one difference in amount of health care use between the two patient 
populations, namely a higher mean number of visits to a medical specialist (2.1 per 6 
months) among ECCF patients than among MHC patients (mean of 1.3 visits per 6 
months). As can be seen in Table 4, the mean costs for consultations to a medical 
specialist (€ 84,- in MHC patients vs. €134,- in ECCF patients) and mean costs for 
prescribed medication (€ 27,- in MHC patients and € 37,- in ECCF patients) showed a 
difference. The total costs of health care use did not differ between the two patient 
samples. 
 
Table 4. CFS-patient’s health care use in six months, expressed in costs, calculated based on  
the Dutch manual for cost analysis (Oostenbrink et al., 2004). 
 Total sample 
(N=263) 
MHC sample 
(N=114) 
ECCF sample 
(N=149)  
 Mean (SD) Mean (SD) Mean (SD) T test sign. 
General Practitioner € 64 (66) € 63 (70) € 65 (62)      0,92 
Medical specialist  € 112 (138) € 84 (111) € 134 (152) 0,00 
Physiotherapist  € 78 (175) € 83 (179) € 76 (171) 0,86 
Psychotherapist  € 150 (391) € 133 (369) € 163 (407) 0,52 
Psychiatrist  € 23 (116) € 20 (105 € 25 (125) 0,74 
Alternative practitioner   € 60 (145) € 55 (118) € 64 (163) 0,61 
Hospital  € 117 (518) € 97 (465) € 134(559) 0,54 
Home care  € 532 (1398) € 561 (1720) € 519 (1063) 0,81 
Informal homecare  € 1122(2375) € 1038 (1849) € 1190 (2222) 0,12 
Prescribed medication  € 33 (65) € 27 (56) € 37 (72) 0,18 
Non prescribed medication  € 56 (24) € 49 (116) € 60 (161) 0,49 
Total costs of health care 
use € 2347 (4883) € 2210 (4558) € 2467 (5024) 0,57 
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 Table 5: Linear regression analysis to predict health care use of CFS patients in three steps  
 (model 1, 2 and 3) (N=263). 
 B Standard 
Error B 
Beta Sign. 
Model 1 (socio-demographic control variables)     
   Age 29.07 9.06 0.23 0.01 
   Sex (woman) 817.17 219.21 0.22 0.00 
   Living situation (married/cohabiting)  568.27 207.47 0.17 0.02 
   Somatic co-morbidity (yes) 347.48 199.65 0.10 0.07 
   Patient group (MHC/ECCF) 166.51 192.81 0.05 0.40 
R2: 0.14     
F: 10.14 (p 0.00)     
Model 2 (fatigue factors added)     
   Age 26.78 9.52 0.18 0.04 
   Sex (woman) 647.94 221.46 0.18 0.01 
   Living situation (married/cohabiting)  663.58 206.95 0.20 0.03 
   Somatic co-morbidity (yes) 304.63 201.89 0.09 0.13 
   Patient group (MHC/ECCF) 306.95 197.67 0.10 0.12 
   Fatigue severity 28.83 16.13 0.12 0.08 
   Impairments in physical functioning 8.76 2.19 0.22 0.02 
   Illness duration 330.46 187.18 0.14 0.04 
   Number of additional symptoms CDC-94 - 51.59 54.80 - 0.06 0.35 
R2 change: 0.03 R2: 0.18     
F change: 2.49 (p 0.32); F: 6.51 (p 0.00)     
     
Model 3 (perpetuating factors of fatigue added)     
   Age 37.34 9.88 0.26 0.02 
   Sex (woman) 641.41 219.55 0.17 0.01 
   Living situation (married/cohabiting)  551.27 208.61 0.16 0.03 
   Somatic co-morbidity (yes) 270.78 198.68 0.08 0.18 
   Patient group (MHC/ECCF) 224.07 199.47 0.07 0.26 
   Fatigue severity 29.28 13.44 0.14 0.07 
   Impairments in physical functioning 6.40 3.20 0.15 0.76 
   Illness duration 308.57 196.43 0.09 0.09 
   Number of additional symptoms CDC-94 - 68.39 55.48 - 0.08 0.22 
   Control over fatigue symptoms 74.23 31.72 0.16 0.01 
   Focus on bodily symptoms 29.68 13.56 0.18 0.02 
   Physical attributions 7.88 38.66 0.01 0.84 
   Psychological attributions - 78.06 38.90 - 0.16 0.03 
   Physical activity   - 28.27 21.30 - 0.08 0.25 
R2 change: 0.05; R2: 0.23     
F change: 3.72 (p 0.03); F: 5.21 (p 0.00)     
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Table 6 shows the comparison of the numbers of patients using a specific type of health 
care. Fewer patients from the MHC population (50%) reported to have consulted a 
medical specialist compared to the ECCF population (71%). In the MHC population 
fewer patients reported to have used antidepressants (16% vs. 25%) and tranquilizers 
(3% vs. 18%) and that less of them reported to have spent a night in a hospital 
compared to the ECCF patients (7% vs. 10%). In none of the other health care 
resources differences between the two patient samples were found.  
 
Discussion 
This study showed that besides illness duration and physical impairment the 
perpetuating factors of fatigue ‘self-efficacy’, ‘focus on bodily symptoms’ and 
‘psychological attributions’ contribute to the explained variance in CFS patient’s health 
care use. Secondly, this study found that differences in use of health care services 
between CFS patients in tertiary and in primary/secondary care are limited. 
Table 6. Comparison of MHC patients (N=114) and medical hospital patients (N=149) on the 
number of patients using a certain kind of health care 
 Total 
sample 
(N=263) 
MHC 
sample 
(N=114) 
ECCF 
sample 
(N=149) 
 
 N (%) N (%) N (%) Chi 2 sign 
General Practitioner (yes or no) 275 (91 %) 124 (93 %) 151 (90 %) 0.52 
Medical specialist (yes or no) 185 (62 %) 67 (50 %) 118 (71 %) 0.00 
Physiotherapist (yes or no)   78 (26 %) 32 (24 %) 46 (28 %) 0.47 
Psychotherapist (yes or no)   68 (23 %) 32 (24 %) 36 (22 %) 0.63 
Psychiatrist (yes or no)   24   (8 %) 13 (9 % ) 11 (7 %) 0.45 
Alternative caregiver (yes or no)   78 (26 %) 34 (25 %) 44 (26 %) 0.85 
Hospital (yes or no)   25 ( 4 %) 9 (7 %) 16 (10 %) 0.02 
Home care (yes or no)   43 (15 %) 20 (16 %) 23 (14 %) 0.45 
Informal homecare (yes or no) 104 (35 %) 43 (32 %) 61 (37 %) 0.37 
Prescribed pain medication (yes or no) 223 (74 %) 98 (73 %) 125 (75 %) 0.74 
Prescribed antidepressants (yes or no) 63 (21 %) 21 (16 %) 42 (25 %) 0.04 
Prescribed tranquilizers (yes or no) 33 (11 %) 4 (3 %) 29 (18 %) 0.00 
Prescribed anxiety medication (yes or 
no) 30 (10 %) 16 (12 %) 
14 (8 %) 0.31 
Non prescribed medication (yes no) 140 (46 %) 56 (42 %) 84 (50 %) 0.14 
*   =  number of patients that made use of this recourse category (and % of the total group of 263   
         patients)  
** =  under ‘consuming patents’ the mean and median were calculated for only those patients that made   
         use of the  concerning health care category as noted in column 1 (N/%) 
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The fatigue factors duration of fatigue and impairments in physical functioning 
appeared to be positively related to a higher health care use. Additionally, the 
psychological factors strong focus on bodily symptoms and self-efficacy towards 
fatigue symptoms showed a positive relation with a higher healthcare use, whereas 
‘psychological attributions’ and ‘physical activity’ showed a negative relation with 
healthcare use. In this results the directions of the predicting factors were all as 
expected, except for ‘self-efficacy’. Surprisingly, self-efficacy showed a positive in 
stead of negative relation with health care use. We checked the direct correlation 
between self-efficacy and health care use, which also appeared to be positive 
(Pearson’s R 0.12, p 0.04). It thus seems that using more health care services might 
form an aspect of, or is stimulated by, a high self-efficacy instead of being the result of 
a low self-efficacy. A recent study among elderly people also did not find the expected 
relation between higher ‘self management’ and lower demand for primary care.35  
Perhaps also surprisingly, fatigue severity itself showed no relation with health care 
use. This may be explained by the fact that within this population of CFS patients, as 
usual in those populations, all scores on fatigue severity were very high.  
Overall, the multivariate regression analysis allowed to explain 22% of the variation in 
health care use. In additional explorative analysis we saw that aspects like 
psychological well-being, sleeping problems, social support and also the variable 
‘referred to MHC or ECCF’ did not add any value to the total explained variance. This 
implies that still other factors yet unknown play a role. Previous cost of illness studies 
including prediction analysis, also in other than CFS patients populations, did until now 
scarcely explain more than a quarter of the total variance in health care use.2, 29-31    
The limited differences between the two patient populations, also in demographic 
sample characteristics, might be explained by the fact that the CFS treatment at the 
MHC was just new at the time this study was performed. In the MHC region possibly a 
pool of CFS patients with long during and severe fatigue had been developed during 
the many years that no effective treatment was available. Since this pool has now been 
shrinking, CFS patients being referred to the MHC to day and in the coming years 
might report less severe complaints, resulting in a larger difference between the 
populations in tertiary and primary/secondary care. A previous study in primary and 
tertiary care CFS patients also found limited differences however between these 
populations.12 Like in the present study they also found more physical illness 
attributions and a little higher levels of fatigue in tertiary care than in primary care CFS 
patients, but no differences in duration of fatigue and in pain severity or other 
complaints. As far as we know, no other study has compared characteristics of 
primary/secondary and tertiary care CFS populations. 
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Concerning the representativeness of our findings on use of health care services, 
McCrone et al.2 found similar percentages of CFS patients using different categories of 
health care services as we did. And Chisholm et al.32 reported that informal care 
accounted for about half of the total costs of chronic fatigue and CFS in general 
practice.  
This study did not include a control group from the general population, which could 
have made visible into what degree the volume of health care use among our CFS 
population was indeed so much higher than that of ‘normal’ people. Yet we can make a 
comparison, based on figures from the Dutch Bureau of Statistics.33  These tell that 73% 
of the general population visited a GP in 2005, 40% visited a medical specialist, 37% 
used prescribed medication and 40% used over the counter medication. All these 
figures, except possibly over the counter medication, are clearly lower than those found 
in the present study (Table 5). And since the CBS covered a period of a year and we 
covered half a year, in real practice the differences might even be bigger. Besides that, 
the mean age of the CFS population lies lower than of the general population, and age 
is one of the main predictors of use of health care services, thus compensating for this 
difference in age would even further increase the difference in health care use. Thus we 
may conclude that CFS patients use of health care services seems indeed to be, as was 
also found in previous studies, higher than that of the general population.5,34 
 
Study limitations 
A limitation of the present study is that it only included CFS patients who were already 
diagnosed as such by their GP or medical specialist. This might have influenced their 
health care use, since they no longer needed diagnostic research from medical 
specialists for example. Secondly, the assessment of patient’s use of health care 
services was based on patient’s recall; questions about accuracy may therefore be 
raised. Besides probable inaccuracy due to inadequate memory over the six months 
period, it might be possible that patient’s recalls were biased by factors like somatic 
attribution of complaints or self-efficacy if these make them more concerned with 
seeking help from doctors. Use of weekly or monthly diaries would probably, although 
not definitely have provided more reliable data.3 But on the other hand they may lead to 
much drop out and missing data. And health care records, another alternative method, 
do not provide information on informal health care and alternative practitioners, which 
both however form an enormous part of CFS patients total health care use.  
 
Future implications 
The results of this study confirm that regarding costs of illness, treatment and 
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management of CFS patients should regard and try to decrease not only fatigue and 
physical functioning itself but should also focus on bodily symptoms and somatic 
attributions of fatigue. Besides that, the finding that health care use does increase with 
longer illness duration implies that an effective treatment that prevents the continuation 
of severe fatigue for so many years might reduce CFS patient’s health care cost.  
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GENERAL DISCUSSION 
 
 
 
Main findings  
The studies presented in this thesis all stem from the project ‘Implementing cognitive 
behavior therapy for chronic fatigue syndrome in a mental healthcare setting’. The first 
study, among GPs in the implementation region (chapter 2), showed that repeated 
dissemination of written materials can be a useful method both for informing GPs 
about the diagnosis and treatment of CFS and for stimulating GPs to refer CFS patients 
to a MHC for CBT. In the evaluation study of the implementation project (chapter 4) 
the following results were found: CFS patients appeared to accept referral to a MHC to 
receive CBT for their complaints, and enough patients were referred to run such a 
project. A disappointing result was that a large number of patients dropped out before 
or shortly after the intake session(s). A long waiting time before intake and 
insufficiently motivating the patient for treatment during intake seemed to have caused 
this early dropouts. Despite these problems, intention-to-treat treatment effects were 
within the range of previous RCTs of CBT for CFS (chapter 5). The costs outcome 
ratio (COR) of implementing CBT for CFS appeared to be acceptable from a societal 
perspective (chapter 6) and is hence in favor of promoting further larger scale 
implementation.   
As far as the referring role of GPs, the acceptation of patients of being referred to a 
MHC, the treatment effects, and the cost outcome ratios are concerned, the 
implementation project can be considered as successful. But the high drop out of 
patients shortly after intake and the several difficulties that were encountered during 
the process were problematic aspects of the project and need attention in future 
projects.  
In this chapter, the results found in our studies will first be discussed against the 
background of national and international developments in the field of CBT for CFS. In 
addition, practical implications will be given for further implementations. Finally, 
suggestions for future directions of research will be made.   
 
International developments  
A comparable study in the UK 
As far as we know our study is the first and so far only one that has evaluated 
implementation of CBT fro CFS in a clinical practice setting. There is one recent study 
though 1 that resembles our study in that way that that it has evaluated whether CBT for 
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CFS can be delivered with the same effectiveness outside RCT context. Quarmby et al. 
compared the treatment results of a RCT performed by an experienced CBT therapist 
between 1993 and 1994 at King’s College CFS Research and Treatment Unit,2 with 
routine outcomes gathered from patients attending that same unit between 1995 and 
2000. Eleven therapists, of whom seven were clinical nurse therapists trained in CBT 
for CFS, performed the clinical practice treatments. Some had been working in the area 
of CFS for several years, and all had been qualified for a minimum of one year and 
received individual supervision by a supervisor familiar with CFS. In addition, one 
CBT trainee and three psychiatrists, all being familiar with CBT for CFS, were 
involved in the provision of treatments. 
The results of this study were disappointing, in the sense that they revealed significant 
lower treatment effects at follow up than found in the RCT it was compared with. 
During treatment the levels of fatigue reduced equally for both groups, but at the 6-
month follow-up the RCT participants showed significantly greater reductions in 
fatigue than the routine clinical practice patients. The author’s explanations for these 
results were, among others, a difference in patient population, routine clinical practice 
patients being significantly older and having longer treatment duration, which might be 
indications for less positive treatment outcomes.  
Another explanation was found in systematic differences between therapists. Treatment 
delivery for the RCT involved one experienced therapist who was also the main 
researcher and hence would have been highly motivated to produce a good result. In 
contrast, the therapists involved in routine care were less experienced and could have 
had varying degrees of motivation. A third possible explanation mentioned was the fact 
that in the RCT a treatment manual was followed, which was not the case in the clinical 
practice condition, although supervisors and therapists were ensured that the therapy 
proceeded through the same stages. Finally, according to the authors the high drop out 
level of patients in routine clinical practice (41%) might have restricted treatment 
effect, assuming that non-completers had already improved to the extend that they no 
longer needed a therapist. However to our opinion the most difficult patients might as 
well have dropped out.   
Although the study of Quarmby et al.1 and our implementation study 3 both contribute 
to expanding the research beyond RCT settings, there is an important difference 
between them. Whereas the first was done in an outpatient clinic that previously had 
participated in a clinical trial of CBT for CFS, our study evaluated the treatment results 
in a real clinical practice setting that was not familiar with research routines.4 Yet 
contrary to Quarmby et al. we found quite satisfying treatment results not significantly 
different from previous RCT results.  
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What could explain this different outcome? Possibly the treatment outcomes were not 
that different at all. Quarmby at al. used a higher standard, namely the RCT of Deale et 
al.,2 to compare their results with than we did. The study of Deale et al. had an effect 
size of 2.05 (CI 1.40-2.65) (calculated as (M Start-M End)/ pooled SD), and our 
benchmark effect size was 1.44 (CI  0.97- 1.89), which makes it difficult to draw 
straight conclusions. But comparing the treatment results of Quarmby et al. directly 
with our study revealed that the treatment effect of Quarmby et al. at six months follow 
up (effect size 1.05, CI 0.88 – 1.21) was only slightly lower than ours (effect size 1.12, 
CI  0.85 - 1.38), and lied within the confidence interval of our benchmark effect size. 
We conclude that CBT for CFS outside RCT settings is most likely to be clinically 
effective.  
 
Scarcity of implementation studies 
To our knowledge, no other publications on implementation or transferal of CBT for 
CFS have appeared besides our study and that of Quarmby et al.1 This scarcity of 
implementation studies is not limited to the field of CFS though. The problem of a 
‘gap’ between controlled trial research and clinical practice treatment also exists in the 
broader field of health care and treatment development. Study results suggest that the 
part of evidence based medical treatments that have found their way to clinical practice 
is that small, that about 30-40% of patients do not receive care according to most recent 
scientific evidence.5-7 Several hundreds of published controlled trials have focused on 
interventions to implement innovations in health care, but much of this research 
concerned educational interventions to improve specific aspects of prescribing drugs or 
preventive services.8 Controlled trials of organizational interventions to implement 
improvements tend to focus on health outcomes and costs, leaving professional 
behaviour and process of care a ‘black box’.9 Little of this research has focused on 
mental health problems, perhaps with the exception of depression. 
In the field of psychology, and especially CBT, quite some treatment manuals have 
been tested in RCTs,10-14 but their effectiveness under clinical practice conditions has 
been evaluated only in a minority of cases.15-18 Besides, widespread and consistent 
utilization of evidence based psychological treatment manuals is still lacking.19 This 
indicates again that implementation activities and evaluation studies are needed to 
realize successful uptake in the field. Our implementation study results might 
contribute to the identification of specific hindrances in the implementation of any 
treatment manual used in a MHC, especially for a ‘new’ patient population such as 
CFS. 
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Practical implications 
Independent implementation 
The project described in this thesis was designed primarily as a first step to determine 
the possibilities for further implementation. In this perspective it is important to realize 
that the results of this project were gained under the conditions of intensive support, 
including monthly project group meetings, the noticeable presence of a researcher, and 
timely interventions on the encountered problems. With the eye on future projects, an 
important question is: are MHCs also capable of independently implementing this 
treatment, without external guidance? The results of an independent implementation 
CBT for CFS should first be evaluated before it can be concluded whether nationwide 
implementation of CBT for CFS in MHCs should be performed.  
 
Implementation manual for MHCs  
To maximize implementation success of future independent projects we have 
developed a manual that MHCs can (and should) use as a guideline for the whole 
process.20 The manual has been written for MHCs who consider implementing CBT for 
CFS in their institution. First it shortly describes the experiences and results of the first 
implementation project, including the specific problems and solutions that were 
encountered in it. Then it specifies in detail the basic prerequisites and gives 
recommendations for successful implementation of CBT for CFS. A summary of these 
recommendations has been described in chapter 4 of this thesis. With this manual, 
future independent implementation projects can take preventive measures at the crucial 
problems and can profit optimally from the experiences encountered in the first project.   
 
Are the conditions that are required for successful implementation feasible? 
The experiences of the present implementation project suggested that successful 
implementation can be expected if the prerequisites as described in chapter 4 are being 
fulfilled. Hereby we tacitly assumed that these conditions could indeed be realized. 
However, concerning the problematic aspects like patient flow, long waiting times and 
high rates of ‘no show’ and ‘not starting’ patients (here together called ‘early drop out’) 
it is less sure whether MHCs are actually able and/or motivated enough to perform 
better in future projects. Waiting lists and (early) treatment drop out are well known 
problems in MHCs 21, 22 and thus are probably not easy to solve. Of the Dutch MHCs 
hardly any reliable data on drop out rates are available,23 but recent international 
studies conducted in MHCs show overall drop-out rates commonly oscillating between 
35 % and 55 %.24 Actually the rate of drop out found in the implementation project 
(total drop out rate of all referred patients 58/143 = 41%, total drop out rate of all 
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patients included for treatment 40/112 = 36 %) was relatively low compared to these 
figures.  
We conclude that some of the problems encountered in our project are quite typical and 
structural phenomena in MHCs. Hence it is really not sure whether MHCs are able to 
solve these problems within the time span of one implementation project.  
 
Best setting for implementation   
Given the above mentioned issues, the question again arises whether CBT for CFS 
could possibly bettter or easier be implemented in another setting. In 2000 several 
potential settings were compared and evaluated,5 that are also described in the 
introduction of this thesis. It turned out that MHCs had the best characteristics to offer 
effective CBT for CFS. To check whether all arguments found at that moment 
(2000/2001) are still valid, as several changes in health care have taken place since 
then, we will shortly reconsider this comparison:  
The main big disadvantages of general hospitals are still that most general hospitals do 
not have employed psychologists in sufficient numbers, and patients cannot be referred 
directly to psychologists by their GP.  
As far as primary care psychologists are concerned some developments have taken 
place. Their position has been reinforced politically and financially, and some more of 
them have been or will be qualified as cognitive behavior therapists. But still there are 
not enough primary care psychologists with a CBT certification. Still only short during 
treatments of maximum seven sessions are being repaid to the patient in primary care.  
In rehabilitation centers the main problem was that they only offer inpatient 
multidisciplinary treatments. Recently a debate has been going on about the possibility 
to also offer mono-disciplinary treatments, but to date as far as we know it has not yet 
been introduced.  
Another development is the intended wider implementation of practice nurses for 
mental health problems in primary care. These health professionals cannot deliver the 
full CBT for CFS, but they may have a role in treatment of minor cases of CFS, as part 
of a stepped care approach. 
Thus despite the problems in patient flow and early drop out, MHCs still seem to have 
the most advantages and the best profile for further implementation. However, since 
the organization of health care is developing quickly and continuously, pros and cons 
of different settings might change and it is not impossible that a future shift in best 
setting for implementation might occur. 
 
 
 138      Chapter  8 
 
Certification of therapists 
As mentioned in the general introduction, CBT for CFS is a difficult psychological 
treatment. Clinical experience has learned that behavioural therapists should have 
specific training and experience in CBT for CFS in order to be able to perform the 
treatment successfully.  
In the present implementation project it appeared that the formation and maintenance 
of a team of therapists with sufficient training and experience is difficult, because of 
the following factors:  
(1) Turnover of therapists. As experienced in the present project, once enough 
therapists are being trained and supervised this does not automatically guarantee that 
they remain available for several years. There is a risk of being left with insufficient 
qualified therapists. (2) Gaining (too) little experience with CFS. If therapists do not 
get enough CFS patients in their caseload (due to too few referrals of to 
mismanagement) they do not gain enough experience to learn how to overcome 
problems and difficulties that are typical in CBT for CFS. (3) Partial non-attendance at 
supervision sessions. It might be hard to find a time and place for supervision that fits 
all therapists. Partial non-attendance of these sessions is then a problem, with the risk 
of performing treatments without enough guidance and supervision. (4) Refraining 
from the assessment of treatment effects by formal tests. Therapists who are not used to 
perform pre- and post treatment measurements to evaluate the effects of therapy might 
easy forget to do this.  
During the present project these factors all appeared relevant, but they were under 
control due to intervening management by the project group. Several times extra 
actions were taken to make sure that enough therapists with sufficient training and 
experience were available. Concerns did arise though about the time after the 
implementation period, when control over these factors will be reduced and hence the 
continuation of a team of qualified therapists would not be guaranteed.  
Therefore a certification and re-certification program for therapists was developed and 
introduced by the ECCF. In the Netherlands the Association for Behaviour and 
Cognitive Therapy (VGCt) works with a certification program for therapists since 2000 
to optimise the professional quality of it’s members. This program prescribes that 
therapists should follow at least one day of education that is accredited by the VGCt to 
continue their membership for another 5 years. In the US, where certification and re-
certification are a well established process to control and maintain professional 
standards, a systematic review of studies published between 1966 and 1999 26 and a 
recent literature review 27 found positive associations between certification and quality 
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of healthcare outcomes across a range of clinical specialties and geographical locations, 
although all research was observational.  
The arrangement of CBT for CFS describes the minimum requirements that a therapist 
should fulfill in order to be certified for performing CBT for CFS. These requirements 
enclose the training prerequisites, namely (trainee) membership of the Dutch 
Association for Behaviour and Cognitive Therapy (VGCt), a 30-hours accredited 
training in CBT for CFS, and two years supervision in CBT for CFS in two-weekly 
sessions. Additionally, based on the above mentioned risk factors, it asks for: sufficient 
treatment experience (having finished 6 complete CFS treatments under supervision), 
keeping up to date knowledge about CFS (having joined a continuing educational 
meeting about CFS at least once a year), and performing good treatment evaluations 
(having evaluated every treated CFS patients at pre- and post treatment with CIS-20 
and the SF-36 physical and social functioning). Every 2 years the certificate can be 
prolonged if the therapist still fulfils the criteria.  
By the time the project was finished most therapists who participated in the pilot 
project fulfilled the criteria for certification, and got their certificate. The criteria for 
prolonging their certificates might guarantee that quality and effectiveness of delivered 
treatments remain at a high level also after the control’ of the implementation project. 
 
Recognition of CFS by GPs could possibly still be improved 
The referral of CFS patients elapsed rather well in the present project, in the sense that 
enough patients were being referred to continue the project. In most of these patients 
the diagnosis of CFS was made correctly by the GP. Still the question can be raised: 
Are now all CFS patients who could benefit from CBT for CFS recognized and 
referred by their GP?  
It is quite possible that despite our repeated information many CFS patients are still not 
being recognised or diagnosed and referred as such by their GP. In the first place, the 
estimated number of CFS patients living in the MHC implementation region as 
estimated beforehand 28, 29 is more than 5 times higher than the number of patients that 
has been referred during the implementation project. We do not know exactly if they 
were misdiagnosed and/or why they were not referred. GP’s most reported reason for 
not referring was that they did not see new CFS patients. This might mean they actually 
did not meet them because these patients did not visit their GP, but GPs might also just 
not have recognised these patients as suffering from CFS. Yet another reason might be 
that they did recognize them but did not diagnose them as such because they did not 
agree with the diagnosis of CFS, or did not refer them to the MHC because they have 
doubts about the treatment with CBT. 
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A second reason to assume a certain level of under recognition is the long illness 
durations of the CFS patients being referred to the MHC during this project. As 
mentioned in chapter 7, this might indicate that a reservoir of patients in the MHC 
region existed, of which the CFS patients with the most severe complaints have now 
been recognized and referred. It might be that at least part of all patients with shorter 
illness duration and less dramatic complaints did see their GP but were not labeled and 
diagnosed as CFS patients.   
Whether not recognized or not having visited their GP, the question remains: how can 
these patients be reached in future? One option is that the methods and frequencies of 
the informational interventions for GPs and for patients are being increased and 
intensified in future implementation projects. Another and possibly more effective way 
is the development and implementation of a national guideline for CFS. Such a 
guideline can help GPs to diagnose the right patients with CFS. Besides it can also 
influence the initiative of patients to go to their GP, as they know it will lead to an 
effective treatment. Finally, patients with CFS could be informed directly, so that they 
can ask for referral if they want. We will return to this issue later in this discussion.  
 
Future Directions 
Stepped care  
Concerning the cost effectiveness of implementing CBT for CFS the question might 
arise: are there probably more efficient (cost-effective without decreasing efficacy) 
ways of delivering treatments for CFS than individual CBT? For example: might group 
CBT or computer/ internet CBT be more efficient?  
The possibility of group CBT has been evaluated. Until now it appeared to have a low 
effectiveness.30, 31 Possible explanations were that group CBT is more difficult to 
perform than individual CBT, because patients reinforce each other’s dysfunctional 
behaviors or because the treatment cannot be individualized easily. Group CBT 
effectiveness might get improved when the reasons for its limited effectiveness have 
been detected. Before applying group treatment for CFS in MHCs further research has 
to be done concerning the improvement of this treatment, its cost-effectiveness that 
might demonstrate its efficacy.   
Recently it was tested in a RCT whether for a subgroup of patients a less intensive 
treatment would suffice.32 This intervention was based on the individual 16-sessions 
CBT protocol and consists of self-instructions combined with e-mail contact. The 
results were promising, as it appeared to be an effective treatment for relatively less 
severely disabled and fatigued CFS patients.  
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In a stepped care model, this minimal intervention might serve as the first step before 
the second step of individual CBT. With the eye on costs and cost-effectiveness it 
might be kept in mind in future implementation projects that this minimal intervention 
could also be implemented and tested in a clinical practice setting. However, 
concerning the selection of patients it is not known yet which patients, with what scores 
on fatigue and impairments, should be indicated for which form of treatment. This not 
only holds for the first versus second step in stepped care, but also for the second step 
(second line MHCs) versus a third line setting such as the ECCF or a rehabilitation 
center.  
Concerning third line settings such as the ECCF some might argue that in principle 
MHCs can take over the treatment for CFS patients as soon as sufficient larger scale 
implementations through over the country will have taken place. Would this then imply 
that the expert center (ECCF), that until now provides most treatments for CFS, would 
become redundant?  No. Actually, regardless of the type of setting of further 
implementation the assistance of an expert center is needed to deliver the right 
knowledge, training and supervision. Besides, knowledge centers fulfill a crucial role 
in treating the most difficult patients who show up with so much complicating factors 
that secondary care cannot deal with it. In this way the expert center fulfills the 
function of a third line setting. This does not only hold for the treatment of CFS. In 
previous years, apart from the ECCF, several expert centers in MHCs have developed 
in The Netherlands.33 They have formed a network, in which the ECCF also 
participates. The main aims of all these centers are: providing specialized patient care, 
performing scientific research on further refinement and development of treatments and 
delivering training and education. At the ECCF the specific patients groups for whom 
treatments have been developed and/or are being performed are chronically fatigued 
patients with or recovered from cancer and chronically fatigued patients with chronic 
diseases.   
 
Guidelines development  
Whereas implementation studies on treatment manuals itself are scarce, there is quite a 
lot attention for the implementation of multidisciplinary clinical guidelines.34-37 These 
guidelines are being developed with the aim to decrease the variability of treatment 
delivery and to increase the percentage of patients receiving effective treatment. They 
are concerned primarily with the indication of which treatment should be applied when 
and to which patients.  
As with treatment manuals, clinical guidelines do not automatically find their way to 
clinical practice. And for some professions, such as GPs in The Netherlands, 
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multidisciplinary guidelines need to be translated into monodisciplinary guidelines 
before effective dissemination can be expected. Hence several research projects have 
investigated and identified best methods, strategies and bottlenecks for implementing 
clinical guidelines or health care innovations in general 5, 6, 8, 38. Besides many studies 
evaluated the implementation of a specific guideline.39, 40 Regarding guidelines 
implementation it is still a challenge to achieve sustainable improvements, and avoid 
relapse of the improvements on a longer term. It requires well-trained and motivated 
health professionals, positive incentives for recommended procedures, and often 
(investment in) favorable organizational conditions.  
Multidisciplinary guidelines on the management of CFS have been published in 
Australia 41 and recently in the UK.42,43 In The Netherlands no specific guideline for the 
treatment and management of CFS is available yet and there is a large variation in the 
diagnosis and clinical management of patients with CFS or chronic fatigue. In 2005, 
the Dutch Health Council therefore advised the relevant institutes and societies for 
cooperation of to develop such guidelines. In 2007 the Institute of Healthcare (CBO) 
started to develop multidisciplinary guidelines for CFS.  Implementation of this 
guideline might promote the further implementation of CBT for CFS, as the demand 
for it grows.  
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SUMMARY         
 
The studies presented in this thesis all stem from the project ‘Implementing cognitive 
behaviour therapy (CBT) for chronic fatigue syndrome (CFS) in mental health care 
centers (MHCs)’.  
CFS is characterized by persistent or relapsing severe fatigue that lasts for at least six 
months, results in substantial reduction in previous levels of daily activities, is not 
substantially alleviated by rest, and is not the result of ongoing exertion or a somatic 
disorder.  
At the Expert Centre Chronic Fatigue (ECCF) a theoretically based bio-psychosocial 
model of CFS was designed and tested. Based on this model, a CBT protocol for CFS 
was developed and tested in a randomised controlled trial (RCT) and it proved to be 
effective.  
Since a huge shortage of treatment capacity of CBT for CFS existed, there was a need 
for expansion of this treatment. In a working group the possibilities for implementation 
in diverse organizations were investigated. The outcomes of this investigation led to the 
implementation project mentioned above and the studies described in this thesis.   
 
In chapter 1 a general introduction to the presented studies is given. Chapter 2 presents 
a study that investigated the impact of a repeated informational intervention among 
general practitioners (GPs) on their knowledge and attitudes towards CFS and on their 
actual referrals of CFS patients for CBT to the MHC. The GPs completed a short 
questionnaire survey on CFS knowledge and attitudes, and referral data were obtained 
from the MHC. The survey results showed that 70% of the GPs had remembered the 
intervention’s message about the new treatment possibility. It also appeared that the 
information had increased GP’s knowledge and positive attitude towards CFS. During 
16 months 22% of all GPs in the concerning region had referred at least one CFS 
patient. It was concluded that repeated dissemination of written materials is a useful 
method for stimulating GPs to diagnose CFS and to refer CFS patients for CBT.  
Effective treatment of CFS with CBT relies on a correct classification of so called 
‘fluctuating active’ versus ‘passive’ patients. Actometers are good and objective 
instruments, but they are too expensive and time consuming for clinical practice 
settings. It is especially important to recognize passive patients, since they do not 
recover when they receive the protocol for passive patients. The study described in 
chapter 3 evaluated three instruments to assess a CFS patient’s physical activity pattern 
as an alternative for an actometer. The three instruments were the ‘Activity Pattern 
Interview’ (API), the International Physical Activity Questionnaire (IPAQ) or the CFS-
Activity Questionnaire (CFS-AQ). Based on receiver operating characteristic (ROC) 
curves the validity of the three methods was compared. It appeared that al thee 
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instruments had the same and acceptable validity, but that the IPAQ was somewhat 
better in correctly predicting ‘passive’ CFS patients. It was therefore concluded that the 
IPAQ is the preferable alternative for an actometer.   
Chapter 4 evaluates the whole process and the results of the implementation project. 
Besides the main research question, concerning the prerequisites for successful 
implementation, the following sub questions are being answered: Are potential 
referrers sufficiently informed about the new treatment offer? What are possible 
reasons for not referring? Are sufficient patients being referred to realize the 
implementation and to continue the program? How many patients have been referred 
unjustly? How many patients dropped out of treatment and what are reasons for drop 
out? What are the treatment effects? The evaluation showed that implementation of 
CBT of CFS in a MHC possible and largely successful, but that some serious problems 
arose concerning the high drop out of patients. The chapter finishes with a summary of 
the main prerequisites for successful implementation of CFT for CFS. 
Although it has been demonstrated that CBT for CFS was effective, the transferability 
of RCT results from controlled RCT conditions to clinical practice settings had 
scarcely been studied. The study described in chapter 5 focuses on the treatment effects 
of CBT for CFS after implementation in a MHC compared to the previous RCT results. 
The comparison of the treatment results with RCT results was done following the 
benchmark strategy. Patient outcomes were documented with validated self-report 
measures of fatigue and physical functioning before and after treatment. It appeared 
that the treatment effect sizes after implementation were in the effect range of those 
found in the benchmark studies. The conclusion was that implementation of CBT for 
CFS leads to sufficiently successful treatment results.   
In order to let decision makers judge whether implementation of CBT for CFS is 
worthwhile, they also need information about its costs and benefits. Cost effectiveness 
analyses of CBT for CFS are scarce and did only address the costs of performing the 
treatment. The study presented in chapter 6 evaluated the costs and outcomes of the 
implementation project, analyzing both treatment- and implementation costs. Analyses 
were done from both a health care and a societal perspective. After treatment costs of 
patient’s health care and productivity losses had decreased significantly. Implementing 
CBT for CFS in the MHC appeared to have an acceptable cost outcome ratio (COR) 
from a societal perspective. From a health care perspective the COR depended on how 
much a recovered CFS patient is being valued.  
One of the main expenses for CFS patients is their frequent and intensive health care 
use. Nothing is known yet about individual characteristics that contribute to their high 
health care use. Chapter 7 investigates a study that retrospectively performed cross 
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sectional analysis to investigate possible factors determining CFS patient’s health care 
use. A total of 263 CFS patients, derived from two subgroups (149 from tertiary care, 
namely the ECCF, and 114 from primary/secondary care, namely GGNet) participated. 
Regression analysis revealed that, after controlling for patient characteristics 
(explaining 13%), and fatigue factors (adding 4% predictive value) some perpetuating 
factors of fatigue, namely ‘sense of control over fatigue symptoms’, ‘focusing on 
bodily symptoms’ and ‘psychological attributions of fatigue’ added another 5%. The 
costs of health care between two subgroups, namely primary/ secondary care (GGNet) 
versus tertiary care (ECCF), did not differ.  
In chapter 8 the results found in our studies are discussed against the background of 
national and international developments in the field of implementation of CBT for 
CFS. In addition, practical implications for further implementation are given and 
suggestions for future directions of research are made.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMENVATTING            
 
 
De studies die in dit proefschrift beschreven staan komen allen voort uit het 
‘Implementatieproject cognitieve gedragstherapie (CGT) voor het chronisch 
vermoeidheidssyndroom (CVS) in de geestelijke gezondheidszorg  (GGZ)’.  
CVS wordt gekenmerkt door aanhoudende of telkens terugkerende ernstige 
vermoeidheid die ten minste zes maanden aanhoudt, niet overgaat na (bed)rust, die 
resulteert in aanzienlijke beperkingen in het dagelijks functioneren, en die niet 
veroorzaakt wordt door een somatische aandoening.  
Door het Nijmeegs Kenniscentrum Chronische Vermoeidheid (NKCV) is een bio-
psychosociaal model voor CVS ontwikkeld en getoetst. Vervolgens is er, gebaseerd op 
dit model, een protocollaire behandeling met CGT voor CVS ontwikkeld. Deze 
behandeling is getoetst in een randomised controlled trial (RCT) en bleek effectief te 
zijn.  
Omdat de vraag naar deze behandeling het aanbod ver oversteeg was uitbreiding van de 
behandelcapaciteit nodig en wenselijk. Door een hiervoor ingestelde werkgroep werden 
de mogelijkheden voor implementatie in verschillende soorten organisaties 
geïnventariseerd. De uitkomsten van deze inventarisatie waren aanleiding voor het 
hierboven genoemde implementatie-project en de studies in dit proefschrift.  
   
In hoofdstuk 1 wordt een algemene inleiding gegeven op de beschreven studies. 
Hoofdstuk 2 beschrijft het onderzoek naar het effect van herhaalde informatieve 
interventies bij huisartsen op hun kennis en houding ten aanzien van CVS en op hun 
feitelijke verwijzingen van CVS patiënten voor CGT naar de GGZ. Huisartsen kregen 
bij de laatste toegezonden informatie een korte vragenlijst meegestuurd met vragen 
over hun kennis en attitude over CVS. Verwijsdata werden verzameld door de GGZ 
instelling. Het bleek dat 70% van de huisartsen door de informatievoorziening op de 
hoogte was geraakt van de nieuwe behandelmogelijkheid. Tevens bleek de informatie 
te hebben geleid tot een positievere attitude ten aanzien van CVS. Gedurende 16 
maanden had 22% van alle huisartsen ten minste één CVS patiënt verwezen voor CGT. 
Uit deze studie is gebleken dat het herhaaldelijk verspreiden van informatiemateriaal 
een zinvolle methode is om huisartsen ertoe te brengen dat zij CFS patiënten gaan 
diagnosticeren en verwijzen voor CGT.    
Bij de start van een CGT voor CVS dient correct te worden vastgesteld of de 
betreffende cliënt een zogenaamd ‘laag actief’ of ‘relatief actief’ dagelijks 
activiteitenpatroon heeft. Het is met name belangrijk om laag actieve patiënten te 
herkennen, omdat zij geen herstel laten zien wanneer zij met het protocol voor relatief 
actieve patiënten behandeld worden. Een goed en betrouwbaar instrument hiervoor is 
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een actometer. Voor veel praktijkinstellingen zijn actometers echter te duur en te 
arbeidsintensief. De studie die in hoofdstuk 3 beschreven wordt heeft drie instrumenten 
vergeleken die als alternatief voor een actometer gebruikt zouden kunnen worden. De 
betreffende instrumenten zijn het ‘Activiteitenpatroon Interview’ (API), de 
‘International Physical Activity Questionnaire’ (IPAQ) en de ‘CVS-Activiteitenlijst’ 
(CVS-AL). De validiteit van deze drie instrumenten werd vastgesteld en vergeleken op 
basis van receiver operating characteristic (ROC) curves. Uit deze studie bleek dat de 
drie instrumenten een gelijke en acceptabele validiteit hebben. Wel was de IPAQ iets 
beter dan de andere twee instrumenten in het correct voorspellen van laag actieve CVS 
patiënten. Daarom werd geconcludeerd dat de IPAQ het beste alternatief is voor een 
actometer.  
Hoofdstuk 4 beschrijft  het proces en de resultaten van het implementatieproject. De 
centrale vraagstelling van deze studie luidde: wat zijn de voorwaarden voor succesvolle 
implementatie van CGT voor CVS in de GGZ? Daarnaast werden de volgende 
subvraagstellingen onderzocht: Werden potentiële verwijzers voldoende geïnformeerd? 
Waren de verwijzingen correct gediagnosticeerd? Wat zijn mogelijke redenen voor 
verwijzers om CVS patiënten niet te verwijzen? Werden voldoende CVS patiënten 
verwezen om het project te kunnen realiseren en behandeleffecten te evalueren?  
Hoeveel patiënten vielen uit tijdens het verwijs- en behandelproces en wat waren de 
redenen voor drop-out? Wat waren de behandelresultaten? De evaluatie liet zin dat 
implementatie mogelijk is en in grote lijnen geslaagd is maar dat met name rondom 
uitval van patiënten zorgwekkende problemen optraden. Het hoofdstuk wordt 
afgesloten met een samenvatting van de belangrijkste voorwaarden voor succesvolle 
(vervolg)implementatie van CGT voor CVS.  
Hoewel reviews en eerdere RCTs hebben laten zien dat CGT voor CVS een effectieve 
behandeling is, is het nog niet onderzocht of deze behandeling ook in een niet 
gecontroleerde praktijksetting goede resultaten geeft. Hoofdstuk 5 gaat over de 
behandelresultaten van CGT voor CVS na implementatie ervan bij GGNet in 
vergelijking tot de eerdere in RCTs gevonden behandelresultaten. De vergelijking is 
uitgevoerd door middel van een benchmark analyse. De behandeluitkomsten werden 
gemeten met gevalideerde zelfrapportage vragenlijsten voor vermoeidheid en fysieke 
beperkingen voor en na behandeling. Het bleek dat de effect sizes van de 
behandelresultaten na implementatie bij GGNet binnen de effectrange van de 
benchmarkresultaten lagen. Hieruit werd geconcludeerd dat het implementeren van 
CGT voor CVS in een GGZ instelling leidt tot voldoende effectieve 
behandelresultaten.  
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Om te kunnen beslissen of het verstandig is om CGT voor CVS te implementeren 
hebben beleidsmakers ook behoefte aan informatie over de kosten en opbrengsten 
ervan. Tot op heden zijn kosteneffectiviteitstudies naar CGT voor CVS schaars en 
alleen gericht op de kosten van het uitvoeren van de behandeling. De studie die 
beschreven wordt in hoofdstuk 6 betreft een kostenevaluatie van het 
implementatieproject, waarbij zowel de kosten voor het uitvoeren als ook voor het 
implementeren van de behandeling zijn meegenomen. Analyses werden uitgevoerd 
vanuit een gezondheidszorg-perspectief en vanuit een maatschappelijk perspectief. Het 
bleek dat de kosten van CVS patiënten voor gezondheidszorg en 
productiviteitsverliezen na behandeling significant gedaald waren ten opzichte van 
voor behandeling. Vanuit het maatschappelijk perspectief  liet implementatie van CGT 
voor CVS een acceptabele kosten-uitkomsten ratio zien. Vanuit het gezondheidszorg-
perspectief hing deze ratio af van hoeveel een herstelde cliënte gewaardeerd wordt.  
Eén van de grootste kostenposten voor CVS patiënten is hun frequente en intensieve 
gebruik van gezondheidszorgdiensten. Tot op heden is nog nooit onderzocht welke 
individuele kenmerken nu bijdragen aan die hoge medische consumptie. In hoofdstuk 7 
wordt een crossectionele studie beschreven die enkele factoren die hier mogelijk aan 
bijdragen onder de loep neemt. Voor deze studie werden 263 CVS patiënten (149 
vanuit het NKCV en 114 vanuit GGNet) geïncludeerd. Uit regressieanalyses bleek dat 
na te hebben gecontro-leerd voor patiëntkenmerken (die 13% van de variantie 
verklaarden) en voor vermoeidheidsgerelateerde kenmerken, (die hier nog 4% aan toe-
voegden) een aantal instandhoudende factoren van CVS nog eens 5% van de variantie 
verklaarden. Het ging hier om de factoren ‘gevoel van controle over 
vermoeidheidssymptomen’, ‘psychologische attributie van vermoeidheid’ en 
‘gerichtheid  op lichamelijke signalen’. 
In hoofdstuk 8 worden alle studieresultaten bediscussieerd tegen de achtergrond van 
nationale en internationale ontwikkelingen op het gebied van implementatie van CGT 
voor CVS. Verder worden in dit hoofdstuk implicaties van dit proefschrift voor 
toekomstige CGT voor CVS implementatie- en onderzoeksprojecten gegeven. 
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Wat vliegt de tijd. Haast ongemerkt is het inmiddels niet meer drie, of vier, maar ruim 
vijf jaar geleden dat ik gestart ben met dit onderzoeksproject. De jaren van actie, 
waarin we met veel betrokkenen het programma opstartten, data verzamelden en 
processen bijstuurden, zijn langzaam overgegaan in jaren reflectie, waarin ik vooral 
zelf zat te schrijven, analyseren, submitten en re-submitten. Zo komt het dat ik 
inmiddels al veel ‘CGT voor CVS’ betrokkenen nog maar zelden zie of spreek. 
Hoogste tijd dus om het geheel echt af te ronden en ieder officieel te bedanken! 
 
Gijs, gefeliciteerd met het succesvol begeleiden van je ongeveer 30e ste promovendus. 
Het was af en toe flink zweten! Maar je liet het gelukkig niet aankomen op verdrinken 
of verdwalen. Het wekelijkse onderzoekeroverleg én de individuele begeleidingen 
boden ruimschoots houvast en wezen duidelijk de weg. Bovendien vroegen deze 
bijeenkomsten wekelijks om een nieuwe sprint voorwaarts, en ze hielden zo de vaart er 
flink in. Ik heb van jou naast inhoudelijke kennis nog ten minste drie belangrijke 
vaardigheden geleerd. Ten eerste om secuur te werken. Ik werd genoodzaakt om een 
stuk tekst pas aan jou voor te leggen of als ‘af’ te beschouwen na het ten mínste nog 
eens drie keer kritisch te hebben doorgelezen en gecheckt tot in elk detail. Ten tweede 
heb je mij één en ander laten ervaren omtrent ‘commitment’. Aanvankelijk vond ik dit 
wat confronterende leerstof, dat weet je vast nog wel, maar het stelde mij wel in staat 
meer eigen keuzes te maken binnen het bestaande project. Wat ik hiervoor ten derde 
wel óók heb moeten leren, is degelijk onderbouwen. Mijn wensen of voorstellen 
verloren het zonder gedegen onderbouwing steevast van jouw ideeën. Al ploeterend 
ontdekte ik tot mijn genoegen dat jij bij onderbouwde argumenten heus voor rede 
vatbaar bleek. Hierbij veel dank voor je inzet en alle leermomenten.  
Michel, jij hebt dit project een groot stempel gegeven. Met je grote deskundigheid op 
het gebied van zowel implementatieonderzoek als huisartsengeneeskunde heb ik ook 
van jou veel kunnen leren en heb je dit project van allen kanten van zinvolle adviezen 
voorzien. Veel dank voor al je bijdragen.  
 
In de projectgroep: Co Wildeboer Schut, Roel Evertse, Frans van Mierlo, Marianne 
Ros, en later ook Dick Kleinlugtenbelt en Jan Willem van Heertum. In de maandelijkse 
‘projectgroepvergaderingen’ heb ik genoten van jullie praktische en plezierige inbreng. 
Jullie moesten na deze vergaderingen steevast even ‘ontgijzen’, zo werd mij eens met 
een bedrukte glimlach onthuld, maar hebben je daarna toch telkens weer enorm ingezet 
voor de te nemen stappen. Co, Roel en Frans, jammer dat jullie door de reorganisaties 
binnen GGNet voortijdig de projectgroep hebben moeten verlaten. Co, je verzorgde 
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vakkundig ons ‘communicatieplan’ en de persberichten en hebt me veel geleerd en 
geholpen bij de uitvoering ervan. Ik vond het bovendien erg gezellig hierin met jou 
samen te werken. Dick en Jan Willem, jullie hebben je enthousiast ingezet om de 
knelpunten tijdens het project goed op te vangen en ervoor te zorgen dat de CGT voor 
CVS bij GGNet nu goed ‘geborgd’ en gecontinueerd is.  
In de stuurgroep: Maarten Cox, Hedy Draaier, Jos van der Meer, Carola Mes, Mary 
Rietdijk en Michel Wensing. Bedankt voor jullie inzet bij het nauwkeurig volgen van 
de ontwikkelingen van het project, het kritisch lezen van de tussen- en eindrapportages, 
en voor jullie adviezen en ervaringen vanuit ‘het veld’ van GGZ instellingen, 
huisartsen en patiënten. Carola Mes, dank voor de vlotte en plezierige samenwerking 
bij het huisartsenonderzoek, dat leidde tot hoofdstuk 1 van dit proefschrift. 
Voor econimisch advies: Hans Severens, jouw hulp bij de kostenkant van dit project 
was onmisbaar. Mijn ´Maastrichtse periode´ was een leuk en effectief intermezzo, ik 
voel mijn hersens nog rammelen van je privé stoomcursus in kostenanalyses. Daarmee 
is het een economische leek als ik toch gelukt om onze methodisch nogal niet 
conventionele analyses in tekst en tabel op papier te krijgen.   
In het CVS-therapeutenteam: Astrid de Vries, Guido Machielsen, Peter Meulenbeek, 
Marja van Wuytswinkel, Marianne Ros, Jan Willem van Heertum, Ines Folgering, 
Sanny Uitentuis, Pollyanna Kramer en Esther Landsdaal. Bedankt voor jullie inzet voor 
het project, medewerking aan het onderzoek en natuurlijk het behandelen van CVS.  
Op de secretariaten van GGNet: Ruth Radstake en Marit Lenting. Jullie hebben alle 
nodige cliëntgegevens bijgehouden, ingevulde vragenlijsten apart bewaard en mij twee 
jaar lang wekelijks tot in elk gewenst detail voorzien van  instroom en doorstroom data. 
Hiermee kon het databestand van het evaluatieonderzoek worden opgebouwd. 
En als CVS-pioniers bij GGNet: alle deelnemende cliënten. Dank voor durven aangaan 
van de ´nieuwe behandeling voor CVS´, voor het invullen van de vragenlijsten, (wat 
voor velen gezien de timing direct na het intakegesprek best een pittige klus was), en 
voor deelname aan de telefonische interviews.  
 
Mijn NKCV collega’s! Ik denk met veel plezier en soms wat heimwee terug aan de 
fijne jaren op het letterlijk en figuurlijk knusse NKCV. We hebben heelrijke grote en 
‘kleine’ rondjes gemaakt in de pauzes, en om het werk heen heel veel gezellig gekletst, 
leed gedeeld en werkdruk verdragen door geregeld nog harder te lachen. Gelukkig zie 
ik jullie nog geregeld op deze of gene borrel, en ik hoop dat dit nog even zo blijft.  
Mijn medeonderzoekers: Joke, Marieke, Hans, en later ook Martine, Harmen en Dewy. 
Hoeveel junioronderzoekers passen er ook al weer op 15m2 ? Als ze maar leuk zijn kan 
er altijd nog een bij! Met jullie was mijn leven als onderzoeker gelukkig alles behalve 
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dat van een eenzame kluizenaar. Marieke en Joke, in mijn periode van twijfel maakte 
jullie dagelijks gezelschap het een stuk makkelijker om te besluiten door te gaan. Ook 
heb ik enorm veel gehad aan alle hulp en uitleg bij methoden, analyses en programma’s 
waar jullie meer ervaring mee hadden als ik. Hans jij verzorgde de CVS-supervisies 
aan de GGNet therapeuten, en was mij vaak ook van dienst met het doorgeven van het 
laatste nieuws over lopende behandelingen. Liesbeth, vooral sinds ik niet meer veel 
fysiek op het NKCV aanwezig was heb je me geholpen met lastig te plannen afspraken, 
waarvoor veel dank. Gerard, dank voor je hulp bij de vragenlijst voor medische 
consumptie en bij het screenen van verwijsbrieven op somatische co-morbiditeit. 
Daarnaast complimenten voor je vrolijke en stimulerende invloed op onze borrels, 
uitjes en BBQs.  
Maya en Anja, mede junioronderzoekers, bedankt voor alle gezellige muzikale en 
sportieve uurtjes. Het was leuk om in de voor mij nieuwe stad Nijmegen ook jullie te 
leren kennen. Een paar jaar terug had ik niet verwacht dat we nog eens alle drie 
dezelfde ‘vervolgstap’ (of beter gezegd parallelstap) zouden gaan maken met de GZ-
opleiding. Beiden nog veel succes toegewenst met dit duo-traject. Gewoon doorgaan! 
Marieke Effting, we hebben in 2004 geregeld samen heen en weer getreind, en  
ontdekten toen naast verrassende parallellen tussen onze onderzoeken ook 
overeenkomstige loopbaan- en levensvragen. Het was wel even wennen toen ik je 
gezelschap moest missen, maar ben blij voor je dat je nu in Amsterdam op je plek bent. 
Nog veel succes én plezier met de voortgang en afronding van jouw promotie! 
 
Lieve vrienden en vriendinnen, dank voor jullie interesse in de voortgang van dit 
onderzoek, maar vooral ook voor de trouwe vriendschap tijdens mijn afgelopen drukke 
jaren! Alle heerlijke ontspannende en inspirerende uitjes, etentjes, videoavonden, 
wandelingen, feestjes, concerten, weekends weg en méér waren stuk voor stuk 
genieten. Jullie zijn inmiddels allen student af en serieus aan het werk, maar ik hoop 
van harte dat we nog lang en veel met elkaar mogen ondernemen.  
Femke en Jacoline, erg fijn en gezellig dat jullie mij als bosnimf, eh, paranimf willen 
ondersteunen bij het toneelstukje van de 20e februari! Met beiden van jullie heb ik wel 
eerder en vaker samen op een podium gestaan, dus het voelt vast vertrouwd.  
 
Lieve papa en mama, bedankt voor jullie interesse en aanmoediging bij dit project. Al 
was ik destijds een brave scholiere, in mijn studie en loopbaankeuze bleef ik maar 
switchten en hebben jullie veel twijfels geduldig begeleid. Door jullie betrouwbare 
steun kon ik me op mijn manier ontwikkelen en uiteindelijk ook dit boekwerk 
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schrijven. Voor dit project ben ik helemaal van het Wilde Westen naar het Wijze 
Oosten getrokken. Qua kilometers veel te ver, maar gelukkig voelt het zo niet. 
Lieve Hannes, eerst: je bent mijn lief, en ja, ik ook van jou! Ook als ik soms chagrijnig 
was van de werkstress. En voor dit dankwoord: je hebt inmiddels al tegen ik weet niet 
hoéveel vrienden gezegd dat je nóóit maar dan ook nóóit moet gaan promoveren! Maar 
als ik het even niet meer zag zitten heb je me steeds weer bemoedigd dat ik het 
natuurlijk wél af moest maken. Al je geduld en begrip ga ik nu zeker belonen ☺. 
Josephientje, je gaf me met de timing van je geboorte preciés genoeg tijd om alle 
geplande artikelen de resubmitten. Hierdoor kon ik dit werk in jouw eerste 
levensmaanden heerlijk helemaal loslaten. Daarna heb je wel geregeld bij mij op schoot 
gezeten terwijl ik zat te typen. Hierbij moest ik het toetsenbord steeds iets verder naar 
voren schuiven om je handjes er vanaf te kunnen houden. Maar nu krijg jij je beurt, en 
wel het laatste woord, ik zou zeggen: leef je uit!        6 jmh   nbuyf       e   .d,,¢ v vc   5e 
c dxxxxxxxxxxxxxxxxxxxxzzn v bbbbbbbbbbbbbbbcxb b 8ullllllllkkkkkkkkk 
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